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Summary 
The aim of this body of work was to determine the method of action of 
mesenchymal stromal cell immunomodulation, and their potential benefits in treating 
pulmonary fibrosis.  This was achieved through a series of in vitro studies and an in 
vivo model of lung disease, namely, bleomycin induced pulmonary fibrosis. 
 Firstly MSC expansion of Treg cells was shown to be dependent on Jagged 1 
signalling.  MSC inhibition of DC maturation and antigen presentation was shown to 
also involve Jagged 1 however IL-6 signalling is also necessary.  MSC inhibition of 
DC maturation resulted in a semi mature or “tolerogenic” DC, expressing lower levels 
of co-stimulatory markers. These cells were capable of suppressing antigen specific T 
cell proliferation and inducing Treg cells from a naive population. 
 MSC trophic factors were further examined for their ability to promote wound 
healing.  MSC conditioned media cultured with lung epithelial cells encouraged 
proliferation through the release of the growth factor HGF.  MSC CM also reduced 
the proliferation and activation of primary lung fibroblasts, yet encouraged their 
migration. These results suggest MSC do not hinder the body’s natural wound healing 
efforts but prevents unsolicited fibroblast activity and encourages epithelial growth 
and repair.  The positive effects of MSC treatment were further examined in vivo, 
where MSC were shown to improve pathology in a bleomycin driven model of lung 
fibrosis.  
The bleomycin model was examined and refined in order to more accurately 
represent therapeutic intervention, allowing for investigation of MSC as an anti-
fibrotic cell therapy. 
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1.1 Mesenchymal Stromal Cells 
Murine mesenchymal stromal cells (MSC) were first discovered in 1966 as a 
population of plastic adherent bone marrow cells with the potential to differentiate into 
bone (Friedenstein et al., 1966).  Over 13 years later they were isolated from human 
bone marrow (Castromalaspina et al., 1980).  In 1990 Caplan et al.  coined the term 
mesenchymal stem cells, based on the potential of these cells to differentiate into 
multiple cell types, thus suggesting them as a potential agent for regenerative medicine 
(Caplan, 1991).  In 1999, multilineage differentiation of MSC was demonstrated in 
vitro (Pittenger et al., 1999).  Over the next decade scientists become more 
uncomfortable with the term mesenchymal stem cells, as MSC failed to meet 
previously established criteria for stemness; “a long-term self-renewing cell that is 
capable of differentiation into specific, multiple cell types in vivo”  (Horwitz et al., 
2005).  As the acronym had become synonymous with the cells, it had to be 
maintained, however “stem” was substituted for “stromal” to more accurately reflect 
the cell’s phenotype.  (Horwitz et al., 2005).   
A fundamental role of MSC in the bone marrow is controlling the homeostasis 
of hematopoietic stem cells (HSC) while maintaining their undifferentiated state.  
(Omatsu et al., 2010).  MSC also contribute to maintaining an immunosuppressive 
environment in the bone parenchyma, suppressing autoimmune reactions by maturing 
lymphocytes  until naive immune cells are released to the periphery (Dazzi et al., 
2006).  The interplay between MSC and immune cells coupled with the ease of MSC 
isolation and culture ex vivo, makes them an attractive candidate for cell therapy.  
Additionally, MSC demonstrate an immune privileged nature, expressing low levels 
of MHC class I and no MHC class II, allowing them to evade allogeneic reactions and 
NK killing (Grinnemo et al., 2004), In 2011 the cell therapy market was valued at $2.7 
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billion, by 2016 it is estimated to be worth somewhere close to $8.8 billion (Syed and 
Evans, 2013).  To date the positive effects of MSC have been demonstrated in a broad 
range of experimental animal models including multiple sclerosis (MS) (Zappia et al., 
2005), type II diabetes (Lee et al., 2006), myocardial infarction (Lee et al., 2009) and 
critical limb ischemia (Lian et al., 2010).  MSC cell therapy has advanced from a 
purely academic to a clinical/ industrial setting.  Osiris Therapeutics Inc., a USA-based 
company, are currently assessing their proprietary stem cell product, Prochymal(R) in 
multiple clinical trials.  MSC have also shown promising results in phase II clinical 
trials for graft versus host disease (GvHD)(Kebriaei et al., 2009).  Phase II trials are 
also being carried out on type 1 diabetes mellitus and chronic obstructive pulmonary 
disease (COPD)(Mills, 2009).  The major focus of the cell therapy field currently is 
the application of MSC research as evidenced by the 308 clinical trials currently 
ongoing or in preparation (ClinicalTrials.gov), and FDA approval already granted for 
MSC in the treatment of multiple sclerosis (MS). 
Despite the promising results from clinical trials, there are drawbacks to using 
MSC.  Unlike pluripotent stem cells, the excessive in vitro culture of MSC can lead to 
a reduction in their efficacy and senescence (Katsara et al., 2011).  One possible 
solution to this problem currently being explored in the generation of MSC from 
inducible pluripotent stem cells (iPSC).  iPSC are genetically reprogrammed adult 
stromal cells that share morphology, proliferation, gene expression and differentiation 
capacity with embryonic stem cells (Takahashi et al., 2007).  iPSC can replicate 
indefinitely and MSC differentiated from these cells retain this trait while still 
conforming to the characteristics of normal MSC (Gruenloh et al., 2011).  These novel 
MSC are still undergoing safety testing but may have potential in regenerative 
medicine, allowing for autologus, patient matched cell replacement therapy. 
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1.2 Innate and Adaptive immunity 
To understand the role of MSC in immune modulation it is important to 
consider the diversity and nuanced functions of cells that collectively comprise the 
innate and adaptive immune system.  The innate immune system is the body’s first 
line of defence against foreign pathogens.  There exists an array of pathogen 
recognition receptors (PRR), which are expressed by innate immune cells and are 
responsible for identifying pathogen associated molecular patterns (PAMPS) on 
foreign material (Akira and Takeda, 2004).  Upon activation, the primary objectives 
of the innate immune system are: the recruitment of immune cells to the site of 
infection through release of anaphylatoxins, cytokines and chemokines, the activation 
of the cytotoxic biochemical defences such as the complement cascade, and the 
removal of foreign material by phagocytic cells (Akira et al., 2006).  This is achieved 
through the actions and interactions of leukocytes.  Neutrophils, being the most 
abundant leukocytes, are commonly the first cells to arrive at the site of infection.  
Along with basophils and eosinophils they destroy pathogenic cells through 
respiratory burst, a process by which destructive free radicals are generated and toxic 
proteins are released from granules in the cell.  Mast cells, similarly release granules 
containing chemokines, cytokines and hormonal mediators, however, they are more 
commonly found in connective and mucosal tissues.  Phagocytic leukocytes, including 
neutrophils, macrophages, and dendritic cells (DC) are responsible for engulfing and 
removing pathogens as well as dead cells from the affected site.  DC and to a lesser 
extent macrophages also act as antigen presenting cells, designed to activate the 
adaptive immune system.  DC are generated in the bone marrow and released into the 
periphery in an inactive form (Steinman and Cohn, 1973), they are constantly 
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sampling their surrounding environment for foreign material, which once encountered, 
they will engulf, process into peptides, and present to T cells on major 
histocompatibility complexes (MHC).  Activation of T cells requires a second signal 
from co-stimulatory molecules such as CD80/CD86 on activated DC, which will 
interact with CD28 on the T cell surface (Banchereau and Steinman, 1998).  Distinct 
form other immune cells, natural killer cells are responsible for targeting tumor cells 
and virus infected cells of the host, responding to low levels of “self” antigens known 
as MHC I.  Cells expressing low levels of MHC I are eliminated by NK cells through 
induction of apoptosis (Noone et al., 2013). 
The adaptive immune system, comprised of T lymphocytes and B 
lymphocytes, orchestrates specific responses to infection based on immunological 
memory, thus adapting the body against reoccurring infection (Gershon et al., 1971).  
A corner stone of the adaptive immune system is the ability to distinguish self from 
non-self.  T cells and B cells are selected or deleted based on their auto reactivity 
before they are released from the thymus or bone marrow respectively.  T cells that 
fail to recognise self-MHC or strongly react to self-antigen undergo apoptosis in 
processes known as positive selection and negative selection respectively (Cantor and 
Weissman, 1976, Scollay et al., 1980).  The remaining T cells are termed naïve T cells, 
they are permitted to leave the thymus, and will activate and proliferate when they 
come in contact with antigen cognate to their T cell receptor.  In the bone marrow pre 
and pro B cells are B cells are tested for reaction to self-antigens.  If they express low 
affinity to self the recombination activating genes (RAG) are switched off, otherwise 
they undergo apoptosis (Buhl et al., 2000).  Upon activation T cells either kill pathogen 
infected cells directly (CD8+ T cells) or through influencing the microenvironment 
and recruiting other immune cells (CD4+ T cells).  B cells function through the 
18 
 
production of antibodies, resulting in the elimination of extracellular microorganisms 
(Coombs et al., 1969). 
 
1.3 The effect of MSC on immune cells 
Initially, in vitro work provided insights into MSC interactions with cells of 
both the innate and the adaptive immune system.  More often than not, MSC have an 
inhibitory effect on immune cells, impeding activation and proliferation, neutrophils 
are an exception to this observation (Cassatella et al., 2011, Raffaghello et al., 2008).  
Human MSC interaction with IL-8 activated neutrophils was shown to improve 
cellular fitness and survival at ratios as low as 1:500.  Co-culture also increased 
neutrophil respiratory burst capacity (Cassatella et al., 2011, Raffaghello et al., 2008).  
Conversely, MSC cultured in vitro with other granular immune cells, namely mast 
cells, resulted in inhibition of cytokine production and degranulation by both human 
and mouse MSC (Su et al., 2011, Brown et al., 2011).  A key in vivo study also 
demonstrated murine MSC capacity to inhibit infiltration of eosinophils in a mouse 
model of allergic asthma (Kavanagh and Mahon, 2011).  MSC interaction with 
phagocytic macrophages and DC also resulted in inhibition of activation but more 
importantly switching from a pro-inflammatory phenotype to regulatory one.  In vitro 
co-culture of human MSC with macrophages resulted in a reduction in TNFα and IL-
12 production and increased IL-10 and IL-6 secretion.  This was accompanied by an 
increase the expression of a cell surface marker associated with alternatively activated 
macrophages (Kim and Hematti, 2009).  Similar results were seen in macrophages co-
cultured with murine MSC, where macrophages were driven from a classically 
activated pro-inflammatory (M1) phenotype to an alternatively activated pro-repair 
(M2) phenotype.  This process, when utilised in a mouse model of sepsis, helped 
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prevent the infiltration of neutrophils and thus reduced pathology in the gut (Nemeth 
et al., 2009).  MSC “education” of DC to become regulatory DC has been more 
intensely studied than MSC and macrophages.  Co-culture experiments using human 
and murine MSC showed a reduction in DC activation, reduced co-stimulatory cell 
surface markers, and a reduction in IL-12 production (Djouad et al., 2007, English et 
al., 2008, Jiang et al., 2005).  In vitro studies with murine MSC have also shown a 
reduction in DC migration and antigen presentation (English et al., 2008).  MSC have 
further inhibitory effects on natural killer cells (NK), preventing proliferation of 
freshly isolated human NK cells, while inhibiting the cytotoxic activity of IL-2 or IL-
15 activated NK cells  (Spaggiari et al., 2006).  Low level expression of MHC class I 
on MSC allows them to avoid resting NK cell mediated apoptosis but not the actions 
of activated NK cells.  However, IFNγ stimulation of human MSC was shown to 
increase their MHC class I expression, resulting in increased resilience to NK killing 
(Spaggiari et al., 2006, Noone et al., 2013).  MSC effects on immune cells are 
summarised in figure 1.1.   
MSC also interact with and influence cells of the adaptive immune system.  
Though there are few consistent reports on the influence of MSC on B cells.  Human 
MSC have been reported to increase the in vitro proliferation of activated B cells 
isolated from patients with systemic lupus erythematosus (SLE), compared to healthy 
donors (Traggiai et al., 2008).  On the other hand, several publications show a more 
inhibitory effect, with MSC suppressing B cell activation and proliferation in both 
human and mouse cells (Corcione et al., 2006, Glennie et al., 2005, Schena et al., 
2010).  MSC effect on T cells has been extensively studied.  MSC are known to induce 
T cell anergy, leading T cells to become unresponsive to proliferative stimuli and 
unable to produce cytokines (Zappia et al., 2005).  In addition MSC inhibit the 
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differentiation of Th-17 cells (Duffy et al., 2011) and promote the expansion of 
regulatory T cells (Treg) (Del Papa et al., 2013, English et al., 2009, Selmani et al., 
2008) (Fig.  1.1). 
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Fig 1.1 Summary of MSC effects on immune cells.  MSC inhibit the proliferation 
of NK cells, T cells, and in some cases B cells.  They promote the expansion of Treg 
cells and drive macrophages towards a regulatory M2 phenotype.  They also inhibit 
the migration and function of DC and mast cells.  Although predominately inhibitory 
towards immune cells, MSC may promote the cellular fitness and survival of 
neutrophils. 
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1.4 Soluble factors involved in MSC immunomodulation 
MSC communicate with immune cells through the release of soluble 
mediators, through direct cell-cell contact or through a combination of both.  The latter 
is best demonstrated by MSC production of nitric oxide and the enzyme indoleamine 
2,3-dioxygenesae-1 (IDO), both of which require initial IFNγ stimulation of MSC 
(Krampera et al., 2006, Ren et al., 2008, Ryan et al., 2007).  Nitric oxide is a bioactive 
gas implicated in murine MSC mediated inhibition of T cell proliferation (Ren et al., 
2008, Sato et al., 2007).  Both murine and human MSC use IDO, an enzyme which 
catalyses the degradation of tryptophan to N-formyl-kynurenine, to regulate T cell 
proliferation (English et al., 2007).  Murine MSC release of IDO was further 
implicated in MSC regulation of T cells in an animal model of renal allograft 
transplantation.  Administration of MSC as a cellular therapy resulted in donor specific 
tolerance through up-regulation of Treg.  Decreased Th1 cytokines in favour of Th2, 
decreased levels of donor-specific IgG, and inhibition of DC maturation were 
mediated through MSC release of IDO (Ge et al., 2010).  The up regulation of various 
soluble mediators in response to specific stimuli supports the hypothesis that MSC can 
sense their environment and adapt their responses accordingly.  Previous studies in 
human MSC have also demonstrated that activation of MSC by different TLR signals 
can result in a pro-inflammatory phenotype or an immunosuppressive one (Waterman 
et al., 2010).  Further, in a murine model of sepsis, Nemeth and colleagues elegantly 
demonstrate the importance TNFα stimulation of MSC to achieve PGE2 dependent 
expansion of alternatively activated macrophages.  TNFα present in the sepsis model 
bound to TNFR-1 on the surface of MSC and through NFκB signalling, up-regulated 
expression of COX-2, a pre-requisite of PGE2 formation (Nemeth et al., 2009).   
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Several studies have revealed that the lipid mediator PGE2 plays a 
considerable role in MSC modulation of multiple cell types.  Production of PGE2 by 
murine MSC plays a definitive role in the expansion of Treg cells (English et al., 
2009), the inhibition of Th17 cell differentiation (Duffy et al., 2011) and the switching 
of macrophages to an M2 phenotype (Nemeth et al., 2009).  In human MSC, PGE2 
signalling was shown to be responsible for MSC inhibition of NK cell activation 
(Spaggiari et al., 2008) and mast cell infiltration in a model of contact hypersensitivity 
(Su et al., 2011).  Taken together these studies suggest a pivotal role for PGE2 
signalling in MSC immunomodulation, however, many of the above studies cite a 
requirement for cell-cell contact signalling in conjunction with soluble mediator 
release to illicit immunomodulatory effects (Duffy et al., 2011, English et al., 2009, 
Spaggiari et al., 2008). 
 
1.5 Cell contact dependent MSC immunomodulation 
There is considerable overlap between studies into soluble mediators produced 
by MSC and cell contact signalling, though, far less is known about cell-cell contact.  
English et al. demonstrated this using a transwell system, where they highlighted a 
requirement for PGE2 and TGFβ signalling but also a need for cell contact (English 
et al., 2009).  Further evidence of a role for contact dependent signalling came from 
Akiyama et al., who showed that MSC administration in a mouse model of 
experimental colitis led to the reduction of a Th-17 phenotype and an increase in Treg.  
This study elegantly identified FASL signalling as the key contact dependent 
mechanism utilised by MSC.  Binding of FASL to its receptor on T cells resulted in 
increased apoptosis of activated T cells in vitro and in vivo, the apoptotic cells 
stimulated the secretion of TGF- β from macrophages leading to an increase in Treg 
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(Akiyama et al., 2012).  Another potential candidate for MSC contact signalling is the 
B7 homolog and co-stimulatory programmed cell death receptor (PD) and ligand (PD-
L). Both regulatory molecules have been implicated in MSC immunomodulation, with 
neutralising antibodies against PD-1 resulting in murine MSC suppression of T cell 
and B cell proliferation in vitro (Augello et al., 2005).   
 
1.6 Notch Signalling 
The Notch family of receptors (Notch 1-4) and ligands (Jagged 1, 2, Delta-like 
ligand 1, 2 and 4) are part of a highly conserved signalling pathway, primarily involved 
in cell growth and development, dictating how cells respond to developmental cues 
(Artavanis-Tsakonas et al., 1999).  Their signalling is involved in diverse cell fate 
decisions such as the generation of neural glial cells, development of tip-cells in 
angiogenic sprouting and ventricular myocardial development (Furukawa et al., 2000, 
Hellstrom et al., 2007, Niessen and Karsan, 2008).  Signalling occurs through the 
binding of Jagged or Delta-like ligands to the extracellular binding subunit of the 
hetrodimeric Notch receptor complex, followed by cleavage within the 
transmembrane domain by a metalloprotease enzyme called γ-secretase, this cleavage 
releases the Notch intracellular signalling domain (NCID) from the cell membrane.  
The NCID translocates to the nucleus where it heterodimerises with the transcription 
factor RBP-J to form a nuclear transcription complex and regulates the expression of 
the effector genes hairy enhancer of split (HES) and hairy related (HEY) (Gordon et 
al., 2008).  The signalling pathway is illustrated in figure 1.2. 
The Notch family of receptors and ligands are widely expressed on many cell 
types including immune cells and MSC.  Early studies examining the role of Notch 
signalling in immune cells involved immature DC and soluble ligand Jagged 1.  
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Following DC stimulation with soluble Jagged 1, there was an increase in DC 
maturation markers and proliferation (Weijzen et al., 2002).  The following year 
another study found that DC isolated from Notch-1 deficient mice had significantly 
lower levels of MHC Class II and the co-stimulatory marker CD86, classic markers of 
DC maturation.  Interestingly this study also demonstrated that fibroblasts 
overexpressing Jagged 1 cultured with DC, inhibited the maturation of the cells, 
leading to the accumulation of immature DC precursors (Cheng et al., 2003).  This 
conflicting data was partially explained by Bugeon et al. using soluble Jagged 1 to 
activate immature DC.  They observed a similar increase in maturation markers to that 
seen after lipopolysaccharide (LPS) activation, however only activation with Jagged 
1 resulted in an increase in the cytokines IL-10 and IL-2.  Further, these novel DC 
promoted the proliferation of CD4+CD25+ T cells, which in turn were capable of 
suppressing CD4+CD25- T cells (Bugeon et al., 2008).   
In 2004 Fu et al. demonstrated that TGFβ signalling can induce 
CD4+CD25+FoxP3+ Treg cells from a CD4+ population (Fu et al., 2004).  More 
recently evidence has emerged for Notch signalling is an essential component of this 
process.  Inhibition of Notch translocation to the nucleus by GSI prevented the 
expansion of Treg cells, even in the presence of TGFβ (Samon et al., 2008).  
Overexpression studies with Jagged 1 and T cells also showed a decrease in IL-2 
production and an increase in TGFβ.  The resulting Treg cells were shown to be 
functionally suppressive in a lymphocyte proliferation assay (Yvon et al., 2003). 
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Fig 1.2 The Notch signalling pathway.  Signalling occurs through the binding of a 
Jagged or Delta-like ligands to the extracellular binding subunit of the hetrodimeric 
Notch receptor complex, followed by cleavage within the transmembrane domain by 
a metalloprotease enzyme called γ-secretase, this cleavage then releases the Notch 
intracellular signalling domain (NCID) from the cell membrane.  The NCID 
translocates to the nucleus where it heterodimerises with the transcription factor RBP-
J to form a nuclear transcription complex and regulates the expression of the effector 
genes hairy enhancer of split (HES) and hairy related (HEY) 
  
MSC 
T cell/DC 
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1.7 MSC and DC 
 As previously mentioned, the primary objective of DC is to sample the 
environment for foreign material, engulf and process the material into smaller 
peptides, migrate to the lymph nodes and present the antigen to antigen specific T cells 
(Cella et al., 1997).  MSC have been reported to interrupt all of these processes, 
ultimately preventing T cell activation and proliferation.  MSC disruption of 
maturation was discovered through in vitro co-culture experiments, they demonstrated 
MSC reduced the expression of co-stimulatory molecules CD80 and CD86, and 
reduced cell surface expression of MHC class II (Jiang et al., 2005).  Inhibition of 
maturation was achieved in a dose dependent manner and soluble factors, namely IL-
6 played an important role in this effect, however Djouad et al. alluded to the 
requirement for a contact signal (Nauta et al., 2006, Djouad et al., 2007).   
MSC disruption of antigen presentation was established by examining the 
presentation of the antigen ovalbumin (OVA) following co-culture with MSC.  OVA 
pulsed DC which were co-cultured with MSC significantly reduced the amount of 
proliferation of antigen specific CD4+ T cells (English et al., 2008).  Similarly DC 
presentation of OVA by MHC class I receptors to CD8+ T cells was impaired by MSC 
co-culture (Chiesa et al., 2011).   
In addition to disrupting DC maturation and antigen presentation, MSC had an 
inhibitory effect on the migration of DC.  This was a result of increased expression of 
the adhesion molecules E-cadherin and reduced expression of the chemokine receptor 
CCR7, thus impairing migration towards the chemokine CCL19.  (English et al., 
2008).  CCR7 is the chemokine receptor responsible for migration of DC towards to 
the lymph node, this down regulation of this receptor means DC do not migrate to the 
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lymph node and thus cannot interact with T cells and leads to impaired T cell priming 
(Sousa et al., 1997).  The impact of MSC on DC migration was best demonstrated by 
Chiesa and colleagues.  DC pulsed with OVA were fluorescently tagged with CFSE 
and subcutaneously injected into syngeneic mice followed by IV administration of 
MSC.  These mice previously received an injection of DO11.10 naïve T cells.  T cells 
from DO11.10 mice are genetically modified to recognise OVA.  Analysis of draining 
lymph nodes was examined after 3 days.  MSC treated mice had significantly fewer 
DC in the lymph nodes than PBS control mice, indicating impaired migration of 
activated DC to the lymph node (Chiesa et al., 2011).   
 
1.8 MSC and T cells 
MSC modulation of lymphocytes has become one of the defining 
characteristics of this cell type.  As discussed above MSC mechanisms of inhibition 
can occur through various pathways involving cell contact and soluble factors (Di 
Nicola et al., 2002, Krampera et al., 2003).  MSC are believed to modulate T cells 
through direct suppression of proliferation, induction of T cell anergy, class switching 
and expansion of Treg cells.  In 2003, Krampera et al.  showed that MSC inhibited 
antigen specific memory and effector T cell proliferation in a contact dependent 
manner, potentially through physically disrupting APC interactions with T cells.  This 
theory has since been modified as our understanding of MSC, APC and T cell 
interactions has deepened (Krampera et al., 2003).  Studies on the proliferation of T 
cells following MSC co-culture revealed an impaired transition through the stages of 
cell cycle division.  T cells cultured with MSC did not progress past G1 phase, 
however, when removed from culture and stimulated there was increased expression 
of IFNγ, but no increase in proliferation, these results suggest MSC induced a state of 
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split T cell anergy, where not all function is anergised (Glennie et al., 2005).  Induction 
of T cell anergy was further examined in an animal model of experimental 
autoimmune encephalomyelitis (EAE), an autoimmune disease driven by T cells and 
macrophages.  Following administration of MSC there was a significant reduction in 
inflammatory infiltrates and a reduction in demyelination, T cells isolated from MSC 
treated EAE animals were stimulated ex vivo and found to be un-responsive to the 
encephalitogenic peptide MOG35-55 (Zappia et al., 2005).  Given the right 
environmental cues, MSC are capable of polarising T cells towards Th1 or Th2 
phenotypes.  In vitro analysis of the cytokine profile of T cells following MSC co-
culture revealed a down regulation in IFNγ, TNFα, and IL-1α & β, and an up-
regulation in Th2 cytokines IL-3, IL-5, IL-10, and IL-13 (Batten et al., 2006).  In a 
TNFα rich animal model of GvHD, administration of MSC reduced levels of IFNγ+ T 
cells and increased IL-4+ T cells, indicating in vivo skewing of T helper cells to a Th2 
phenotype (Lu et al., 2009).  Conversely when MSC are used in a Th2 driven murine 
asthma model, they reduce levels of IL-4, IL-5 and IL-13 while increasing levels of 
IFNγ (Kavanagh et al., 2010).  Finally, MSC have been shown to expand the Treg 
population naturally found in the body, a trait discussed in greater detail in the next 
section. 
 
1.9 MSC and Regulatory T cells  
Immunologcal tolerance is an essential part of immune regulation, and as such 
has many check points to prevent auto immunity.  As previously discussed, positive 
and negative selection ensures the abolition of self-reactive T cells, however a small 
sub-population of CD4+CD25+FoxP3+ T cells known as regulatory T cells (Treg), play 
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a crucial role in the suppression of excessive or inappropriate T cell proliferation in 
the periphery.   
Stimulation of MSC with IFNγ can up-regulate the expression of MHC 
molecules on the cell surface, rendering them susceptible to clearance by the host 
immune system (Le Blanc et al., 2003).  For this reason it is believed that the long 
term effects seen with MSC therapy are a result of MSC education of immune cells 
and employment of the body’s natural regulatory machinery.  This hypothesis is 
supported by MSC expansion of Treg cells (Del Papa et al., 2013, English et al., 2009, 
Ge et al., 2010, Kavanagh and Mahon, 2011, Selmani et al., 2008) and education of 
undifferentiated to tolerogenic DC (Beyth et al., 2005, Li et al., 2008).   
MSC co-cultured with a purified population of CD4+ T cells were found to 
expand a population of CD4+CD25highFoxP3+ Treg cells, when these cells were re-
purified and cultured with MHC mis-matched lymphocytes, they significantly reduced 
alloantigen driven proliferation.  MSC expansion of Treg required a cell contact signal, 
however there was a non-redundant role for PGE2 and TGFβ signalling (English et 
al., 2009).  In 2011 Kavanagh et al. demonstrated the relevance of MSC expansion of 
Treg in an OVA driven animal model of allergic asthma.  Mice were primed by 
intraperitonial injection of OVA and then challenged by intranasal instillation to 
produce an allergic response.  MSC administration resulted in reduced pathology, 
inflammation and antigen specific IgE production.  In addition, there was a reduction 
in IL-4 and an increase in IL-10 levels in bronchial alveolar fluid (BAL) and from 
OVA stimulated splenocytes.  Ablation of Treg through administration of 
cyclophosphamide abrogated the effects of MSC therapy demonstrating a critical role 
for Treg expansion by MSC (Kavanagh and Mahon, 2011). 
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While regulatory cells are often associated with the adaptive immune system, 
the past 10 years has uncovered regulatory cells associated with the innate immune 
system, namely regulatory macrophages (M2), previously discussed in this chapter, 
and regulatory or tolerogenic DC.  These cells express lower levels of MHC Class II 
and co-stimulatory markers, reduced IL-12p70 and increased IL-10 production 
(Morelli and Thomson, 2007).  These tolerogenic DC are capable of inducing Treg 
cells for a naïve T cell population (Beyth et al., 2005, Bugeon et al., 2008, Nauta et 
al., 2006).  The benefits of tolerogenic DC have been observed in vivo, in an animal 
model of organ transplantation.  Higher levels of both tolerogenic DC and Treg cells 
were observed in the spleens of the recipient animals following MSC administration.  
MSC education of these regulatory cells is believed to be responsible for the tolerance 
of the allogeneic graft (Ge et al., 2009).   
 
1.10 Fibrosis, wound healing, and repair in the airway 
Pulmonary fibrosis is a chronic disease associated with remodelling of the 
organ architecture and excessive deposition of parenchymal tissue by activated 
fibroblasts.  This leads to formation of scar tissue, which becomes a permanent fixture 
once formed.  Treatment is based upon reducing or preventing further progression, a 
strategy contingent on identifying and reversing the underlying cause.  Fibrosis 
commonly results from chronic stimuli, i.e. physical, chemical, or biological sources, 
however many cases are classified as idiopathic.  The cause of idiopathic pulmonary 
fibrosis (IPF), as the name suggests, is unknown, and is associated with a poor survival 
prognosis of 2-4 years (Raghu et al., 2006).  Many researchers believe an underlying 
genetic predisposition triggers the disease following an initial epithelial injury (Maher 
et al., 2007, Selman et al., 2006).  Unfortunately without a deeper understanding of 
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the onset of IPF the disease is extremely difficult to treat leaving lung transplantation 
as the only treatment option in severe cases.   
 
1.11 Epidemiology of Pulmonary Fibrosis 
In 2000 the American Thoracic Society (ATS) and the European Respiratory 
Society (ERS) released guidelines for the diagnosis and treatment of idiopathic 
pulmonary fibrosis (IPF) (ATS, 2000).  While these were useful, it wasn’t until the 
guidelines were updated in 2011 that diagnosis of IPF gained accuracy (Raghu et al., 
2011).  For this reason studying the epidemiology of IPF has proven very difficult 
leading to large variability between published studies.  In 2012 Nalysnyk et al. 
published a literature review of 15 publications pertaining to epidemiology, incidence 
and prevalence of IPF between 1990 and August of 2011.  They found that when 
following tight definitions of IPF the prevalence in the USA is between 14 and 27.9 
cases per 100,000 with an annual incidence of 6.8–8.8 per 100,000.  In Europe the 
prevalence is 1.25 to 23.4 per 100,000, and the annual incidence is 0.22 to 7.4 per 
100,000 population.  There a higher prevalence in men than women in both the USA 
and Europe with the exception of Norway, and incidence increases with age.  This 
means there are approximately 89,000 IPF patients in the USA with 14,000–34,000 
new patients per annum.  In the UK the figure stands somewhere around 15,000 and 
approximately 5,000 new patients diagnosed each year (Nalysnyk et al., 2012).  
According to the Irish Central Statistics Office (CSO) there were 1,334 deaths from 
chronic lower respiratory diseases in 2010 and 1488 in 2011, accounting for 4.8% and 
5.2% respectively of all deaths each year (Central Statistics (Office, 2010). 
 
1.12 Wound Healing and the immune system. 
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Normal wound healing can be divided into three principle stages; 
inflammation, proliferation and repair (Fig.  1.2).  In the case of pulmonary fibrosis 
the initial injury can come in the form of a chemical, biological or physical insult, 
more often than not the stimulus is chronic (Wilson and Wynn, 2009).  Irrespective of 
the source, damage to the lung epithelium results in exposure of endothelium and the 
basement membrane proteins leading to the recruitment and activation of innate and 
adaptive immune cells (Wick et al., 2013). 
Inflammation commonly occurs within hours of injury.  Early inflammation 
involves the infiltration of neutrophils by diapedesis in response to TGFβ secretion 
from α granules in the cytoplasm of platelets.  They phagocytose and remove any 
foreign bodies and damaged tissue (Robson et al., 2001).  Neutrophils generally do 
not persist in the wound site, once they have served their purpose they undergo 
apoptosis and macrophages take over (Wick et al., 2013).  The persistence of 
neutrophils results in chronic inflammation associated with some chronic “non-
healing” wounds.  Late inflammation is characterised by the arrival of macrophages 
which are attracted to the site of injury by cytokines such as PDGF and TGFβ, as well 
as the connective tissue protein elastin, and collagen breakdown products 
(Ramasastry, 2005).  Macrophages are the primary source of TGFβ and FGF which 
promote fibroblast activation and proliferation (Robson et al., 2001), they are also the 
primary source of matrix matalloproteinases (MMP), specifically MMP2 and MMP9, 
both responsible for the breakdown of collagen (Okuma et al., 2004).  In an 
inflammatory Th1 predominant environment macrophages tend towards a classically 
activated phenotype, as inflammation subsides monocytes can become alternatively 
activated (M2).  M2 macrophages tend to be more anti-inflammatory and produce 
tissue inhibitors of matrix matalloproteinases (TIMP) (Sica and Mantovani, 2012).  
34 
 
The final cell type recruited is the lymphocyte, these cells are responsible for the 
increase in IFNγ and TNFα.  Apart from the production of cytokines, their role, if any, 
in wound healing and fibrosis has not been determined, however, there is some 
evidence that Treg cells have a positive effect on disease state by dampening the 
inflammatory response (Wilson and Wynn, 2009). 
The proliferative phase involves the migration of fibroblasts from the 
surrounding tissue into the site of damage, they are attracted by TGFβ and PDGF 
released by platelets and macrophages (Hunt, 1988).  The fibroblast will secrete the 
matrix proteins hyaluronan, fibronectin, proteoglycans as well as type I and II pro-
collagen (Hunt, 1988).  Myofibroblasts, the activated form of fibroblasts are involved 
in wound contraction by attaching to collagen and fibronectin in the extracellular 
matrix and retracting their pseudopodia.  Collagen deposited by the fibroblasts acts as 
structural support to the intracellular matrix (Eckes et al., 2000). 
The final phase of wound healing, repair, is a delicate balance between the 
degradation of scar tissue and the generation of new epithelium, and depending on the 
type of wound can take years (Robson et al., 2001).  MMPs are produced by 
fibroblasts, macrophages and neutrophils and their activity is closely regulated by 
inhibitors called tissue inhibitors of matrix metalloproteinases (TIMPs).  As 
remodelling continues the presence of inflammatory cells and fibroblasts is no longer 
required and they undergo apoptosis, this is critical for resolution of wound healing 
and the aberrant signalling at this juncture is believed to play a critical role in fibrosis.  
Fibroblasts isolated from patients with IPF have been shown to be more resistant to 
apoptosis then those from a healthy lung (Moodley et al., 2003) (Fig.  1.2).   
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Fig 1.2 Stages of Normal Wound Healing.  Damage to airway epithelium leads to 
exposure of basement membrane proteins which attract platelets to the site of damage.  
Platelets, through the release of TGFβ and PDGF recruit neutrophils and ultimately 
macrophages, thus initiating the first phase of wound healing, the inflammatory phase.  
The release of TGFβ and FGF by macrophages activates fibroblasts to myofibroblasts.  
The inflammatory environment created leads to neutrophil infiltration.  The second 
phase of wound healing involves the proliferation of fibroblasts and myofibroblasts, 
these cells create a backbone across the wound area and myofibroblasts contraction 
leads to closure of the wound edges.  They also produce ECM proteins and collagen.  
The final phase of wound healing is remodelling.  This phase is maintained for weeks 
to months and involves the gradual replacement of collagenous and fibrosis scar tissue 
with functional epithelial cells.  Activated fibroblasts undergo apoptosis and MMPs 
breakdown the scar tissue.  HGF is a key growth factor in encouraging the proliferation 
of alveolar epithelial cells into the wound site. 
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1.13 Fibroblasts, Myofibroblasts, and Fibrosis 
Fibrosis is a well characterised disease state and has been studied extensively 
in the last number of years, however it is still unclear precisely what causes normal 
wound healing to become dysregulated, leading to the excessive deposition of collagen 
and destruction of functional tissue.  Fibroblasts are known to be a major cause of 
disease pathology, more specifically, the activated form, myofibroblasts, however it 
is important to note that their initial presence in the site of injury is essential to the 
healing process (Eckes et al., 2000).  As mentioned above myofibroblasts play an 
important role in wound contraction and along with fibroblasts their production of 
ECM products protects the basement membrane from further exposure to the external 
environment.  Fibrosis occurs with excessive proliferation of myofibroblasts 
potentially through resistance to programmed cell death (Moodley et al., 2003).  This 
leads to disparity between the deposition and breakdown of collagen and an imbalance 
between MMPs and TIMPs (Gillard et al., 2004).  Patients with IPF also have higher 
numbers of myofibroblasts and higher levels of TGFβ in their lungs (King et al., 2011).  
Myofibroblasts are characterised by the expression of α-smooth muscle actin (αSMA) 
and increased production of collagen, and are thought to arise from TGFβ activation 
of fibroblasts (Hu et al., 2003).  Another potential source of myofibroblasts is alveolar 
epithelial cells (AEC) through a process of epithelial to mesenchymal transition 
(EMT).  EMT is a process by which epithelial cells loose cell-cell contact, re-organise 
their actin cytoskeleton, and acquire a fibroblast like morphology (Hay, 1995).  In 
fibrotic lungs, AEC are believed to undergo this process under the influence of TGFβ, 
resulting in increased myofibroblasts marker expression and collagen deposition 
(Willis et al., 2005).   
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1.14 Therapeutic Approaches to Pulmonary Fibrosis 
The majority of drugs used in clinical trials for lung fibrosis were previously 
tested in animal models, unfortunately there has been a poor correlation between 
animal model success and results achieved in clinical trials, the potential reasoning 
behind this, is discussed in section 1.4.1.   
 
1.15 Murine models 
Several animal models of pulmonary lung fibrosis have been established, some 
of these include the use of organic particles such as silica, irradiation, gene transfer of 
cytokines, namely TGFβ, TNFα or IL-1β, adoptive transfer of fibroblasts, and the most 
common model, bleomycin.  There are advantages and disadvantages to each model, 
and while their use has helped characterise the milieu associated with the pulmonary 
fibrosis, none of the models fully recapitulate the human disease (Moore and 
Hogaboam, 2008).   
Bleomycin was originally used in the treatment of various cancers, however 
generation of pulmonary fibrosis in up to 5% of patients receiving the drug limited its 
use.  The damaged to lung architecture was caused by bleomycin induced reactive 
oxygen species and cleavage of DNA strands (Lown and Sim, 1977).  Many cytokine 
and chemokines have also been implicated in bleomycin induced pulmonary fibrosis 
including TNFα (Piguet et al., 1989), TGFβ (Nakao et al., 1999), IL-1β (Scheule et 
al., 1992), macrophage-inflammatory protein-1α (MIP 1α) (Smith et al., 1994), and 
monocyte chemoattractant protein-1 (MCP-1) (Zhang et al., 1994), though the exact 
mechanism of action is still unclear.  Intranasal instillation of the drug results initially 
in damage to the alveolar epithelial cells followed by infiltration of inflammatory cells, 
proliferation of fibroblasts and deposition of extracellular matrix.  Histological 
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changes are generally observed by day 14 and collagen deposition peaks anywhere 
between days 21 to 28 (Moore and Hogaboam, 2008).  This model of fibrosis is self-
limiting and after 28 days begins to resolve, this is one of the major differences from 
the human disease, and in the absence of the continuous stimulus suspected to be 
involved in the human disease, the benefits seen in the animal model can fail to 
translate in clinical trials.  There are also differences between mouse strains, C57BL/6 
mice are high responders to bleomycin treatment, resulting in reproducible fibrosis, 
however, they also recover faster.  DBA/2 mice are medium responders and BALB/c 
mice are low responders.  Importantly both of these strains are Th2 biased, while 
C57BL/6 mice are Th1 biased.  Given the capacity for IFNγ to inhibit TGFβ and 
reduce collagen production, this bias have been suggested as a reason for the 
inconsistency in bleomycin induced fibrosis between strains (Chung et al., 2003). 
One of the major issues arising from recent in vivo publications is the time 
point at which treatment is administered.  In 2006 Chaudhary et al. described a switch 
in the cytokine profile associated with bleomycin treated rats, describing an initial 
increase in inflammatory cytokines, with an increase in fibrotic cytokines following 
later.  This “Switch” was hypothesised to occur between day 7 and 9 (Chaudhary et 
al., 2006).  Following on from this work Moeller et al published a review examining 
all publications involving anti-fibrotic therapy in the bleomycin model between 1980 
and 2006.  232 publications were identified and of those boasting successful anti-
fibrotic effects only 13 documented administration of the therapeutic after the switch 
from inflammatory environment to fibrotic one.  The authors believe that many of the 
beneficial effects witnessed in these studies were associated with reduced 
inflammation in the early stages of the disease.  Unfortunately when these results are 
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translated to a clinical setting where fibrosis has already occurred they cannot recreate 
the same efficacy (Moeller et al., 2008).   
 
1.16 Drug Intervention 
To date the main focus in the treatment of fibrosis has been on controlling and 
reducing the associated inflammation, either through inhibition of the activation and 
proliferation of immune cells or by killing them.  This approach has demonstrated 
limited success as it does not address the underlying fibrotic condition.  Examples of 
such therapies include cytokine antibodies such as anti- TGFβ (Arribillaga et al., 2011, 
Kolb et al., 2001), anti-PDGF (Chaudhary et al., 2007), TNFα inhibitors (Piguet and 
Vesin, 1994), and angiotension receptor blockers (Marshall et al., 2004, Molina-
Molina et al., 2006).  Despite the number of papers published about anti-fibrotic 
compounds, and trails testing new drug candidates, lung transplant is still the most 
common treatment for idiopathic pulmonary fibrosis.  The future of therapeutic 
discovery will more than likely lie in targeting excessive fibrosis and not associated 
inflammation.   
There have been many studies on blocking TGFβ signalling as potential 
treatments for lung fibrosis.  Recently Arribillaga et al. described the TGFβ inhibitor 
peptide P17 as a potential drug candidate.  Studies in vitro on human lung fibroblasts 
showed a decrease in the production of connective tissue growth factor (CTGF), a 
mediator of TGFβ1 signalling.  In vivo studies using bleomycin treated mice receiving 
P17 two days after bleomycin IN, showed a reduction in αSMA expressing 
myofibroblasts in lung tissue sections, a decrease in lymphocyte infiltration and lower 
mRNA expression levels of collagen and fibronectinin lung tissue (Arribillaga et al., 
2011). 
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The angiotensin II (ANG II) receptor antagonist Losartan was originally 
approved for the treatment of systemic hypertension and diabetic nephropathy, 
however several labs have tested the drug in animal models of pulmonary fibrosis and 
demonstrated inhibition of fibrotic progression (Fang et al., 2002, Marshall et al., 
2004, Molina-Molina et al., 2006, Yao et al., 2006).  Angiotensin II became a target 
in lung fibrosis when it was discovered to be a pro-apoptotic factor for lung epithelial 
cells and high levels have been recorded in BAL samples from patients with IPF 
(Wang et al., 1999).  In 2006 Marshall et al showed increased levels of ANG II 3 days 
after bleomycin treatment in wistar rats, ANG II levels increased periodically until 
death at day 21.  Treatment with Losartan decreased ANG II levels while also reducing 
levels of pro-collagen production (Marshall et al., 2004).  The positive effects of 
Losatran potentially arise from increased production of PGE2 in bleomycin animals 
treated with the compound (Molina-Molina et al., 2006).  Typically after bleomycin 
administration there is a fall in PGE2 levels, given the capacity of PGE2 to inhibit 
fibroblast proliferation (Lama et al., 2002), the restoration of PGE-2 by Losartan 
would explain the positive effects demonstrated following administration. 
 
1.17 Clinical Trials 
To date there have been few successful clinical trials on patients with IPF, it 
should be noted however that the endpoints of a successful phase III trial are not 
consistent between trials as they have not been officially standardised (Table 1.1).  The 
principle endpoints commonly used are based on how a patient feels, functions, and 
survives.  Mortality is the most robust endpoint but can be measured in 3 different 
ways, namely, “all cause” mortality, respiratory-related mortality, or IPF-related 
mortality.  “All Cause” mortality encompasses all outcomes resulting in death of the 
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patient and is a more useful endpoint as it accounts for any secondary reactions to the 
drug being tested.  
 Some of the most common methods for recording function are, forced vital 
capacity (FVC), the diffusion of carbon monoxide (D˪CO), and the “6 minute walk 
test” which measures the distance the patient can walk in 6 minutes.  The results from 
these and other pulmonary tests are compiled into a composite physiologic index 
(CPI), an overall score of pulmonary function.  While this information is useful it does 
not give an accurate indication as to how the patients manage day to day tasks.  A set 
of more robust and standardised endpoints would greatly improve quality of the 
clinical trials being conducted (Raghu et al., 2012b). 
N-Acetylcysteine (NAC) is a precursor to the anti-oxidant glutathione, it has 
been studied as a protective agent in bleomycin models of fibrosis, abrogating the 
destructive effect of oxidant/antioxidant imbalance in lung alveolar epithelial cells 
(Kinnula et al., 2005).  The IFIGENIA study was a placebo controlled double blind 
study involving NAC as part of a combined therapy with azathioprine and prednisone.  
The study followed 155 patients for 1 year with primary endpoints being, FVC, D˪CO 
and CPI.  The results significantly favoured the combination therapy that included 
NAC over the azathioprine and prednisone alone, although the difference was 
moderate and there was a large drop-out rate (Demedts et al., 2005).  A follow on 
study PANTHER-IPF explored the combination therapy against NAC treatment alone, 
however after recommendation from the safety committee the combination therapy 
was abandoned as there was a higher mortality rate when compared to the placebo.  
The NAC alone groups are still being followed however to date not enough data exists 
to determine its efficacy as a standalone treatment (Raghu et al., 2012a).   
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 One of the more recent trials to take place was the CAPACITY trial of the 
anti-fibrotic drug Pirfenidone.  Studies of the drug demonstrated an ability to inhibit 
the transcription of TGFβ by up to 33% in a bleomycin model of fibrosis, it also 
inhibits the translation of TNFα resulting in reduced fibroblast proliferation and 
collagen deposition in vivo (Iyer et al., 1999, Nakazato et al., 2002).  The phase III 
double blind clinical trial was separated into 2 groups 004 and 006, the difference 
being the dose of Pirfenidone received.  Group 004 contained 435 patients who 
received a daily dose of either a placebo or Pirfenidone in a 2:1:2 ratio for 72 weeks, 
group 006 received a 1:1 dose of Pirfenidone.  The primary endpoint of the study was 
a change in FVC.  After 72 weeks patients in group 004 showed a statistically 
significant change in predicted FVC levels, however group 006 failed to meet the 
primary endpoint.  Pirfenidone was well tolerated with few reported adverse events 
and those reported were mild to moderate in severity (Noble et al., 2011).  These 
results suggest Pirfenidone could be a potential candidate for IPF treatment, further 
study is being carried out in the US in the ASCEND trial to determine a clinically 
meaningful effect on FVC (Rafii et al., 2013). 
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Table 1.1 List of clinical trials in fibrosis. 
Name Drug Target Details Outcome 
Imatinib 
Tyrosine kinase 
inhibitor PDGFR 
A&B 
119p  96w 
Good time to onset, Bad 
DlCO, absolute change in 
FVC, and the distance 
walked using a 6-minute 
walk test 
IFNγ1β 
(INSPIRE) 
IFNγ1β 826p  48w 
Trial halted at 64 weeks, as 
failed to meet min benefit to 
mortality ratio compared to 
placebo 
Pirfenidone 
(CAPACITY) 
Regulate TGFβ 
and TNFα 
Study 004:           
435p  72w  
Study 006:         
344p  72w 
004: Significant reduction in 
FVC decline. 
006: Failed to meet primary 
endpoint 
Bosentan         
(Build 1-3) 
Endothelin A&B 
Receptor 
Antagonist 
Build 1: 
158  1y 
Build 3: 
616p  1y 
Build 1: No significant 
positive result for survival, 
but there was a trend towards 
prolonged survival 
Build 3: Failed to meet 
primary endpoint, a measure 
of time to worsening of IPF 
or death. 
Ambrisentan 
(ARTEMIS-IPF) 
Endothelin A 
Receptor 
Antagonist 
492p  34w 
Terminated due to low 
likelihood of demonstrating 
efficacy, along with 
increased risk of pulmonary 
hospitalisation 
N-Acetylcysteine 
(IFIGENIA) 
Reduces free 
radicals 
182p  1y 
No improvement in survival 
but significantly delayed 
onset of FVC deterioration. 
Etanercept 
TNFα Receptor 
antagonist 
88p  48w 
No difference in endpoints 
vs placebo (FVC, D˪COHb, 
P(a–a)O2) 
Sildenafil         
(STEP-IPF) 
Pulmonary 
vasodilation 
180p  12w 
Failed to meet primary 
outcome of 20% increase in 
6 minute walk test. 
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1.18 Cell therapy 
The use of MSC in cell therapy has become increasingly popular in the last 
number of years, and is gaining momentum.  In 2010 there were 63 ongoing clinical 
trials involving MSC and 23 completed (Ankrum and Karp, 2010), in 2013 a search 
of clinicaltrails.gov returned 338 trials involving MSC, 202 of which were still open.  
A range of diseases are currently being examined including myocardial infarction 
(MI), graft versus host disease (GvHD) and chronic obstructive pulmonary disease 
(COPD) to name but a few (Hare et al., 2009, LeBlanc et al., 2008, Mills, 2009).  
There have been varying levels of success but one of the most promising aspects of 
MSC as a cell therapy is how well received they are by the recipient.  Procyhmal, A 
proprietary MSC based cell therapy product developed by Osiris Therapeutics tested 
in patients with MI, reported very few adverse reactions following human MSC 
administration (Hare et al., 2009). 
. 
1.19 MSC in fibrosis 
MSC have previously been examined for their potential benefit in treating 
fibrosis, a wide variety of in vitro and in vivo publications have demonstrated their 
efficacy however the reason behind the pathological and immunological 
improvements observed are still unclear. 
MSC have been used to demonstrate the importance of chemotaxis, 
engraftment (Ortiz et al., 2003, Rojas et al., 2005) and cytokine production (Ortiz et 
al., 2007, Maher et al., 2010, Mizuno et al., 2005) in preventing bleomycin induced 
pathology, however there is still much unknown about how they function.  In 2003 
Ortiz and Gamelli et al. pursued the theory that intravenous administered MSC travel 
to the lung and can engraft at the site of damage.  Using the bleomycin model in female 
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C57BL/6 mice he administered male BALB/c MSC and after 14 days the lungs were 
examined by PCR and fluorescent in situ hybridization (FISH) for presence of the Y 
chromosome.  They discovered that there was an increase in male DNA at the site of 
bleomycin induced injury, they also detected male DNA in type II alveolar epithelial 
cells suggesting the MSC were engrafting and differentiating into epithelial cells.  
Reduced collagen deposition and MMP 2 and 9 expression indicated that MSC are 
involved in preventing excess extracellular matrix build-up (Ortiz et al., 2003).  
Though it is possible some MSC may engraft or simply become stuck in the lung 
architecture, it is now widely believed that MSC function through paracrine means 
and are cleared from the body after they become activated.  Experiments using whole 
bone marrow fractions were not as effective at reconstituting the lung epithelium 
indicating high numbers of purified MSC are required for cell therapy (Kotton et al., 
2005).  In the case of epithelial damage, MSC are known to interact with macrophages 
in the mound bed, MSC attract pro-inflammatory M1 macrophages to deal with the 
initial insult (Chen et al., 2008).  Further MSC can repolarise the M1 cells to anti-
inflammatory M2 macrophages (Maggini et al., 2010), which promote wound healing, 
thus combining immunomodulatory properties with repair. 
 
1.20 MSC Cytokine Influence on Pathogenesis 
MSC release of certain cytokines may play an important role in the benefits 
observed from MSC therapy.  As previously discussed there are many ongoing trials 
involving cytokine treatment for IPF, two such cytokines, produced by MSC are 
hepatocyte growth factor (HGF)  and PGE2.   
HGF is paracrine growth factor involved in growth proliferation and migration 
of epithelial and endothelial cells, its primary function being tissue repair (Matsumoto 
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and Nakamura, 1993).  As early as 1997, Yaekashiwa and colleagues demonstrated 
the positive effect that administration of HGF exerted on bleomycin induced fibrosis.  
This study showed a reduction in pathology and collagen deposition following 
immediate and delayed administration (Yaekashiwa et al., 1997).  HGF treatment also 
encouraged the proliferation of epithelial cells both in vitro and in vivo (Dohi et al., 
2000).  HGF interaction with its receptor, c-met, on the surface of myofibroblasts 
resulted in increased production of MMP2 and MMP9, which in turn reduced collagen 
levels and encouraged myofibroblasts apoptosis (Mizuno et al., 2005).  Further 
evidence of the importance of HGF in IPF was demonstrated by Phin et al. when 
examining the difference in pro-HGF and HGF levels in bleomycin treated mice.  
Activation of HGF from pro-HGF is achieved through the actions of the serine 
protease HGF activator (HGFA), following bleomycin administration the ability of 
lung BAL fluid to activate pro-HGF diminished, along with mRNA expression of 
HGFA (Phin et al., 2010).   
PGE2 is a lipid mediator of growth and repair in the lung, acting as an anti-
inflammatory agent.  In vitro studies have shown PGE2 produced by lung alveolar 
epithelial cells had an inhibitory effect on the proliferation of fibroblasts (Moore et al., 
2003).  PGE2 was also shown to inhibit the TGFβ driven differentiation of fibroblasts 
to myofibroblasts, an effect mediated through the E prostanoid receptor 2 (Kolodsick 
et al., 2003).  Bronchial epithelial cells taken from the lungs of IPF patients express 
significantly lower levels of PGE2 further supporting the beneficial effects of PGE2 
signalling in lung fibrosis.  In vivo studies using PGE2 in bleomycin treated mice 
demonstrated a positive effect on lung pathogenesis and cellular infiltration when 
administered 7 days prior to bleomycin treatment, PGE2 administered 14 days after 
bleomycin had no therapeutic effect.  These results suggested a role for PGE2 in 
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dampening down early inflammation, and preventing activation of fibroblasts, 
however when given retrospectively PGE2 has no effect on reversing the existing 
damage (Dackor et al., 2011).  The limitations of the bleomycin model become 
apparent when comparing results from animal and human studies of PGE2 treatment.  
Fibroblasts from patients with IPF display resistance to Fas mediated apoptosis, 
contributing to higher fibroblast presence associated with the disease.  Administration 
of PGE2 increases susceptibility to FasL killing and conversely protects ACE cells 
from apoptosis, essentially opposing the effects of TGFβ signalling (Maher et al., 
2010). 
 
  
49 
 
1.21 Aims and Objectives 
This chapter has briefly introduced the potential of cellular therapy in the future 
treatment of an array of diseases.  At the forefront of this is the capacity of MSC to 
serve as a therapeutic in the treatment, not only of inflammatory disease but also in 
regenerative medicine.  Modulation of immune cells and trophic manipulation of the 
microenvironment are key characteristics of MSC that can be exploited for therapeutic 
intervention.  The goal of this work is to further our understanding, not just of what 
MSC can accomplish but how they achieve it.  The hypothesis put forward in this 
study is that MSC, through cell education and trophic manipulation can serve as a 
viable candidate for cellular therapy, with particular focus on pulmonary fibrosis.  This 
hypothesis was tested under the following aims: 
1. To discover the contact dependent signal through which murine MSC 
modulate immune cells, namely T cells and DC. 
2. To determine the effects of MSC paracrine signalling on pulmonary cells, 
with an aim to examine MSC mechanisms of action in vivo. 
3. To refine the bleomycin murine model of fibrosis to more accurately 
represent therapeutic intervention, consequently using this model to 
determine MSC efficacy as a cellular therapy in fibrosis. 
4. To utilise platform technologies such as neutralising antibodies, siRNA, 
and shRNA to investigate potential key mechanisms of action in MSC 
inhibition of inflammation and fibrosis. 
Overall this study will advance the understanding of MSC function in vitro and in vivo.  
It will also offer greater understanding of therapeutic in vivo screening, with particular 
emphasis on bleomycin induced fibrosis.   
  
50 
 
 
 
 
 
Chapter 2 
Materials & Methods 
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2.1  METHODS 
 
2.2  ETHICAL APPROVAL 
All procedures involving animals were carried out by licensed personnel.  
Ethical approval for all work was received from the ethics committee of NUI 
Maynooth. Licence number B100/2562. 
 
2.3 COMPLIANCE WITH GMO AND SAFETY GUIDELINES 
 All GMO/GMM work was performed according to approved standard 
operation procedures and recording protocols approved by the Environmental 
Protection Agency (Ireland).  Safe working practices were employed throughout this 
study as documented in the Biology Department of Safety manual NUI Maynooth. 
 
2.4 ANIMAL STRAINS 
The following mouse strains were used: BALB/c, C57BL/6 (Harlan, Bichester, 
Oxon, UK), BALB/c-Tg(DO11.10)10Loh/J (Gift from Trinity College Dublin) and 
eGFP FoxP3 Knock-in  (Jackson Labs, Bar Harbour, Maine, USA).  All mice were 
housed according to the Dept. of Health (Ireland) guidelines and used with ethical 
approval.  Sample sizes for animal experiments were determined by statistical power 
calculations.   
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2.5 ISOLATION AND CULTURE OF CELLS 
2.5.1  ISOLATION AND CULTURE OF ADULT MURINE MESENCHYMAL STEM CELLS 
(MMSC)  
 6-8 week old female BALB/c or C57BL/6 mice were sacrificed by cervical 
dislocation.  Femurs and tibias were dissected and the surrounding muscle removed.  
The ends of each bone were removed and the bone marrow was flushed into a sterile 
Petri dish using a 27 gauge needle and either Complete Isolation Media (CIM) (Table 
2.1), or Mesenchymstem (PAA, GE Healthcare, NJ, USA) media supplemented with 
100 U/ml penicillin.  Cell aggregates were disrupted using a 19 gauge needle and 5 ml 
syringe.  Cells were then centrifuged at 400 g for 5 min and re-suspended in 5 ml CIM.  
Bone marrow cells were counted by ethidium bromide/acridine orange (EB/AO) 
viable staining (section 2.6) and seeded at a concentration of 6.0-6.5 × 107 cells in T75 
flasks in 15ml of CIM or complete mesenchymstem or 2.0-2.5 × 107 cells in T25 flasks 
in 8 ml of CIM or complete mesenchymstem.   
 Non-adherent cells were removed after 3 hours, the flasks were washed with 
sterile PBS after 24 and 48 hours.  Cells were maintained in either hypoxic (5% O2) 
or normoxic (21% O2) conditions in 5% CO2 at 37C for 2-3 weeks until colonies of 
fibroblast like cells developed.  Cells were passaged by trypsinisation with 0.25 % 
(v/v) trypsin / 1 mM EDTA (Invitrogen-Gibco) for 2 minutes at 37C.  Trypsin was 
neutralised by addition of CIM and cells were centrifuged at 400 g for 5 min.  Cells 
(passage 1) were counted and  re-seeded at 5-6 × 106 cells in T75 flasks or 1-2 × 106 
cells in T25 flasks in fresh CIM or mesenchymstem media.  Media were replaced every 
3-4 days.  At passage 2 cells were changed to complete αMEM (CEM) (Table 2.1).  
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CEM was replaced every 3-4 days.  At passage 3 cells were characterised before use 
in vitro or in vivo.   
 
2.5.2 GENERATION OF STABLE KNOCKDOWN MSC CELL LINES 
2.5.2.1 LIQUID CULTURE OF PLASMID  
Five Jagged-1 and HGF short hairpin RNA (shRNA) plasmids were designed 
and purchased from Open Biosystems (Thermo), they were expressed in the lentiviral 
vector pGIPZ.  10µl of the glycerol stocks were thawed and added to 5 ml of 2X LB 
Broth (low salt) supplemented with peptone and yeast extract (Table 2.3) in a 15ml 
polypropylene tube.  The tubes were incubated at 45° angle at 37 °C for 16 h with 
vigorous shaking (300 rpm).  The antibiotic carbenicillin (Merck Millipore, 
Darmstadt, Germany) was added to the liquid culture to select for E.  coli containing 
the pGIPZ vector which infers antibody resistance.   
 
2.5.2.2 MINIPREP EXTRACTION OF PLASMID DNA 
 Vector DNA was extracted from bacteria using a Qiagen HiSpeed Plasmid 
Midi and Maxi Kit (Qiagen) according to the manufacturer’s instructions.  5 ml of 
overnight bacterial culture were harvested by centrifugation at 4500 x g for 20 min at 
4oC.  The supernatant was removed and the pellet was re-suspended in 0.3 ml Buffer 
P1 (Qiagen).  0.3 ml Buffer P2 (Qiagen) was added and mixed vigorously.  The 
samples were incubated at RT for 5 min and 0.3 ml of chilled Buffer P3 (Qiagen) was 
added.  The solution was mixed vigorously and incubated on ice for 5 min.  The lysate 
was then transferred into a 1.5ml eppendorf and centrifuged at 14000 g for 10 min.  
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The supernatant was removed and transferred to a Qiagen-tip 20 that was equilibrated 
with 1ml of buffer QBT.  The supernatant was allowed to empty by gravity flow and 
the tip was washed twice with 2 ml of buffer QC.  The DNA was eluted from the tip 
using 0.8 ml buffer QF.  The DNA was precipitated by adding 0.56 ml of isopropanol 
and centriguged at 12000 g for 30 min.  The supernatant was removed and the 
remaining DNA pellet was washed with 70% ethanol and centriguged at 12000 g for 
10 min.  The supernatant was removed and the pellet allowed to air dry for 5 min.  The 
pellet was re-suspended in 50µl of TE buffer, the DNA yield was determined using a 
Nanodrop 2000 spectrophotometer (ThermoScientific, Wilmington, DE, USA) at 260 
nm. 
 
2.5.2.3 PRODUCTION OF LENTIVIRAL PARTICLES IN HEK CELLS 
HEK293T (HEK) (cells were a gift from Prof.  Paul Moynagh) cells were used as a 
packaging cell line and were split 1:2 each day for 3 days prior to transfection in order 
to ensure active division during transfection.  HEK cells (1.5x106) were plated in a T-
75 flask in complete DMEM (Table 2.1) and left to settle overnight.  Next 1.8µg of 
the Jagged-1 or HGF plasmid DNA was added to 6µl of the packaging plasmid Trans-
Lentiviral packaging mix (Open Biosystems) and brought up to a final volume of 
480µl with serum free DMEM (High glucose, Sigma) then incubated at room 
temperature (RT) for 20 min.  The transfection reagents, Gene Juice (Merck, 
Millipore), TransIT-LT1 or TransIT-293 (Mirus Bio LLC, Wisconsin, USA) were 
brought up to RT, 21µl of transfection reagent was added to the plasmid mix and 
incubated at RT for a further 10 min.  Following incubation the transfection 
reagent:DNA complex mixture was added drop wise to 7mls of serum free DMEM in 
the HEK flask.  After 24h transfection the HEK cells were switched to 30% FBS, 48h 
55 
 
after transfection the supernatant containing the Jagged-1 or HGF lentivirus was 
collected.  BALB/c MSC were seeded at 1x106 cells in a T-75 flask and allowed to 
settle overnight.  The cells were then transduced with 6 ml of viral medium and 6 ml 
of CEM for 72h.  At this point 4µg/ml puromycin was added to the MSC media to 
positively select the cells that had been successfully transfected.   
 
2.5.3 DENDRITIC CELL ISOLATION AND CULTURE 
 6-8 week old female BALB/c or C57BL/6 mice were sacrificed by cervical 
dislocation.  Femurs and tibias were removed intact under aseptic conditions as 
described in section 2.3.1.  Bone marrow cells were counted and seeded at a 
concentration of 6 × 106 cells per 10cm non-tissue culture grade Petri dish (Falcon 
BD) in 10 ml cRPMI supplemented with 20 ng/ml Granulocyte Macrophage-Colony 
Stimulating Factor (GM-CSF) (PeproTech, Rocky Hill, NJ).  On day 3, non-adherent 
cells were removed and 10 mls of fresh cRPMI supplemented with 20 ng/ml GM-CSF 
was added to each dish.  On day 6, 10 ml of fresh cRPMI supplemented with 20 ng/ml 
GM-CSF was added.  After 8 days, cells were harvested by gentle aspiration and 
centrifuged at 300 g for 5 min.  Cells were re-suspended in cRPMI (Table 2.1) and 
counted.  Cells were seeded at appropriate concentrations relevant to experimental 
assays.   
 
2.5.4 MURINE SPLENOCYTE ISOLATION 
Murine spleens were aseptically dissected into cRPMI (Table 2.1).  Spleens 
were homogenised through a 70 µm filter and the homogenate was centrifuged at 300 
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g for 5 min and re-suspended in 2 ml of red blood cell lysis buffer solution (BioLegend, 
San Diego, CA,) for 2 min on ice.  30 ml of cold PBS was added to the suspension to 
neutralise the lysis solution which was then centrifuged at 300 g for 5 min.  
Supernatant was removed and the cells were then re-suspended in fresh cRPMI and 
counted.   
 
2.5.5 T CELL ISOLATION 
CD3+ T cells were isolated using MagCellect CD3+ T cell isolation kit 
according to manufacturer’s instructions (R & D Systems, Minneapolis, MN).  Briefly, 
splenocytes were re-suspended in 1X MagCellect buffer to a cell density of 1.0 × 108 
cells/ml.  For every 1 × 107 cells processed, 10 μl of CD4+ T cell biotinylated antibody 
cocktail was added and cells incubated for 15 min at 4 ˚C.  Following incubation, 12.5 
μl of streptavidin ferrofluid per 1 × 107 cells was added and further incubated for 15 
min at 4 ˚C.  Following the incubations, the cell suspension was brought up to 3 ml 
with MagCellect buffer.  The tubes were placed into a magnetic stand twice for 6 min 
at RT.  The magnetically labelled cells migrated towards the magnet, leaving the 
desired CD3+ T cells behind in suspension.  The CD3+ T cell suspension was 
centrifuged at 300 g for 5 min then re-suspended in cRPMI and counted.  CD4+ T cells 
were isolated using MACS bead technology (Miltenyi Biotec, Surrey, United 
Kingdom).  Splenocytes were re-suspended in MACS buffer (Table 2.2) at a 
concentration of 1x107 cells/90µl.  Next 10µl of CD4+ MACS beads were added to the 
cell suspension and incubated at 4 degrees for 15 min.  Following incubation cells 
were centrifuged at 300 x G for 10 min then re-suspended in 1ml of MACS buffer and 
passed through an LS column by gravity flow.  The beads are removed from the 
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column by adding 5 ml of MACS buffer and forcefully inserting a plunger and 
collecting the resulting flow through.  Cells are centrifuged at 300 x G for 5 min and 
re-suspended in cRPMI and counted. 
 
2.6 ISOLATION OF PRIMARY LUNG FIBROBLASTS 
Primary lung fibroblast were isolated from female C57BL/6 mice which were 
sacrificed by intraperitoneal injection of pentabarbitone.  The lungs were washed by 
perfusion with PBS and sterilely excised.  The lungs were filled intratracheally with 
pre-warmed trypsin solution (40mg trypsin in 10ml Ca/Mg+ solution) and incubated 
for 15min at 37°C. The lungs were then diced and the trypsin neutralised with FBS 
(1ml/lung). The tissue was transferred to a 50ml tube and a DNase I solution (6.25mg 
DNase in 25ml in 10ml Ca/Mg- solution) was added and shook firmly by hand for 4 
min after which it was passed through a 100µm filter and then a 40µm filter. The cell 
suspension was centrifuged at 60xG for 6 min in a bench top centrifuge and the pellet 
re-suspended in DNase II solution (2.5mg DNase in 50ml in 10ml Ca/Mg- solution), 
then spun again and re-suspended in differential attachment medium (Table 2.1).  The 
cell suspension was plated into a 10cm non-tissue grade petri dish and incubated for 
1hr at 37°C during which time, fibroblasts and macrophages adhere to the surface of 
the petri dish.  Non-adherent cells are removed and the adherent cells allowed to reach 
confluence in fibroblast media. Fibroblasts were isolated from macrophages through 
selective passaging with 2min trypsin washes. At passage 2 the cells were 
characterised and stocks frozen in liquid nitrogen. Primary fibroblast were used in 
experiments up to passage 5. 
2.6 MEASUREMENT OF CELL VIABILITY (FLUORESCENT MICROSCOPY)  
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Cells were re-suspended in their specific growth media and diluted 1/10 in 2 % (w/v) 
ethidium bromide/acridine orange (EB/AO) (Sigma-Aldrich, Arklow, Ireland).  10 µl 
was pipetted onto a haemocytometer and live cells (green) were counted using a 
fluorescent light microscope.   
 
2.7 CHARACTERISATION OF MSC  
2.7.1 CHARACTERISATION OF MSC AND GENERAL FLOW CYTOMETRY 
For analyses by flow cytometry, cells (MSC, DC or CD4+ T cells) were harvested, 
washed in sterile PBS and re-suspended in PBS supplemented with 10 % BSA (heat 
inactivated bovine serum albumin) to yield approximately 1 x 105 cells/FACS tube (4 
ml polypropylene tubes) (Falcon, BD Biosciences).  Fluorochrome conjugated 
antibodies (Tables 2.4 & 2.5) or isotype controls were incubated with cells for 15 min 
at 4 C.  After 15 min, cells were washed in 2 ml of PBS supplemented with 10 % 
BSA, vortexed and centrifuged at 300 g for 5 min.  The supernatant was removed and 
cells re-suspended in 200 l PBS supplemented with 10 % BSA or 300 l of cell 
fixative (PBS supplemented with 1 % (v/v) paraformaldehyde (PFA) (Sigma-
Aldrich)).  Cells were then analysed by flow cytometry (FACS Calibur, FACS Accuri, 
California, USA) using CellQuest or CFlowPlus software respectively (BD 
Biosciences, Oxford, UK).   
 
2.7.2 MIXED LYMPHOCYTE REACTION 
 Freshly isolated murine splenocytes from two MHC mismatched strains were 
co-cultured in a two-way MLR at a density of 2 x 105 cells/well in a 96-well tissue 
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culture plate in 225 µl final volume.  MSC effect on lymphocyte proliferation was 
assessed by adding MSC to the MLR at a density of 1.5 x 104 cells/well.  The mitogen 
Concanavalin A (Con A) was used at a concentration of 5 µg/ml as a positive control.  
The 96 well plate was incubated at 37 °C for 72 h after which 0.5 µCi/ml of [3H]-
Thymidine (Perkin Elmer, MA, USA) was added for the final 6 h of culture.  Cells 
were harvested using a Micro96 Harvester (Skatron Flow Laboratories, Oslo, Norway) 
onto 96 well glass fibre filter mat.  The mats were then dried and placed in a plastic 
sample bag, 4ml of β-scintillation fluid (Beta-Plate Scint, Perkin Elmer, MA, USA) 
was added and the dispersed evenly throughout the filter mat, the bag was sealed and 
placed in a cassette.  [3H]-Thymidine uptake was measured using a β-scintillation 
counter (1450 MICROBETA Liquid Scintillation Conter, Wallac-Perkin Elmer).  
Results were expressed in counts per minute (CPM). 
 
2.7.3 DIFFERENTIATION OF MSC 
MSC were seeded at a density of 5 x 104 cells/well in a 6-well tissue culture 
plate in 2 ml CEM for osteogenic and adipogenic differentiation, or 2x105 cells are 
centrifuged in a 15ml falcon tube at 200 g for 8 min to form a cell pellet for 
chondrogenic differentiation.  Once 70 % confluence was reached (typically 2-3 days), 
cells were incubated in osteogenic, adipogenic or chondrogenic differentiation 
medium (Table 2.1), CEM media was added to control wells.  Fresh medium was 
added every 3-4 days for 21 days.  At day 21, the medium was removed from the bone 
and fat cultures and the cells were washed in PBS and then fixed in 10 % (v/v) neutral 
buffered formalin for 20 min at room temperature.  Formalin was removed and cells 
were washed in 2 ml of PBS.  1 ml of 1 % Alizarin Red, or 0.5 % Oil Red O (Table 
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2.2) was added to the fixed bone or fat cells and allowed to stain for 20 min at RT.  
Excess stain was removed and the cells were washed with dH2O.  Finally, 1 ml of 
dH2O was added to each well and cells were examined under the microscope.  The 
chondrocyte cell pellets were harvested by aspirating off all the media and washing 
pellets twice with PBS.  Pellets were placed in 1 ml of trizol and stored at -20◦C.  
Chondrocyte pellets were analysed for the expression of collagen II and aggrecan by 
RT-PCR (Table 2.7 & 2.8).  Briefly, RNA was isolated from the pellets (section 2.9.1), 
reversed transcribed into cDNA (section 2.9.3) and the expression of chondrocyte 
markers were analysed by RT-PCR (section 2.15).   
 
2.8 CELL SORTING 
 CD3+ T cells were isolated as described in section 2.5.4.  Fluorescently labelled 
antibodies for CD3, CD4, and CD25 (Table 2.3) were added to the cells and incubated 
for 15 min at 4 °C.  Following incubation the cells were washed with PBS 
supplemented with 1% FBS and centrifuged at 300 g for 5 min, the cells were re-
suspended in PBS supplemented with 1% FBS at a concentration of 1x107 cells/ml 
and sorted into CD4+CD25+FoxP3-GFP+ and CD4+CD25-FoxP3-GFP- populations 
using the ARIA cell sorter (BD Biosciences).  The cell sorter was set up for aseptic 
sort according to manufactures guidelines and calibrated for sorting using Accudrop 
beads (BD Biosciences).  The sorted populations were aseptically collected in 15 ml 
falcons containing 500µl of FBS and centrifuged at 500 g for 5 min.  The cells were 
counted, prior to use a small sample of both populations were analysed for purity by 
running them through the flow cytometer. 
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2.9 MSC CO-CULTURE WITH CD4+ T CELLS 
CD4+ T cells were isolated as described in section 2.5.4 and cultured in the 
presence or absence of MSC for 24 or 72 h.  The seeding densities used were, 1 x 105 
MSC: 3 x 105 CD4+ T cells in 24 well plate or 3 x 105 MSC: 1 x 106 CD4+ T cells in 
6 well plate.  The expression of notch receptors (Notch 1 & 2), and Notch ligands 
(Jagged 1, 2 & Delta like ligand 1) (Table 2.3) were analysed by RT-PCR after 24 h 
(Table 2.4).  Expression of CD25 and the transcription factor FoxP3 were examined 
after 72 h by flow cytometry, CD4+ T cells isolated from FoxP3-GFP mice were 
genetically manipulated to express the GFP protein at the promoter region of the 
FoxP3 gene.  When the gene is transcribed the nucleus of the cell fluoresces green and 
can be detected by flow cytometry.  For the neutralisation study, mouse anti-Jagged 1 
(5 µg/ml), mouse anti-notch-1 (10µg/ml) or corresponding control antibody was added 
to the co-cultures and the expression of CD25 and FoxP3-GFP were analysed by flow 
cytometry (Table 2.4).  The Notch inhibitor, γ-secretase inhibitor (GSI) (Calbiochem, 
Merck, Germany) reconstituted in DMSO (Sigma-Aldrich), was added to CD4+ T 
cells: MSC at a concentration of 1 µM co-cultures for 72 h and the expression of CD25 
and FoxP3-GFP were analysed by flow cytometry. 
 
2.10 MSC CO-CULTURE WITH DC 
Immature DC were harvested on day 8 (section 2.5.3) and matured in the presence of 
lipopolysaccharide (LPS) (Sigma-Aldrich) at 100 ng/ml for 24 or 48 h in the presence 
or absence of MSC.  The seeding densities used were, 1 x 105 MSC: 3 x 105 DC in 24 
well plate for 24 h YAe analysis or 3 x 105 MSC: 1 x 106 DC in 6 well plate for 48 h 
flow cytometry analysis.  After 48 h, the maturation markers MHCII and CD86 (Table 
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2.4), and corresponding isotype controls were analysed by flow cytometry on DC.  For 
the YAe study 10 µg/ml I-Eα peptide 52-68 (ASFEAQGALANIAVDKA) (Anaspec, 
San Jose, CA) was added to the DC for 24 h in the presence or absence of MSC, as a 
control, DC were cultured with MSC alone.  Peptide binding was detected by flow 
cytometry using an anti-I-Ab: Eα complex specific antibody, Y-Ae (eBioscience).  In 
some experiments, the Notch inhibitor, γ-secretase inhibitor (GSI) (Calbiochem, 
Merck, Germany) reconstituted in DMSO (Sigma-Aldrich), at 1 µM was added to DC: 
MSC co-cultures for 48 h and the expression of maturation markers were analysed by 
flow cytometry. 
 
2.11 TOLEROGENIC DC FUNCTIONAL ASSAY 
 Immature DC were harvested on day 8 (section 2.5.3) and matured in 
the presence of ovalbumin (OVA) (Sigma-Aldrich) at 20µg/ml for 48 h in the presence 
or absence of MSC at a density of 3 x 105 MSC: 1 x 106 DC in 6 well plate.  After 48 
h, a fraction of the cells were analysed for the maturation markers MHCII and CD86 
(Table 2.4), and corresponding isotype controls by flow cytometry.  The remaining 
DC were washed with PBS and co-cultured with CD4+ T cells and plated in a 96 well 
plate at a density of 2 x 105 DC: 8 x 105 CD4+ T cells.  The cells were cultured for 72 
h after which 0.5 µCi/ml of [3H]-Thymidine (Perkin Elmer, MA, USA) for the final 6 
h.  The cells were harvested as described in section 2.7.2 and proliferation was 
measured by [3H]-Thymidine uptake using a β-scintillation counter (1450 
MICROBETA Liquid Scintillation Conter, Wallac-Perkin Elmer).  Results were 
expressed in counts per minute (CPM). 
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2.12 RNA ISOLATION 
Total RNA was extracted using trizol® reagent (Invitrogen) according to the 
manufacturer’s instructions.  Briefly, 1 x 106 cells were lysed in 1ml trizol at room 
temperature for 5 min.  100 µl of RNA-grade 1-Bromo-3-chloropropane (Sigma-
Aldrich) was added to the cells, vortexed for 10 sec and incubated at room temperature 
for 5 min.  Samples were centrifuged at 12,000 g for 15 min at 4 °C.  Two distinct 
layers resulted with RNA remaining in the clear, aqueous upper layer.  350-400 µl of 
RNA was carefully removed, ensuring the lower white DNA layer was not disturbed, 
and precipitated with 500 µl isopropanol (Riedel-deHaen).  The samples were 
incubated at room temperature for 10 min followed by centrifugation for 10 min at 4 
°C.  The resulting RNA pellet was washed with 1 ml 75 % (v/v) ethanol and 
centrifuged at 7,500 g for 5 min at 4 oC.  The ethanol was aspirated and the RNA pellet 
was allowed to briefly air dry prior to resuspension in 30 μl RNase-free water 
(Promega, Southhampton, UK).  The purity and concentration of RNA was determined 
using a spectrophotometer (Nanodrop 2000, ThermoScientific, Wilmington, DE, 
USA) which calculated the ratio of absorbance at 260 nm to 280 nm.  A ratio between 
1.8 and 2.0 indicated sufficient purity of the RNA.  Samples outside this range were 
discarded.   
 
2.13 DNASE TREATMENT OF RNA  
 Genomic DNA was removed from RNA samples by treatment with DNase I 
(Invitrogen, Paisley, UK).  1 μl of DNase (Amplification grade) was added to 1 µg of 
RNA and incubated for 15 min at room temperature.  1 μl of 25mM EDTA (Promega) 
was added to the mixture and incubated at 65◦C for 10 min to inactive the enzyme.   
64 
 
 
2.14 CDNA SYNTHESIS  
Following DNase treatment, total RNA was reverse transcribed using 25 Units 
Superscript II (Invitrogen).  Each reaction contained a 1 x GoTaq reaction buffer 
(Promega), 2.5 mM MgCl2 (Promega) , 10 mM dNTP mix (Promega), 50 U/ml of 
ribonuclease inhibitor (Invitrogen) and 20 µg/ml Oligo (dT) 12-18 primer (Invitrogen)  
diluted in nuclease-free water (Promega).  The conditions for cDNA synthesis were as 
follows:, 42 oC for 50 min, 72 oC for 10 min and 4 oC for 10 min.  Quantification of 
cDNA was performed by measuring the absorbance value of the sample 260 nm.  
Samples were stored -20 oC until required.   
 
2.15 REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION (RT-PCR) 
 PCR was used to determine the presence of specific DNA sequences (or 
mRNA following reverse transcription) using primers summarised in Table 2.6 and 
2.7.  Expression of the housekeeping gene, Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a positive control.  PCR reactions contained 2.5 
mM MgCl2 (Promega), 25 mM dNTP (Promega), 1 x GoTaq reaction buffer 
(Promega), 40 U/ml Taq polymerase (Promega) and 0.4 pM of the appropriate primer 
pairs (Sigma).  The reaction mastermix was adjusted to a final volume of 24 µl with 
nuclease-free water.  The PCR conditions were as follows: denaturation at 95 °C for 
45 sec (2 min for first cycle), annealing for 45 sec (optimal annealing temperatures are 
summarised in Table 2.4 and extension for 45 sec at 72°C.  DNA products were 
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resolved on a 1.3 % w/v agarose gel and detected by binding of gel red (Biotium, 
Hayward, CA). 
 
2.16 REAL TIME-POLYMERASE CHAIN REACTION (QRT-PCR) 
 cDNA was analysed for the quantification of mRNA expression.  Briefly, 
cDNA (1µg) was amplified in the presence of SYBR® Green JumpStart™ Taq 
ReadyMix (Sigma).  Accumulation of gene-specific products was measured 
continuously by means of fluorescence detection over 40 cycles.  Each cycle consisted 
of: denaturation at 95 °C for 15 sec, annealing at optimum temperature (Table 2.4) for 
30 sec, and extension at 72 ◦C for 45 sec followed by a melt curve cycle of 95 °C for 
15 sec, 55 °C for 15 sec and 95 °C for a final 15 sec.  Expression was quantified in 
relation to the housekeeper GAPDH.  Quantification of target gene expression was 
obtained using an Eco Real-Time PCR System (Illumina, Inc.  San Diego, CA USA). 
 
2.17 SILENCING OF RNA (SIRNA) 
 MSC were seeded at 4 × 104/well in 24 well plates in duplicate until 
approximately 60% confluent.  siRNA for murine Jagged-1 was pre-designed 
(Silencer® Select siRNA, Applied Biosystems, Warrington, UK)  and diluted in 
RNase free water (supplied with kit)  to different concentrations, as per manufacturer’s 
instructions.  Lipofectamine (Invitrogen, Paisley, UK) was used as a transfection 
reagent for all siRNA experiments, as per manufacturer’s instructions.  MSC with or 
without siRNA were cultured in Opti-Mem®I media (Gibco-Invitrogen, Paisley, UK).  
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After 24 h, MSC RNA was isolated (Section 2.12) and transcribed into cDNA (Section 
2.14).  Murine Jagged-1 expression on MSC was examined by RT-PCR (Section 2.15). 
 
2.18 IMMUNOFLUORESCENCE 
 Cells were plated at appropriate seeding density on a poly-L-lysine (Sigma) 
coated well of a glass chamber slide (Labtec, Fisher).  Once cells reached the desired 
density the culture medium was removed and the wells washed with PBS.  Ice cold 
methanol was added to the wells and the cells placed at -20°C for 5 min.  Methanol 
was removed and the cells allowed to air dry for 20 min after which they were stored 
at -20°C or used immediately.  Following methanol fixation, the cells were 
equilibrated in 1X Tris buffered saline (TBS; Table 2.2).  Wells were blocked in TBS 
supplemented with 1% w/v BSA for 30 min at room temperature, and washed with 
0.1% TBST (Table 2.2).  Primary antibody was diluted to working concentrations 
(Table 2.3) in 1% BSA/TBS, cells were incubated overnight with primary antibody at 
4°C on a piece of moist tissue.  Wells were washed 3 times with 0.1% TBST for a total 
of 10 min.  Secondary antibody (Table 2.3) was diluted in 1%BSA/TBS and incubated 
for 30 min at room temperature.  Wells were washed a final time in TBST and 
counterstained using 4′,6-Diamidino-2-phenyindole (DAPI) (Table 2.3) for 1 min and 
washed 3 times with water.  A cover slide was mounted onto Faramount aqueous 
mounting medium (Dako, Glostrup, Denmark) and fluorescence was examined using 
a Nikon Eclipse E600 flourescent microscope. 
 
2.19 SCRATCH ASSAY 
67 
 
 The underside of a 6 well plate was scored with 3 parallel lines using a safety 
blade.  Fibroblast or LA4 (lung alveolar epithelial cells) cells were plated a 
concentration of 1x105 cells/well and allowed to form a confluent monolayer 
overnight.  Using a P200 pipette tip (Sarstedt) a line was scratched down the centre of 
the well perpendicular to the 3 lines on the underneath of the plate.  The wells were 
washed with warm PBS to remove floating cells, fresh medium was added to all the 
wells and recombinant FGF or HGF to positive control wells at a concentration of 
10µg/ml.  Conditioned media (CM) collected from MSC plated in the appropriate 
media was concentrated using Amicon Ultra Centrifugal Filters (Merck-Millipore, 
Darmstadt, Germany), the resulting protein was added to designated wells.  The width 
of the scratch was measured using Photoshop (Adobe, San Jose, CA, USA) from 
images taken using an inverted light microscope, the lines scored on the bottom of the 
wells were used as an alignment guide.  The wells were observed daily, once the first 
well fully closed the cells were fixed with ice cold methanol for 5 min and stained 
with crystal violet for 10min.  The width of the scratch was measured from the same 
position and the resulted were graphed as a percentage of closure. 
 
2.20 PROLIFERATION ASSAY 
Fibroblasts or LA4 cells were seeded in a 24 well tissue culture plate (1 x 105 
cells/well) and allowed to form a confluent monolayer.  The cells were scratched with 
a P1000 pipette tip and washed with PBS to remove detached cells.  Fresh media was 
added to all the wells and FGF or HGF was added to fibroblast (10ng/ml) and LA4 
(10ng/ml) cultures respectively as a positive control.  MSC (1 x 105 cells/well) were 
plated in normal CEM and once settled they were washed and switched to LA4 or 
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fibroblast media.  The conditioned media (CM) was collected after 24 hours and 
concentrated using Amicon Ultra Centrifugal Filters before being added to the 
designated wells.  [3H]-Thymidine (Amersham Biosciences, Buckinghamshire, 
England) at 0.5 µCi/ml was added to each well and incubated at 37 °C 5 % CO2.  
Cultures were harvested after 3 days by removing the media and washing each well 3 
times with PBS.  The cells were lysed using 500µl of 1% sodium dodecyl sulphate 
(SDS, Sigma) and the lysate transferred to 3ml plastic counting tubes.  2 ml of β-
scintillation fluid (UltmaGold, Wallac-PerkinElmer) was added to each tube, 
vortexed, and placed in a 24 well cassette for reading.  [3H]-Thymidine incorporation 
was quantified by a β-scintillation counter (1450 Microbeta Liquid Scintillation 
Counter; Wallac-Perkin Elmer) and results were expressed in counts per minute (cpm).   
 
2.21 ELISA 
All ELISAs were carried out according to manufacturer’s instructions.  Specific 
capture antibodies (murine IFNγ, TNFα, IL-1β, TGFβ, IL-6 & HGF) in PBS were 
added to 96 well microtitre plates (NUNC) and incubated overnight at room 
temperature.  Plates were then washed 3 times in wash buffer (Table 2.2) and then 
incubated in blocking solution (Table 2.2) for a minimum of 1 h.  Plates were then 
washed and incubated with 100 µl/well of sample supernatant or corresponding 
cytokine standard for 2 h at room temperature.  After washing, plates were incubated 
with specific detection antibodies for a further 2 h at room temperature.  Plates were 
washed again and incubated with 100 µl/well of streptavidin horseradish peroxidase 
(HRP) (R & D Systems) conjugate diluted 1/200 in specific reagent diluent for 20 min.  
After washing, plates were incubated with 100 µl/well of tetramethylbenzidine (TMB) 
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substrate (Sigma-Aldrich) for 20 min at room temperature out of direct light.  The 
reaction was stopped after 20 min by adding 50 µl/well of 1 M H2SO4.  The absorbance 
(optical density (O.D)) of the samples and standards were measured at 450 nm for all 
ELISA using a plate reader (Labsystems, Helsinki, Finland).  The cytokine 
concentration of each sample was determined by comparison to the standard curve of 
known cytokine concentrations. 
 
2.22 PGE-2 SPECIFIC ELISA (ACE COMPETITIVE ENZYME IMMUNOASSAY) 
 The amount of PGE-2 produced by MSC in unstimulated or stimulated 
conditions was measured using a commercially available ELISA Kit from Cayman 
Chemical (Ann Arbour, MI, USA).  The PGE-2 assay is based on the competition 
between PGE-2 and PGE-2 acetylcholinesterase (AChE) conjugate (PGE-2 tracer) for 
a limited amount of PGE-2 monoclonal antibody.  The concentration of the PGE-2 
tracer is held constant, while the concentration of the PGE-2 varies.  Therefore the 
amount of PGE-2 tracer that can bind to the PGE-2 monoclonal antibody will be 
inversely proportional to the concentration of PGE-2 in the well.    ELISA were carried 
out according to manufacturer’s instructions.  The microplate (96 well polystyrene 
microplate) was pre-coated with goat anti-mouse polyclonal antibody.  Controls 
consisted of blank (Blk), nonspecific binding (NSB), maximum binding (B0), and total 
activity (TA which is analogous to the specific activity of a radioactive tracer) wells.  
100 l and 50 l of EIA buffer was added to Non-Specific Binding (NSB) wells and 
Miximum Binding (B0) wells respectively.  The standards and samples in triplicate 
and controls in duplicate (50 l) were added to the plate.  The PGE-2 AChE Tracer 
(50 l) was then added to all wells except the total activity (TA) wells.  50 l of PGE-
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2 monoclonal antibody was added to the appropriate wells (i.e.  all wells except TA, 
NSB and the Blk wells) and incubated at 4C for 18h with the plate covered.  
Ellmann’s Reagent was prepared fresh by reconstituting one vial of Ellman’s reagent 
with 20ml of ultrapure water.  After washing in wash buffer provided, 200 l of 
Ellman’s Reagent was added to each well and 5 l of tracer was added to the TA wells.  
The plate was covered with plastic film and allowed to develop protected from light 
while on an orbital shaker for 60-90 min.  The plate was checked periodically, until 
the B0 wells had reached a minimum absorbance (OD) of 0.3 with the blank 
subtracted, and read at an absorbance of 405 nm using a multiscan plate reader 
(LabSystems).  Calculations required that the average OD from the blank wells were 
subtracted from all OD.  The corrected maximum binding was then calculated by 
subtracting the NSB average from the B0 average.  Subsequently the % B/B0 (% 
sample or standard bound/maximum bound) was calculated for all remaining wells.  
A standard curve was then plotted of %B/B0 for standards versus PGE-2 concentration 
(pg/ml) on a semi-log scale.  The concentration of each sample was determined using 
a standard curve of known concentration and results were stated as mean concentration 
 SE.   
 
2.23 IN VITRO APOPTOSIS ASSAY 
Murine LA4 cells at 1 x 105/well of a 24 well plate were allowed to settle 
overnight.  The media was changed and replaced with 500µl of fresh cDMEM F:12 
and cultured in the presence or absence of 50ng/ml of TNFα (Peprotech, USA) with 
or without the addition of concentrated MSC CM proteins.  Briefly 500µl of CM from 
MSC, HGF knockdown MSC or non-silencing control MSC were transferred to a 
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Amicon Ultra centrifugal filter unit (Merck-Millipore, Darmstadt, Germany), and 
centrifuged at 14000 g for 20 min, the unit was then inverted into a fresh eppendorf 
and centrifuged again at 1000 g for 2 min.  The concentrated CM protein was collected 
and added to the designated wells.  The analysis of MSC induced apoptosis was 
analysed by flow cytometry.  As a positive control, a chemotherapy drug, cisplatin 
(Sigma-Aldrich) at 250 µg/ml was added to selected wells.  After 24 h, all LA4 cells 
were recovered from culture by trypsinisation with 0.25 % (v/v) trypsin / 1 mM EDTA 
and apoptosis was detected by the binding of Annexin V/Propidium iodide (PI) 
staining (eBioscience,).  Cells were washed in PBS and centrifuged at 300 g for 5 min, 
then re-suspended in 1 X binding buffer at a concentration of 1 x 106 cells/ml.  1 x 105 
cells (100 µl) were transferred to a 5 ml tube.  5 µl of Annexin V-FITC (0.5 mg/ml) 
and 5 µl of propidium iodide (PI) (20 μg/ml) (eBioscience) were added to each tube.  
Cells were gently vortexed and incubated for 15 min at room temperature in the dark.  
After 15 min, 400 µl of assay buffer (eBioscience) was added to each tube and 
analysed by flow cytometry within 1 h.   
 
2.24 BLEOMYCIN INDUCED MOUSE MODEL OF LUNG FIBROSIS 
A Bleomycin model of pulmonary fibrosis was developed and optimised from 
a protocol described by Ortiz et al.  (Ortiz, 1999).  C57BL/6 mice were administered 
4U/kg of Bleomycin by intranasal instillation.  The mice were lightly anaesthetised 
with gaseous isoflourine and 20µl of Bleomycin diluted in PBS was administered to 
the nostrils (i.n.) allowing the solution to be inhaled into the lungs.  Control groups 
were given 20µl of PBS.  MSC or NIH3T3 fibroblasts (4.4x104/g) were administered 
by intravenous injection to the tail vein using a 27 gauge needle and a 1 ml syringe 
either between 6 h and 8 h after i.n.  or 7 days later, PBS was injected as a negative 
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control.  Animals were returned to their cages where they were monitored closely for 
the first hour and at regular intervals thereafter for any signs of distress or ill health.   
 
2.25 ISOLATION OF LUNG TISSUE FROM BLEOMYCIN MOUSE MODEL 
 Lungs were removed aseptically and using a sterile forceps, and transferred to 
a petri dish and sectioned using a sterile scalpel.  The right lobes were divided between 
two 1.5 ml eppendorfs containing either 500µl of RNA Later (Qiagen) or Complete 
Protease Inhibitor Cocktail (Roche) and frozen.  The left lobe was fixed in 10% (v/v) 
formalin (Sigma-Aldrich) for histological analysis.  The tissue in RNA later was 
transferred to 1 ml of trizol and homogenised using a handheld homogeniser (IKA) 
and processed for PCR as described previously.  Similarly the lobe in protease 
inhibitor was homogenised and diluted into a total volume of 3 mls, the homogenate 
was centrifuged and the supernatant collected and used for analysis by ELISA. 
 
2.26 HISTOLOGY 
2.26.1  TISSUE PREPARATION  
Lungs were removed from experimental mice and processed for histology 
using an automated processor (Shandon Pathcentre, Runcorn, UK), which immerses 
the tissues in fixatives and sequential dehydration solutions, including ethanol (70%, 
80%, 95% x 2, 100% x 3) and xylene (x 2) (BDH AnalaR® Laboratory Supplies Poole, 
UK).  Tissues samples were then embedded in paraffin wax using the Shandon 
Histocenter 2 (Shandon) and left to set overnight at 4 °C.  5µm sections were cut using 
a microtome (Shandon Finesse 325, Thermo-Shandon, Waltham, MA, USA).  
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Sections were placed in cold water containing ethanol followed by transfer to a hot 
water bath (42 °C) to smooth out any folding in the sections.  Sections were placed on 
microscope slides (Thermo Scientific), air-dried overnight at RT before staining with 
Trichrome stain. 
 
2.26.2  TRICHROME STAINING 
Prior to staining, 5 µm tissues section slides were incubated at 56 °C for a 
minimum of 1 h to set the tissue on the slide and aid the removal of the wax.  Slide 
sections were immersed in two changes of xylene for 10 min each, following by re-
hydration in three decreasing concentrations of ethanol (100% x 2, 95% and 80% v/v) 
for 5 min each, then placed in two changes of water to rinse off excess xylene.  Bouin’s 
solution (Sigma-Aldrich) was used to mordant the tissue, slides were left in the 
solution overnight at room temperature or for 15 min at 56°C, then rinsed under 
running tap water to remove the yellow colour.  Next the slides were immersed in 
working Weigert’s Iron Hematoxylin Solution (Sigma-Aldrich) for 5 minutes, washed 
in running tap water for 5 min, and finally washed in deionised water.  Slides were 
counterstained in Scarlet-Acid Fucshin for 5 min and washed again in deionized water.  
Slides were immersed in working Phosphotungstic/Phosphomolybdic Acid Solution 
(Table 2.2) for 5 min prior to staining with Aniline Blue solution for 5 min, this step 
aids the binding of the Aniline blue dye to connective tissue.  The slides were then 
rinsed in Acetic Acid, 1%, for 2 minutes.  Finally, slides were put through a series of 
dehydration steps in ethanol (80%, 95% and 100%) for 5 min each.  Slides were then 
mounted with DPX mountant (BDH) and examined under a light microscope. 
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2.26.3  HISTOLOGICAL SCORING 
 Following trichrome staining, slides were coded without reference to prior 
treatment and examined in a blind fashion.  A semi-quantitative scoring system was 
used to assess collagen deposition and changes in lung architechure in the lung, 
(Ashcroft, 2008).  The scoring was carried out as follows:  
 0. Alveolar Septa Lung Structure 
0 1.  Normal Normal 
1 2. Isolated gentle fibrotic changes 
(septum ≤3× thicker than normal) 
Alveoli partly enlarged and rarefied, 
but no fibrotic masses present 
2 3. Clearly fibrotic changes (septum 
>3× thicker than normal) with knot-
like formation but not connected to 
each other 
Alveoli partly enlarged and rarefied, 
but no fibrotic masses 
3 4. Contiguous fibrotic walls (septum 
>3× thicker than normal) 
predominantly in whole 
microscopic field 
Alveoli partly enlarged and rarefied, 
but no fibrotic masses 
4 Variable Single fibrotic masses (≤10% of 
microscopic field) 
5 Variable Confluent fibrotic masses (>10% and 
≤50% of microscopic field).  Lung 
structure severely damaged but still 
preserved 
6 Variable, mostly not existent Large contiguous fibrotic masses 
(>50% of microscopic field).  Lung 
architecture mostly not preserved 
7 Non-existent Alveoli nearly obliterated with fibrous 
masses but still up to five air bubbles 
8 Non-existent Microscopic field with complete 
obliteration with fibrotic masses 
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2.27  CRYOPRESERVATION AND RECOVERY OF CELLS FROM LIQUID NITROGEN 
Cells were suspended at 1 x 106/ml of freezing medium and temperature 
reduced 1 °C per minute overnight and stored in liquid Nitrogen within 24 h.  Freezing 
medium consisted of basic media containing 10%-20% (v/v) FCS supplemented with 
10 % (v/v) Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich).  To recover cells, vials were 
quickly thawed at 37 °C.  Just as the vial contents thawed, 8 ml of warmed medium 
was added and cells were centrifuged at 400 g for 5 min.  Supernatant was discarded 
and the cells washed once more.  The final pellet was re-suspended in 2 ml of desired 
media and placed in T175 flask for culturing in cell specific media. 
 
2.28 STATISTICAL METHODS 
The students paired t test was used when statistical analysis was required 
between two experimental groups.  One way ANOVA was used to test for statistical 
significance of differences when multiple experimental groups were compared.  
Kaplan Meier curves (log rank test) were used to compare survival between treatment 
groups.  Power analysis was carried out to determine the number of animals that would 
yield a significant difference in the in vivo studies.  Statistical methods (Power 
analysis (SISA)) were used to determine the minimum number of animals per 
treatment group to obtain a power in the study.  SISA software is online at 
http://home.clara.net/sisa/power.htm. 
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Chapter 3 
Notch signalling is required for the induction of a functional, 
tolerogenic, dendritic cell population and the expansion of Treg 
cells by MSC 
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3.1 Introduction 
The immunomodulatory potential of MSC can be divided into two categories; 
direct and indirect.  When considered in relation to inflammation and infection, MSC 
predominately respond through indirect cell education, altering the phenotype of 
immune cells so they in turn can temper the local inflammatory environment (Chapter 
1).  Over the past decade, this phenomenon has been examined in the Mahon 
laboratory focusing on DC and Treg.  English et al. demonstrated that murine MSC 
suppress DC migration, maturation and antigen presentation (English et al., 2008) and 
promoted Treg cell expansion (English et al., 2009).  The importance of Treg for the 
therapeutic effect of MSC in vivo was elegantly shown using an animal model of 
allergic asthma (Kavanagh and Mahon, 2011).  Work by Tobin et al further 
investigated the effect of MSC on DC function and concluded that cell contact was a 
key requirement for MSC modulation of DC maturation and antigen presentation, 
(Tobin, Cahill et al., in Submission).  Similar findings have been published on DC, 
detailing MSC inhibition of maturation and a reduction of CCR7+ DC in vivo.  MSC 
were shown to rapidly inhibit DC migration following subcutaneous injection into a 
primed mouse.  The DC were pulsed with OVA and activated with LPS prior to 
injection.  The mice were primed to OVA through adoptive transfer of DO11.10 T 
cells, the T cells from DO11.10 mice are genetically modified to respond to OVA 
antigen (Chiesa et al., 2011).   
A common thread that runs through MSC research is that more is known about 
what MSC can do, and less about how they do it.  This chapter aims to delve into 
precisely how MSC mediate their effects and to determine the pathways being utilised 
by these cells that cause such dramatic changes to their environment.  Murine MSC 
were examined for interactions with T cells to determine their role in expansion of 
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Treg, MSC inhibition of DC maturation and induction of tolerogenic DC were also 
studied.  A great deal has been published about the role of soluble factors released by 
MSC and immune modulation.  Despite the proven need for a contact signal, less is 
known about direct MSC-immune cell interactions.  Using in vitro methods involving 
receptor inhibitors, neutralising antibodies, siRNA and ultimately lentiviral shRNA  to 
create stably knocked down cells, the importance of the Notch family signalling 
pathway in MSC was examined, with particular emphasis on the ligand Jagged 1.  
These experiments aimed to demonstrate the influence of murine MSC on the immune 
system through induction, expansion and education of immune cells and to identify 
the contact dependent signal through which murine MSC modulate the immune 
function of T cells and DC.  
  
3.2  Characterisation of Murine MSC  
Characterisation of murine MSC has been the subject of much scrutiny over 
the last 10 years as different labs have differing culture methods.  There are no absolute 
markers for specifically distinguishing these cells, and so consistency of methodology 
and outcome have proven elusive.  To that end, efforts have been made to standardise 
the characterisation of MSC (Tropel et al., 2004).  As mentioned in the introduction 
the three principle stipulations for characterisation became: adherence to plastic, 
specific cell surface marker expression and tri-lineage differentiation.  This study 
began by characterising the murine MSC to be used subsequently, an issue that would 
need to be returned to following each major MSC manipulation. 
Murine BALB/c or C57BL/6 MSC can be isolated from bone marrow by 
immunodepletion in selective media and by using their capacity to adhere to plastic.  
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Following this, cells must express particular cell surface markers, namely, CD105, 
CD44, CD73 and Sca-1 while lacking haematopoietic and endothelial markers such 
as CD45, CD34, and CD11b.  Typically MSC lack allogeneic reactivity associated 
with reduced expression of MHC class I and Class II and a lack of the co-stimulatory 
markers CD80 and CD86.  Though these guidelines to define MSC are generally 
consistent, different methods of isolation, the strain of mice used and the age of the 
cells can alter levels of expression (K English, unpublished data). Using the 
methodology described in section 2.7, murine MSC were isolated and characterised.   
Flow cytometric analysis of the isolated cells demonstrated expression of 
CD44, Sca-1, CD106, CD73, CD90 and no MHC Class I expression.  This pattern of 
expression coupled with the absence of the haematopoietic marker CD45, the 
lymphocyte maker CD34, the co-stimulatory marker CD86 or MHC Class II indicated 
that the cells isolated were non-hematopoietic, stromal cells (Fig. 3.1).  This method 
of characterisation was routinely used through successive passages and manipulations, 
with a similar outcome to assure the purity of the cells used experimentally. 
MSC must by definition demonstrate multi lineage differentiation capabilities, 
specifically to osteoblasts, adipocytes, and chondrocytes.  Isolated candidate MSC 
were grown as described in section 2.7.3 using selective media for 21 days.  
Differentiation to bone and fat cells was detected by staining using alazarin red and 
Oil Red O respectively, while chondrocyte differentiation was detected by measuring 
mRNA expression of Collagen IIa, collagen III and Aggrecans.  The control cultures 
were treated with the same conditions in the absence of differentiation components, 
but failed to develop the same distinctive patterns of expression (Fig. 3.2).  While 
differentiation into both bone and fat was observed in both C57BL/6 MSC and 
BALB/C MSC, the environment in which they were cultured affected the extent of the 
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differentiation. Cells grown under normoxic conditions tended towards a more 
adipogenic phenotype, while cells grown under hypoxic conditions favoured 
osteogenic differentiation.  It was also observed that cells cultured in hypoxia more 
readily maintained the ability to differentiation at later passages, I feature sometimes 
lost by cells cultured in normoxia.  
Finally, candidate MSC were examined for their capacity to suppress both 
autologous and allogeneic proliferation of lymphocytes.  Though not a defining 
characteristic of MSC, suppression of lymphocyte proliferation has become 
synonymous with the cell type.  MHC mis-matched splenocytes were cultured with 
MSC in the presence or absence of the mitogen Concovalin A (ConA) and analysed 
by tritiated thymidine uptake for incorporation into replicating DNA.  Fig. 3.3 
illustrates the significant immunosuppressive capacity of MSC for mitogen driven 
proliferation.  In an MHC mis-matched environment the MSC significantly reduced 
the proliferation of lymphocytes in a two way mixed lymphocyte reaction (***, 
P<0.001).  
 Taken together these data indicate that the candidate BALB/c or C57BL/6 
MSC used here and in further experiments conformed to the accepted definition of 
MSC isolated from murine bone marrow.   
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Fig. 3.1 MSC characterisation for cell surface markers.  Murine BALB/c or 
C57BL/6 MSC (in this instance from C57BL/6 at passage 7) were characterised by 
staining the cells for variety of cell surface markers (red line) against their 
corresponding isotypes (black line).  The cells were analysed using flow cytometry 
with 10,000 events were recorded for each marker.  These results are representative of 
multiple experiments, with cells analysed at various passages from 3 to 12.  
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Fig. 3.2 Trilineage differentiation of MSC.  C57BL/6 MSC (5x104) were cultured 
for 21 days in control medium or with osteogenic or adipogenic medium.  Cultures 
were stained with Alazarin Red (A) and Oil Red O (B).  In Chondrocyte differentiation 
studies, 2x105 MSC were centrifuged at 200xG for 8 min to form a cell pellet, control 
medium or chondrocyte medium was added to the tube and the cells were cultured for 
21 as a 3D cell mass.  After 21 days trizol was added to the cell pellet, following RNA 
extraction and cDNA synthesis, the mRNA was tested for the chondrocyte markers 
aggrecan and collagen IIa (C).  These results are representative of multiple 
experiments using both BALB/c and C57BL/6 MSC, with cells analysed at various 
passages from 3 to 12. (Magnification x100). 
B 
A. 
B. 
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Fig. 3.3 MSC inhibit A) alloantigen and B) mitogen driven spleen cell 
proliferation.  BALB/c MSC were co-cultured with splenocytes from BALB/c and 
C57BL/6 mice for 72h.  Proliferation was measured by [3H] thymidine uptake over a 
6h period.  Mitogen driven proliferation was examined using Con A (5ug/ml) added 
at day 0.  Results are represented in counts per minute.  The results are representative 
of several experiments over multiple passages using both BALB/c and C57BL/6 MSC, 
and statistical significance determined by ANOVA analysis (p**<0.01), 
(p***<0.001). 
 
A 
B 
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3.3  MSC expand Regulatory T cells 
English et al previously demonstrated that human MSC induce functional Treg 
cells expressing the transcription factor FoxP3 through the release of soluble factors 
PGE2 and TGFβ1, while also requiring a cell contact signal (English et al., 2009).  
That study did not establish whether MSC were inducing Treg from naive cells or 
expanding a pre-existing Treg population.  In order to determine the origin of murine 
Treg following MSC co-culture, in vitro experiments were carried out using CD4+ 
cells isolated from FoxP3-eGFP knock-in mice.  These mice are genetically 
engineered to co-express eGFP and the Treg transcription factor FoxP3 following 
activation of the promoter region.  They accurately determine FoxP3 expression with 
97% of FoxP3+ cells displaying eGFP fluorescence (Lin et al., 2007).  MSC co-
cultured with CD4+ cells isolated from  FoxP3-eGFP reporter mouse splenocytes 
caused an increase in CD25 and FoxP3 expression when compared to CD4+ cells 
cultured alone (Fig. 3.4).  In order to determine if this increase was a result of MSC 
induction or expansion of a regulatory population, CD4+CD25-FoxP3GFP- cells were 
sorted from Foxp3-GFP reporter mouse spleens and subsequently cultured with 
allogeneic MSC for 72h.  In this system, MSC were incapable of inducing 
CD25+FoxP3+ cells (Fig. 3.5).  These data show that MSC do not directly activate 
Treg from a naive population but suggest that they support the expansion of pre-
existing Foxp3+ regulatory T cells. 
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Fig. 3.4 MSC increase the number of cells expressing CD25 and FoxP3.  
Allogeneic murine MSC were co-cultured with CD4+ FoxP3-eGFP spleen cells for 
72h at a ratio of 1:3.  Following this, the CD4+ cells were recovered from co-culture 
by aspirating off the suspension cells from the adherent MSC and examined for 
expression of FoxP3-GFP and CD25. (A); representative example of T cell expression 
of FoxP3-eGFP and CD25-PeCy5 (B); mean of 7 experiments showing an increase in 
FoxP3 expression in T cells co-cultured with MSC.  Statistical analysis by student t 
test (p***<0.001). 
 
  
A 
B 
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Fig. 3.5 MSC promote the expansion but not induction of regulatory T cells in 
vitro.  T cells from FoxP3-eGFP mice were purified either by bead isolation (CD4) or 
cell sorting (CD4+CD25-FoxP3-), the cells were subsequently cultured with or without 
MSC for 72h and examined for CD25 and FoxP3-eGFP expression by flow cytometry.  
CD25+FoxP3-eGFP+ cells isolated during cell sorting were used as a positive control 
for staining after 72h culture with IL-2 (300U/ml).  The sorted CD4+CD25-FoxP3- 
cells alone and those co-cultured with MSC for 72h were unable to induce Treg cells.  
Data representative of 3 experiments.   
94 
 
3.4  MSC inhibit DC maturation and induce a tolerogenic DC phenotype 
Typically, DC encounter with antigen leads to maturation, which involves 
increased co-stimulatory marker, and MHC Class II expression.  A further mechanism 
of MSC immunomodulation is their ability to inhibit the maturation of DC.  MSC 
reduced the DC expression of co-stimulatory markers MHC Class II, and CD86 
(Fig.3.6), and were previously shown to increase DC production of IL-10 while 
reducing Il-12p70 (Tobin, unpublished data).  These semi-mature DC were further 
studied to determine any potential function in immunomodulation. 
To determine the functionality of these semi-mature or candidate “tolerogenic” 
cells, DC derived from BALB/c mice were cultured with or without allogeneic MSC 
in the presence or absence of the protein ovalbumin (OVA) for 48h.  These MSC 
“educated” DC were recovered from the adherent MSC by aspirating the cells 
suspended in the medium, the cells were washed and subsequently co-cultured with 
CD4+ T cells isolated from DO11.10 mice (Fig. 3.7).  DO11.10 mice have been 
genetically modified so that MHC Class II restricted rearranged T cell receptor 
transgene expressing T cells will react to the peptide antigen derived from OVA 
(Murphy et al., 1990).  Mature DC pulsed with OVA, supported the proliferation of 
the CD4+ T cells as expected, however, the “tolerogenic” DC were able to reduce this 
proliferation even in the presence of OVA.  Paraformaldehyde fixed MSC were used 
as a control to demonstrate that live viable MSC were required to confer DC with the 
capability of inhibiting or not supporting T cell proliferation (Fig. 3.7).   
Induction of regulatory T cells was postulated to account for the inhibition seen 
in the proliferation assay (Fig. 3.3).  To test this theory, DC were isolated from 
C57BL/6 mice and co-cultured with BALB/c MSC for 48h in the presence (mDC and 
tDC) or absence (iDC) of LPS.  The DC were separated from the adherent MSC by 
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aspirating the cells suspended in appropriate medium and further co-cultured with 
CD4+CD25+FoxP3- T cells isolated from a FoxP3-eGFP knockin mouse.  CD3+ cells 
were isolated from murine spleen using bead separation, and subsequently stained for 
CD4 and CD25.  The CD4+CD25+FoxP3- cells were separated from the 
CD4+CD25+FoxP3+ population by cell sorting and then co-cultured with the DC for 
72h.  Induction of CD4+CD25+FoxP3+ cells from the null population by immature, 
mature (iDC) and tolerogenic DC (tDC) was determined by FACS (Fig. 3.8).  After 
72h immature and mature DC induced a small population of Treg, 4.6% and 10.0% of 
the total population respectively.  DC that had encountered MSC (candidate 
tolerogenic DC) on the other hand induced a substantially larger population at 35.3%.  
These results support the hypothesis that MSC induce tolerogenic DC and 
consequently Treg cells, which may contribute to the reduction in antigen driven T 
cell proliferation. 
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Fig. 3.6 MSC prevent the LPS induced maturation of DC.  Naive BALB/c derived 
DC were stimulated with 100ng/ml LPS to promote maturation.  Expression of 
maturation markers MHC Class II and CD86 were examined by flow cytometry.  
Histograms depicting isotype controls (purple) and specific markers (green) are 
analysed for mean fluorescence intensity (MFI).  DC which were co-cultured with 
MSC demonstrated reduced maturation marker expression.  Data are representative of 
three experiments.  
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Fig. 3.7 Allogeneic MSC educate DC to inhibit antigen driven T cell proliferation.  
Immature BALB/c derived DC were co-cultured with or without allogeneic MSC in 
the presence or absence of OVA.  Paraformaldehyde fixed MSC were used as a 
control.  The DC were recovered by aspiration after 48h and washed before co-
culturing with DO11.10 CD4+ T cells.  After 72h, proliferation was examined over a 
6h period by measuring tritiated thymidine uptake.  Proliferation was measured in 
counts per minute (CPM).  MSC, but not fixed MSC educated DC were capable of 
significantly suppressing OVA driven T cell proliferation (p***<0.001).  Statistical 
analysis performed by ANOVA with an n=3. 
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Fig. 3.8 Tolerogenic DC induce regulatory T cells.  BALB/c DC cultured with or 
without allogeneic MSC in the presence or absence of LPS, were re-purified after 48h. 
iDC received no LPS, mDC were cultured in the presence of LPS, and tDC were 
cultured with LPS and MSC but separated from the MSC before co-culture with T 
cells.  The cells were washed and further cultured with CD4+CD25-FoxP3- T cells 
from an eGFP knock in mouse, at a ratio of 1:4, for 72h.  T cells were labelled for CD3 
to discriminate them from the DC and expression of CD25 and FoxP3-eGFP was 
examined by flow cytometry.  Tolerogenic DC had a greater capacity to induce 
regulatory T cells.  Data are representative of two experiments. Gating strategy (D). 
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3.5  Notch Receptor and Ligand Expression on Murine MSC 
Soluble factors play an important role in the immunological effects of MSC, 
however there is a non-redundant role for cell-cell contact.  This was previously 
described by English et al.  in human MSC (English et al., 2009), and Tobin et al.  in 
mouse MSC (unpublished data).  Many potential contact signals have been 
investigated by the Mahon laboratory, Siglecs, LICOS, Nestin, SDF1, and PDL, 
however, to date the most compelling results have come from studying the Notch 
signalling pathway.  Further work by Tobin et al. demonstrated an important role for 
Notch in MSC modulation of DC (Tobin, Cahill et al, in submission)  
Notch-Notch ligand expression on MSC and T cells was determined by PCR 
(Fig. 3.9).  MSC express high levels of Notch 2, Jagged 1 and Delta-like ligand 1, 
while T cells express high levels of the receptor Notch 1 and 2 and low levels of Jagged 
2 and Delta like ligand 1 (Fig. 3.9). 
Given the high level of Notch receptor expression and the low level of ligand 
expression on T cells, it was hypothesised that MSC signal to CD4 T cells and DC.  
This theory was further supported by examining the manner in which Notch signals.  
The intracellular domain is cleaved and translocates to the nucleus of the cells, 
signalling downstream changes through the target genes HES and HEY (Gordon et al., 
2008).  Notch 1 signalling has been shown to be involved in Smad-3 binding to the 
promotor region of the FoxP3 gene and plays a key role in induction of Treg cells by 
TGFβ (Samon et al., 2008).  While MSC ligand signalling to T cells and DC is the 
most likely scenario, the presence of Notch ligands on the T cells means signalling 
may be occurring in reverse.   
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Fig. 3.9 Notch/Jagged family expression profile on murine MSC and CD4+ T cells.  
Murine MSC and CD4+ T cells were examined for expression of the Notch/Jagged 
family mRNA by RT-PCR.  Cells were cultured separately for 24h, mRNA was then 
isolated and cDNA produced according to the method outlined in sections 2.13 and 
2.14.  Known positive control cells were used for each set of primers, Notch 1, Delta 
Like ligand 1 (spleen), Notch 2 (bone marrow), Jagged 1 and Jagged 2 (J774). Results 
are representative of BALB/c and C57Bl/6 strains.   
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3.6  Is the Notch family involved in Regulatory T cell Induction? 
Gamma secretase is a cell membrane integrated protease complex involved in 
the cleavage of the Notch intracellular domain (NICD), thus facilitating NCID 
translocation to the nucleus and subsequent gene transcription.  The function of these 
secretases is inhibited by gamma secretase inhibitors (GSI) (LaVoie and Selkoe, 
2003).  By exploiting this pathway all Notch receptors can be simultaneously blocked 
and receptor participation in MSC signalling can therefore be studied.   
The use of FoxP3-eGFP CD4+ T cells in flow cytometry allowed for the rapid 
and accurate observation of CD4+FoxP3+ regulatory T cells.  As previously shown 
MSC readily expand Treg (Fig. 3.4), in order to determine whether a role existed for 
Notch in this expansion a global inhibitor of Notch receptor signalling, GSI, was used.  
FoxP3-eGFP spleen cells were isolated and CD4+ cells separated by bead extraction.  
These cells were cultured with allogeneic MSC for 72h in the presence or absence of 
GSI (1µM) or DMSO (vehicle control).  Cells were examined by flow cytometry, 
where by CD4+ cells were gated and expression of FoxP3 was determined.  While 
MSC enhanced Treg expansion, the presence of GSI ablated this effect.  (Fig. 3.10).  
These results clearly indicate MSC expansion of Treg cells involves Notch receptor 
signalling 
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Fig. 3.10 Murine MSC expand a regulatory T cell population in a Notch 
dependent manner.  FoxP3eGFP CD4+ T cells were co-cultured for 72h with 
allogeneic MSC in the presence or absence of GSI (1µM) or its diluent DMSO.  MSC 
expansion of the Treg population is reduced by the addition of GSI but not the diluent 
alone.  Treg expansion was examined by flow cytometry for FoxP3-eGFP expression.  
Data representative of at least three experiments. 
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3.7  Notch signalling is required for Murine MSC induction of Tolerogenic DC 
In order to examine the possible role of Notch signalling in the induction of a 
tolerogenic DC by murine MSC, a co-culture system was employed.  BALB/c DC 
were pulsed with OVA in the presence or absence of C57BL/6 MSC.  DC were then 
harvested by gentle aspiration from adherent allogeneic MSC and placed in a 
proliferation assay with OVA specific DO11.10 CD4+ T cells.  As seen previously, 
DC pulsed with OVA were capable of supporting DO11.10 CD4+ T cell proliferation.  
However, DC pulsed with OVA in the presence of allogeneic MSC were unable to 
support CD4+ T cell proliferation.  Interestingly, by blocking Notch signalling through 
the addition of GSI, MSC were no longer able to induce functional tolerogenic DC, as 
indicated by a significant increase in CD4+ T cell proliferation (p<0.0001) (Fig. 3.11).  
The increase in T cell proliferation with GSI treated tDC beyond that of mDC can be 
accounted for by considering GSI treated MSC no longer inhibit the maturation of DC, 
conceivably the DC could therefore react to the mis-matched MHC in the allogeneic 
MSC co-culture.  Vehicle control had no effect.  These data confirmed that Notch 
signalling was required for the induction of a functional, tolerogenic DC population 
by MSC in vitro. 
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Fig. 3.11 GSI prevents MSC generated tolerogenic DC ability to inhibit T cell 
proliferation.  Immature DC, isolated from BALB/c bone marrow, were co-cultured 
with or without allogeneic MSC in the presence or absence of OVA.  GSI or DMSO 
was added at a concentration of 1µM.  The DC were pulled back after 48h and washed 
before co-culturing with DO11.10 CD4+ T cells.  After 72h, proliferation was 
examined over a 6h period by measuring tritiated thymidine uptake.  Proliferation 
levels were measured in counts per minute (CPM).  GSI treated tolerogenic DC 
restored OVA driven T cell proliferation when compared to untreated tolerogenic DC 
(p**, 0.01). Statistics generated by ANOVA with three repeats.. 
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3.8  Attempted strategies for determining which Notch receptor and ligand 
pairing is involved in MSC immunomodulation. 
 After determining that the Notch/Jagged pathway is involved in MSC 
immunomodulatory functions, the next step was to find out which ligand or receptor 
was specifically involved in signalling.  Notch 1 and Jagged 1 have previously been 
identified to play key roles in DC/Treg modulation, using inhibitors to show increases 
in Treg cells and inhibition of DC maturation (Liotta et al., 2008, Bugeon et al., 2008).  
Furthermore, MSC express high levels of Notch 1 and Jagged 1 and thus were chosen 
as potential candidates.  Three approaches were used to determine the precise 
signalling pathway, they included; a Notch 1 neutralising antibody, a Jagged 1 
neutralising antibody and Jagged 1 siRNA.   
 CD4+ cells were co-cultured with allogeneic MSC for 72h in the presence or 
absence of Notch 1 neutralising antibody (10µg/ml) or isotype control (mouse IgG2b).  
Cells were examined by flow cytometry, CD4+ cells were gated and expression of 
FoxP3 was determined.  Cells co-cultured with MSC have increased levels of FoxP3 
however this is only marginally reduced with the addition of the anti-Notch 1 antibody 
and the result was neither reproducible nor statistically significant (Fig. 3.12).   
The role for Jagged 1 was examined using a neutralising antibody in MSC-T 
cell co-culture.  Anti-Jagged 1 was used at 5µg/ml (concentration determined by L. 
Tobin, unpublished) and the isotype control was mouse IgG1.  As seen in Fig. 3.13 
the neutralising antibody did not reduce the levels of FoxP3 in the CD4+ cells, there 
was however a mild effect from the isotype control.  These experiments demonstrated 
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that neutralising antibodies can be insufficient in reductionist studies and were not a 
reliable approach here. 
In order to obtain full, quantifiable, knockdown of Jagged 1, small interfering 
RNA (siRNA) constructs were designed as described in section 2.17.  Jagged 1 KD 
was examined using RT-PCR.  Analyses were performed on all samples, after 24h 
there was clear knockdown of Jagged 1 mRNA at 15nM siRNA concentration (Fig. 
3.14), unfortunately after 48h, mRNA levels began to increase again.  As with the 
neutralising antibodies, the time frame of the MSC and T cell co-culture (72 h) 
exceeded the maximum length of knockdown achievable with siRNA.  In order to 
pursue Jagged 1 as a potential target in MSC signalling a stably knocked down cell 
line was required. 
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Fig. 3.12 Neutralisation of Notch 1 has little effect on MSC expansion of Treg.  
CD4+ T cells were co-cultured for 72h with MSC in the presence or absence of Anti 
Notch 1 (10µg/ml) or its control isotype mouse IgG2b.  MSC expansion of the Treg 
population is marginally reduced by the addition of anti Notch 1 but not the isotype.  
Anti-Notch 1 cultured with the CD4+ cells alone do not expand a Treg population.  
Treg expansion was examined by flow cytometry for FoxP3-eGFP expression.  Data 
representative of three experiments. 
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Fig. 3.13 Jagged 1 neutralising antibody was ineffective at reducing MSC 
expansion of Treg.  CD4+ T cells were co-cultured for 72h with MSC in the presence 
or absence of anti Jagged1 neutralising antibody (5µg/ml) or its isotype mouse IgG1.  
MSC expansion of a Treg population was not affected by the addition of anti Jagged 
1.  Ant-Notch 1 cultured with the CD4+ cells alone did not expand a Treg population.  
Treg expansion was examined by flow cytometry for FoxP3-eGFP expression.  Data 
representative of three experiments. 
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Fig. 3.14 Jagged 1 silencing using siRNA was ineffective at reducing MSC 
expansion of Treg.  A concentration gradient for siRNA ranging from 15nM to 25nM 
revealed 15nM to be an effective dose for Jagged 1 silencing as determined by PCR 
after 24h (A).  This dose was used in a co-culture experiment involving CD4+ T cells 
and MSC.  There was no reduction in the expansion of Treg cells over a 72h period as 
determined by flow cytometry for FoxP3-eGFP (B).  Data representative of two 
experiments. 
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3.9  Establishment of a stably transduced Jagged 1 knock out cell line 
In order to create a stably knocked down Jagged 1 MSC line, lentiviral particles 
containing short hairpin RNA (shRNA) were employed.  shRNA uses the cell’s 
internal processing to turn shRNA into siRNA which activates RISC (RNA induced 
silencing complex).  This in turn cleaves the RNA of interest, preventing it from being 
transcribed (Paddison et al., 2002).  Five different Jagged 1 shRNA plasmids were 
designed and pooled to achieve maximum knockdown.  The plasmids were transfected 
into HK293T cells along with lentiviral packaging plasmids.  The HEK cells packaged 
the Jagged 1 plasmid into functional virus which was released into the medium and 
collected for transduction of the MSC (Fig. 3.15).   
Initial transfections into HEK293T cells using lipofectamine resulted in a 
substantial amount of cell death, leading to a very low viral titre.  Optimisation of three 
different transfection reagents was carried out, each designed to protect the cell during 
transfection.  Fig. 3.16 shows how each of the three constructs were capable of 
producing high levels of virus; however, Gene Juice was chosen based on microscopic 
examination of the cells.  Cells cultured with Gene Juice displayed greater levels of 
proliferation and looked healthier.  For the remainder of the project GeneJuice was 
used at the transfection reagent in all shRNA work. 
The viral titre of media obtained from HEK cells was determined by the 
number of transducing units (TU) per ml of media.  2x105 HEK were transduced with 
a serial dilution of viral media and left to culture for 48h.  The plasmids used in this 
experiment were all GFP tagged and the number of GFP positive cells was counted 
after 48h.  Using the following formula the titre was determined (Fig. 3.16). 
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# GFP colonies counted x dilution factor x 40 = #TU/mL 
 
Multiplicity of infection (MOI) is the number of TU required to achieve knockdown 
in any given cell line.  The accuracy of the MOI with regard to the MSC was not vital 
in this case as the non-transduced MSC would be purified out by Puromycin selection.  
Resistance to the antibiotic is only conferred to cells that have been positively 
transduced. 
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Fig. 3.15 Creation of a GFP expressing Jagged 1 knock down MSC.  pGIPZ GFP 
plasmid constructs containing Jagged 1 shRNA were packaged into lentiviral vectors 
by HEK293T cells (A).  The packaged virus was used to transduce MSC and positively 
selected for by consequential puromycin resistance.  The positively selected cells 
containing pGIPZ fluoresced green due to the presence of the GFP gene in the vector 
(B); (x400).   
50µm 
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Fig. 3.16 Viral titres achieved using different transfection reagents with 
HEK293T cells.  HEK cells were seeded at 1x106 in a T75 flask overnight.  Each 
transfection reagent was used in a 3:1 ratio with plasmid DNA.  HEK cells were 
transfected for and viral particles collected after 48h.  A serial dilution of the viral 
media was made and added to 4x105 HEK cells plated in a 24 well plate. After 48h, 
the cells were examined by flow cytometry for GFP expression and the viral titer 
determined.  All cells treated were viable 48h after transfection and capable of 
producing high levels of virus  
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3.10  Jagged 1 Knockdown MSC retain their stromal cell characteristics 
In order to ensure treatment of MSC with lentiviral particles had no adverse 
effect on the defining characteristics of the cells.  MSC were subjected to cell surface 
characterisation and differentiation following shRNA knockdown. The following 
results demonstrate that transducing the MSC with lentivirus did not alter the cell’s 
basic characteristics.  Figure 3.17 shows that Jagged 1 shMSC still expressed all the 
required cell surface markers while maintaining a low level of MHC Class I.  This is 
important for any potential in vivo experiment for which the cells may be utilised.  As 
with the cell surface characterisation, MSC were adherent to plastic, confirmed 
through successive passages and while undergoing differentiation in a 6 well plate.  
Figure 3.18 demonstrates that lentiviral knockdown of MSC did not affect their 
capacity to differentiate into bone, fat or cartilage like cells. These results are 
comparable to characterisation of non-transduced MSC indicating lentiviral treatment 
does not alter the defining characteristics of MSC. 
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Fig. 3.17 Jagged 1 shMSC at Passage 8 continue to express appropriate MSC 
surface markers.  BALB/c Jagged 1 shMSC were characterised by looking at the 
expression levels of a variety of cell surface markers (Red Line) against their 
corresponding isotypes (Black Line).  10,000 events were recorded for each marker.  
These results are representative of multiple experiments 
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Fig. 3.18 Trilineage differentiation of Jagged 1 KD MSC.  Jagged 1 KD MSC and 
Non-silencing control MSC (5x104) (Jag1 KD MSC shown above) were cultured for 
21 days in control medium, osteogenic medium (A), or adipogenic medium (B).  
Cultures were stained with Alazarin Red for bone and Oil Red O for fat.  2x105 MSC 
were centrifuged at 200xG for 8 min to form a cell pellet, control medium or 
chondrocyte medium was added to the tube and the cells were cultured for 21 as a 3D 
cell mass.  After 21 days trizol was added to the cell pellet, following RNA extraction 
and cDNA synthesis, the mRNA was tested for the chondrocyte markers aggrecan and 
collagen IIa (C).  The results are representative of two experiments. (Magnification 
x100) 
C 
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3.11  Jagged 1 shRNA results in knockdown of Jagged 1 on MSC. 
The GFP positive MSC that were puromycin resistant were collected and 
tested for Jagged 1 expression at both the protein and the mRNA level.  Cells were 
stained with a Jagged 1-PE antibody and examined by flow cytometry, the distribution 
of the peak in the non-transduced MSC graph indicates that nearly all the cells express 
Jagged 1 on some level, though many only weakly express the ligand.  However, 
following shRNA transduction there was a dramatic reduction in the cell surface 
expression of Jagged 1 (Fig 3.19 A).  The cells were also tested for expression of 
Jagged 1 by real time PCR analysis. There was a slight increase in the expression of 
Jagged 1 in non-silencing control MSC compared to Jagged 1 KD MSC however 
expression did not return to non-transduced levels (Fig 3.19 B).  The non-silencing 
plasmid is a control used in lentiviral work, where an empty vector is packaged into 
viral units and the MSC are transduced to ensure there are no unintentional side effects 
to the viral transduction. In the case of MSC, the non-silencing control delivered by 
means of a lentivirus probably stimulates the TLR3 ligand responsible for detecting 
viral double stranded DNA. TLR3 stimulation on MSC results in the down regulation 
of Jagged 1 at both the mRNA and protein level (Liotta et al., 2008), for this reason 
the non-silencing control cannot be used as a valid control for lentiviral transduction 
in this case. In an effort to overcome this, reverse transcriptase PCR was also 
performed on lentiviral treated MSC to establish whether knock down of Jagged 1 
may interfere with expression of the other Notch ligands. Jagged 2 is not expressed by 
MSC but primers for Delta-like ligand 1 (Dll 1) expression was tested. Figure 3.19 C 
shows visible bands for Dll1 in both Jagged 1 KD MSC and non-silencing control 
MSC.  These results confirm that treatment of MSC with Jagged 1 shRNA results in 
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significantly reduced expression of Jagged 1 at both an mRNA level and a protein 
level. Though non-silencing control cells also showed knocked down expression of 
Jagged 1, there was no change in the expression of other Notch ligands. Taken together 
these results show knockdown of Jagged 1 was achieved in MSC.  However, due to 
the off target knockdown observed in the non-silencing control, steadfast conclusions 
cannot be drawn from this work alone. 
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Fig. 3.19 Jagged 1 knockdown MSC no longer express Jagged 1.  Jagged 1 shMSC 
were positively selected using puromycin and allowed to reach confluence, the cells 
were passaged and 5x106 cells were collected using trizol for mRNA analysis.  RNA 
was isolated and cDNA produced.  The cells were examined at a protein level or 
Jagged 1 expression by flow cytometry (A).  The cells were also tested by real time 
PCR for the expression of Jagged 1 (B) and reverse transcription PCR for Delta like 
ligand 1 (C) and the results compared with non-transduced MSC or non-silencing 
control MSC.   
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3.12  Jagged 1 knockdown MSC no longer support the expansion of regulatory 
T cells. 
Jagged 1 knockdown MSC were used in co-culture with allogeneic CD4+ T 
cells to determine the importance of Jagged 1 in MSC expansion of Treg.  CD4+ cells 
were separated from the spleens of FoxP3-eGFP mice and co-cultured with either 
knockdown MSC or non-transduced MSC for 72h.  The CD4+ cells had a low base 
level of FoxP3+ cells present after 3 days, T cells cultured with non-transduced MSC 
showed a significant increase in expression of FoxP3 and CD25, indicating expansion.  
The CD4+ T cells co-cultured with Jagged 1 shMSC showed levels of expression 
similar or lower than that of the CD4+ cells cultured alone.  This result indicates that 
the ability of MSC to expand Treg requires MSC expression of Jagged 1 (Fig. 3.20). 
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Fig. 3.20 Jagged 1 knockdown MSC are unable to expand a regulatory T cell 
population.  CD4+ T cells were separated from spleen cells isolated from a FoxP3-
eGFP mouse were co-cultured with Jagged1 KD MSC or non-transduced MSC.  After 
72h the T cells were pulled back, washed and stained for CD4 and CD25.  The CD4 
cells were gated and expression of FoxP3-eGFP and CD25-PeCy5 were examined by 
flow cytometry.  As previously shown CD4+ cells cultured with non-transduced MSC 
expand a FoxP3+CD25+ population, however Jagged 1 KD MSC showed significantly 
reduced expansion, equivalent to CD4+ cells cultured alone (A).  This experiment was 
repeated several times and the average was graphed (B).  Statistics achieved by 
ANOVA analysis, (**<0.01, ***<0.001), N=3. 
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3.13  Jagged 1 knockdown MSC in conjunction with anti IL-6 inhibit the 
maturation of DC. 
Jagged 1 knockdown MSC were further used in co-culture with DC to ascertain 
whether Jagged 1 also plays a role in MSC modulation of DC maturation.  DC were 
cultured with either knockdown MSC or non-transduced MSC in the presence or 
absence of LPS for 48h.  The DC were recovered and washed before staining for the 
maturation markers CD86, CD40 and MHC Class II.  Initial studies found that the 
knockdown MSC alone were not capable of fully reversing MSC inhibition of 
maturation, leading to the hypothesis that soluble factors may play a more important 
role in inhibition of DC maturation than expansion of Treg cells.  This hypothesis was 
supported by unpublished work in the Mahon lab (English, K.E.) and previously 
published work showing an important role for IL-6 in the inhibition of DC maturation, 
while also indicating a need for cell contact (Djouad et al., 2007).  Further co-culture 
experiments were set up with the addition of an IL-6 or control neutralising antibody.  
The DC matured with LPS had expressed high levels of CD86 and MHC Class II and 
as expected these levels were reduced in the presence of MSC (Fig. 3.21).  The Jagged 
1 KD MSC slightly increased expression of CD86 (A) and greatly increased levels of 
MHC Class II (B) but when used in conjunction with anti-IL-6, the expression level 
of both CD86 and MHC Class II were comparable to those seen in the LPS matured 
DC (A&B).  These results indicate an additive role for IL-6 and Jagged 1 in MSC 
inhibition of DC maturation.  While preventing the Jagged 1 interaction with DC 
Notch receptors somewhat reverses MSC inhibition of DC maturation, abolition of IL-
6 signalling is required to completely restore a mature phenotype. 
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Fig. 3.21 Jagged 1 Knockdown MSC in combination with anti IL-6 reduces the 
expression of maturation markers on DC.  DC were cultured for 48h in the presence 
or absence of MSC or Jag1 shMSC with or without the addition of an anti-IL-6 
neutralising antibody.  The DC were pulled back and examined by flow cytometry 
following staining for CD11c and the maturation markers MHC Class II (A) and CD86 
(B).  Data presented in histograms of mean fluorescence intensity (MFI) and 
representative of two experiments. 
  
A 
B 
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3.14  MSC inhibition of antigen presentation by DC is attenuated by removal 
of Jagged 1 signalling 
Murine MSC co-cultured with DC has previously been shown to reduce the 
ability of DC to present a peptide/MHC class II complex on the cell surface (English 
et al., 2008).  Unpublished work by the Mahon laboratory demonstrated addition of 
GSI to co-cultures reversed MSC suppression of antigen presentation (L. Tobin, 
unpublished data).  Following on from this work, Jagged 1 knockdown MSC were co-
cultured with DC in an antigen presentation assay to determine a role for Jagged 1 in 
this process.  DC were cultured with either non-transduced MSC, or Jagged 1 
knockdown MSC in the presence or absence of a peptide (52-68) from the alpha chain 
of I-E of the MHC Class II receptor for 24 h.  The DC were recovered and washed 
before staining with the flurochrome labelled Y-Ae antibody, which binds to the E  
peptide bound to I-Ab molecules (Honey et al., 2004).  High levels of the Y-Ae 
antibody were detected on DC matured by LPS indicating high levels of antigen 
presentation.  DC co-culture with non-transduced MSC led to a reduction in the level 
of antigen presentation, and co-culture with Jagged 1 knocked down MSC somewhat 
reversed this effect but not to levels seen with mature DC.  This could in part be due 
to IL-6 signalling, which was previously shown to compensate for the lack of contact 
signalling in MSC inhibition of DC maturation (Fig. 3.22). Nevertheless, MSC 
inhibition of antigen presentation by DC is attenuated by the removal of Jagged 1 
signalling. 
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Fig. 3.22 Jagged 1 is involved in MSC suppression of DC antigen presentation.  
C57BL/6 DC pulsed with I-Eα peptide were co-cultured with wild-type allogeneic 
MSC or Jagged-1 knocked down MSC for 48h.  The percentage of DC presenting I-
Eα peptide was measured using a YAe biotin conjugated anti-I-Ab: Eα complex 
specific antibody.  Percentages of cells within the marked regions are represented.  
Data representative of two experiments. 
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3.15  Summary 
In Chapter 3, the aim was to demonstrate the influence of murine MSC on the 
immune system through examination of the induction, expansion and education of 
immune cells and to identify the contact dependent signal through which murine MSC 
modulate the immune function of T cells and DC.  To this end, in vitro co-culture 
experiments were carried out between murine MSC, T cells and DC in order to address 
how MSC suppress immune function defining a role for Notch signalling through the 
ligand Jagged 1. 
The immunomodulatory properties of MSC were confirmed by 
demonstrating their ability to expand a regulatory population of T cells and to induce 
tolerogenic DC.  The data herein suggest that MSC can support or even initiate a cycle 
of suppression by inducing tolerogenic DC, these cells in turn induce regulatory T 
cells from a Treg negative population.  MSC promote the expansion of these 
regulatory cells and thus suppress excessive proliferation of activated lymphocytes 
(Fig 3.4).  The fact that MSC alone cannot induce regulatory T cells gives a level of 
elegance to the system, as the MSC cannot create a suppressive environment unless 
DC are initially activated. The importance of this is discussed in Chapter 6, 
Tolerogenic DC were also shown to be functional in that they had the capacity to 
suppress the proliferation of antigen specific T cells (Fig. 3.7). 
 Previous work in the Mahon laboratory indicated Notch was involved in DC 
maturation.  Use of a gamma secretase inhibitor extended that finding, indicating that 
Notch was also involved in the expansion of Treg.  In order to determine the precise 
ligand involved, many approaches were tested.  Lentiviral knockdown of Jagged 1 on 
the MSC was the most effective means of investigating its importance in signalling.  
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The results from experiments with the knockdown MSC demonstrate a role for Jagged 
1 in MSC expansion of Treg, a point of conjecture to this point (Liotta et al., 2008).  
Jagged 1 in partnership with IL-6 also plays a vital role in MSC induction of 
tolerogenic DC, and MSC inhibition of antigen presentation by DC.   
 In summary, the Notch pathway is required for the induction of a functional, 
tolerogenic DC population by MSC.  These tolerogenic DC are in turn capable of 
inducing a Treg population.  This work demonstrates an essential role for Jagged 1 in 
MSC expansion of Treg cells.  MSC inhibition of DC maturation, also involves Notch 
as a contact signal but where IL-6 plays an additive role. 
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Chapter 4 
Murine MSC produce trophic factors that influence tissue 
repair in simple models of pulmonary wound healing 
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4.1 Introduction 
 Fibrosis is characterised by the excessive production and deposition of 
connective tissue, leading to permanent reorganisation and loss of function in the 
affected organ.  The most obvious example of fibrotic damage is scarring seen in the 
skin following injury, where native tissue is replaced by non-functional collagenous 
cicatrix.  Wound healing is a form of damage control, a key part of which is the 
creation of a barrier between exposed tissue and the external environment.  This 
process serves to prevent infection and stop blood loss, depending primarily on 
platelets, the coagulation cascade and fibroblasts (Robson et al., 2001).  Fibrosis might 
be viewed as an aberrant or incomplete form of wound healing but the mechanisms 
responsible for the switch from wound healing to fibrosis are poorly understood.  In 
terms of phenomena,  the presence of activated fibroblasts, their excessive 
proliferation, and apoptosis of epithelial cells are hallmarks of fibrotic  pathogenesis 
(King et al., 2011).  In pulmonary fibrosis, the replacement of healthy alveolar tissue 
with non-functional fibrotic scaring, leads to reduced maximal oxygen consumption 
(V02 max), a measure of lung function (Raghu, 2012).  If left unchecked, the fibrotic 
lesions will render the organ non-functional, with lung transplantation being the only 
treatment option. 
In the previous chapter, murine MSC were shown to have a dramatic effect on 
the cells of the immune system.  In this chapter the focus switches to the reparative 
aspects of MSC.  The ability of MSC to reduce T cell proliferation and expand 
populations of regulatory cells, combined with potential regenerative effects make 
MSC attractive candidates for the  treatment of pulmonary fibrosis, potentially 
dampening the initial inflammatory response to injury and repairing tissue damage.  
Thus MSC could have dual benefits therapeutically.  This chapter sought to examine 
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the latter property, to determine the effects of murine MSC paracrine signalling on 
pulmonary cells, in advance of examining MSC mechanisms of action in vivo.  This 
was achieved by investigating the effects of MSC on the cells directly affected in 
pulmonary fibrosis, namely pulmonary fibroblasts and alveolar epithelial cells.  The 
paracrine effects of MSC were examined in relation to proliferation and migration of 
epithelial cells and fibroblasts.  Using neutralising antibodies, inhibitors and shRNA 
technology, the importance of HGF and PGE2 in MSC signalling was determined. 
 
4.2 Characterisation of primary lung fibroblasts 
The first challenge to studying lung fibrosis is the isolation of appropriate cells.  
Primary lung fibroblasts can be isolated from murine lung and purified in vitro by 
adherence to plastic.  The method of isolation and morphology of the cells is very 
similar to that of murine bone marrow derived MSC, however, there are distinct 
characteristics to each cell type.   
 Primary lung fibroblasts were isolated from the lungs of C57BL/6 mice 
according to the method described in Chapter 2.6 and were subjected to the same 
characterisation as MSC, in order to distinguish them from potential lung resident 
MSC.  Flow cytometric analysis of the cells demonstrated expression of CD44, 
CD106, CD73, CD90, weak expression of the mesenchymal marker Sca-1, and TGFβ 
receptor subunit CD105, and MHC Class I.  There was no expression of the 
haematopoietic marker CD45, lymphocyte marker CD34, or the co-stimulatory 
marker CD86 (Fig.  4.1).   
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As previously described in Chapter 3, MSC demonstrate multi lineage 
differentiation capabilities, specifically to osteoblasts, adipocytes, and chondrocytes.  
Isolated primary fibroblast cells were subjected to the same culture conditions and 
differentiation media.  After 21 days the possible presence of bone and fat cells were 
examined using alazarin red or Oil Red O stain respectively, while the presence of 
chondrocyte marker mRNA was tested by PCR Collagen IIa, collagen III and 
Aggrecan.  The control wells were treated with the same conditions in the absence of 
differentiation components.  No evidence of differentiation was observed (Fig.  4.2).   
A final test to distinguish fibroblasts from lung MSC involved staining both 
cell types for vimentin and αSMA.  Vimentin is a major component of mesenchymal 
cell cytoskeleton, αSMA, another cytoskeletal protein is expressed by MSC and 
myofibroblasts, the activated form of fibroblasts.  Murine MSC used in these studies 
expressed both proteins, in contrast isolated murine pulmonary fibroblasts expressed 
vimentin but not αSMA.  These results not only distinguish the cells used in this study 
but also indicates the population of fibroblasts used for in vitro work hereafter are not 
activated myofibroblasts (Fig.  4.3). 
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Fig.  4.1 Characterisation of Fibroblasts at Passage 3.  Primary C57BL/6 lung 
fibroblasts were characterised by measuring the expression of a variety of cell surface 
markers (Red Line) against their corresponding isotypes (Black Line).  10,000 events 
were recorded for each marker.  These results are representative of multiple 
experiments at passage 3, 4, and 5. 
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Fig.  4.2 Trilineage differentiation of Fibroblasts.  Murine lung fibroblasts (5x104) 
were cultured for 21 days in control medium, osteogenic medium (A), or adipogenic 
medium (B).  Cultures were stained with Alazarin Red for bone and Oil Red O for fat.  
2x105 MSC were centrifuged at 200xG for 8 min to form a cell pellet, control medium 
or chondrocyte medium was added to the tube and the cells were cultured for 21 as a 
3D cell mass.  After 21 days trizol was added to the cell pellet, following RNA 
extraction and cDNA synthesis, the mRNA was tested for the chondrocyte markers 
aggrecan and collagen IIa (C).  The results are representative of two experiments.  
(A&B magnification x100).  
C 
A 
B
 
134 
 
 
 
 
Fig.  4.3 Alpha smooth muscle actin and vimentin staining.  MSC and fibroblasts 
(5x104) were cultured in a 6 well plate until 70-80% confluent.  The cells were fixed 
with ice cold methanol and stained overnight with either vimentin or αSMA primary 
antibodies.  The cells were washed and incubated with alexa-fluor 488 conjugated 
secondary antibody and counterstained with DAPI.  The cells were examined for 
αSMA (A&B) or vimentin (C&D) expression using a fluorescent microscope (x100).   
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4.3 MSC conditioned medium promotes wound closure in a scratch model. 
 Studying fibrosis in vitro has proved challenging as wound healing is a 
complex system involving multiple cell types and signals.  Due to the unknown trigger 
involved in its disregulation and the induction of fibrosis, it is difficult to replicate on 
the bench.  In order to determine whether MSC were having an effect on this system, 
a simplified in vitro model of wound healing was used.  The scratch model involves 
scoring the bottom of a 6 well plate with 3 horizontal lines, these act as microscope 
guides to align the plate in the same position for before and after photographs.  A 
monolayer of fibroblasts or epithelial cells is cultured on these plates then disrupted 
by a “scratch” from a sterile pipette tip, this scratch is a mimic of damage from a 
physical injury.  The distance between the wound edges is measured prior to and 
following the addition of specific treatments.  The assays are inherently variable 
(depending on batch) so wells are closely observed and the assay stopped once the 
first scratch was completely closed rather than at a set time point.  The extent of closure 
in the remaining wells was plotted as a percentage of the first, an approach which also 
removes the variability of scratch width. 
This assay was used to examine MSC trophic effects on primary murine 
fibroblasts and lung alveolar epithelial cells (LA4).  Medium collected from confluent 
MSC (24h) was concentrated using centrifugal filters for protein above a specific size 
and used in treatment of designated wells.  Concentration of MSC conditioned 
medium (CM) ensured the proteins generated by MSC were applied while avoiding 
the detrimental effects of use of depleted medium (eg small metabolic products).  
When generating the MSC CM, the same number of MSC as test cells were plated in 
the same volume of medium and the total volume was concentrated after 24h, thus 
ensuring each test well received a standard amount of CM.  The addition of MSC CM 
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to scratch cultures significantly increased percentage wound closure at day 3 in both 
fibroblasts (Fig.  4.4 A&B) and epithelial cells (Fig.  4.4 C&D), when compared to 
wells receiving only control medium.  These data demonstrate soluble factors 
produced by MSC significantly promote wound closure by epithelial cells and 
fibroblasts.  Traditionally the above method has been associated with investigation of 
cell migration (Liang et al., 2007), therefore, these results can also conclude that MSC 
CM supports the migration of both epithelial cells and lung fibroblasts.    
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Fig.  4.4 MSC conditioned medium significantly enhances Fibroblast and 
Epithelial wound closure in a scratch assay.  Fibroblasts and LA4 cells (1x105) were 
seeded in a 6 well plate and allowed to form a confluent monolayer.  The wells were 
scratched and wound closure measured as described in section 2.19.  MSC CM and 
control medium was concentrated, and the resulting protein fraction was added to 
designated wells.  The width of the scratch in fibroblasts (A&B) and LA4 cells (C&D) 
was measured and graphed as a percentage of closure (x100).  Representative of three 
experiments. 
C 
D 
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4.4 MSC encourage epithelial cell but inhibit fibroblast proliferation. 
 Excessive proliferation of fibroblasts is a hallmark of fibrosis and while 
fibroblasts play a vital role in wound healing, their accumulation is associated with 
pathogenesis.  The closure of the wound area described in the previous section could 
be a result of cell migration into the site of damage or cell proliferation.  Determining 
which process is affected by MSC CM has important implications for the use of MSC 
as a therapy in fibrosis.   
 In order to investigate whether MSC CM was promoting the proliferation of 
these cells, tritiated thymidine was added to the cultures.  The scratched cells were 
cultured in the presence or absence of MSC CM, with the addition of tritiated 
thymidine at day 0.  Interestingly MSC CM had opposing effects on the two cell types.  
When cultured with LA4 cells, MSC CM significantly increased the proliferation of 
the epithelial cells (Fig.  4.5 A).  However, the addition of MSC CM to scratched 
fibroblast cultures not only prevented an increase in proliferation but reduced the 
proliferation to levels significantly lower than basal division, FGF was added to 
scratched fibroblasts as a positive control (Fig.  4.5 B).  Combined, these results 
suggest MSC CM has the ability to encourage fibroblast migration while preventing 
proliferation.  Conversely, MSC CM appears to promote the proliferation of murine 
lung epithelial cells. 
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Fig.  4.5 MSC conditioned medium results in epithelial but not fibroblast 
proliferation.  1 x 105 Fibroblasts or LA4 cells were seeded in a 24 well plate and 
allowed to form a confluent monolayer.  The cells were scratched and fresh media was 
added.  FGF (10ng/ml) or HGF (2ng/ml) were added as positive controls.  MSC CM 
was concentrated, and the resulting protein was added to designated wells.  [3H]-
Thymidine was added to each well and incubated for 3 days.  Cultures were harvested, 
washed, lysed and combined with 2 ml of β-scintillation fluid.  [3H]-Thymidine 
incorporation was quantified by a β-scintillation counter and results were expressed in 
counts per minute (CPM).  Data representative of three experiments. 
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4.5 MSC reduce the TGFβ induced differentiation of fibroblasts. 
 The greatest damage inflicted by fibroblasts in fibrosis is mediated by their 
activated form, myofibroblasts.  These cells are characterised by increased expression 
of alpha smooth muscle actin (αSMA) and increased production and deposition of 
collagen.  As with fibroblasts, myofibroblasts are very important in wound healing 
especially closure, however excessive activation and proliferation is associated with 
fibrotic disease.  Building on the work from section 4.4 it was important to examine if 
MSC influence the differentiation of fibroblasts to their activated form.  This was 
achieved through examination of αSMA mRNA levels by real time PCR.  In order to 
activate the fibroblasts in vitro they were stimulated with 50ng of recombinant TGFβ, 
this resulted in increased expression of αSMA.  The addition of MSC CM to the culture 
medium along with TGFβ resulted in a significant decrease in αSMA expression, 
indicating a reduction in myofibroblasts differentiation (Fig.  4.6).  These data indicate 
that MSC derived soluble mediators inhibit the differentiation of fibroblasts to their 
activated phenotype. 
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Fig.  4.6 MSC inhibit the differentiation of fibroblasts to myofibroblasts.  
Fibroblasts were cultured at 2x106 cells/well of a 6 well plate.  The cells were 
stimulated with 50ng/ml of TGFβ, the control well receiving no stimulant.  MSC CM 
was added to a further well containing TGFβ, and cultured for 24 h.  The cells were 
collected in trizol reagent, and examined for expression of αSMA by quantitative real 
time PCR.  Statistics achieved by student t test, n=3. 
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4.6 PGE2 is required for MSC suppression of Fibroblast proliferation 
Many studies have been carried out to determine which growth factors and 
cytokines are involved in wound healing and fibrosis.  In vitro studies provide 
evidence that lung epithelial cells release PGE2 at levels capable of inhibiting the 
proliferation of fibroblasts (Moore et al., 2003).  Direct stimulation of fibroblasts with 
PGE2 has also been shown to reduce proliferation (Cilli et al., 2004).  The use of COX 
1 and 2 knockout mice demonstrated COX 2 was important in PGE2 inhibition of 
fibroblast proliferation (Lama et al., 2002).  Previous work by the Mahon laboratory 
demonstrated murine MSC produce PGE2, and that levels are significantly increased 
following stimulation with TNFα (L. Tobin & K.  English, unpublished data).  The 
increase in PGE2 following TNFα stimulation was interesting considering the 
inflammatory environment associated with early wound healing.  In order to test the 
relevance of PGE2 in MSC inhibition of fibroblast proliferation, the specific COX 2 
inhibitor NS-398 was added to MSC cultures to inhibit the production of PGE2.  When 
added to a fibroblast scratch assay containing tritiated thymidine, MSC CM from NS-
398 treated cultures were no longer capable of inhibiting the proliferation of 
fibroblasts.  Removing the inhibitory effect of PGE2 did not however lead to an 
increase in proliferation beyond basal levels (Fig.  4.8).  These data show PGE2 plays 
an important role in MSC inhibition of fibroblast proliferation.  Though NS-398 is 
commonly used as an inhibitor of PGE2 signalling, it should be noted that despite its 
lack of involvement in inflammatory processes, COX-1 may also result in PGE2 
synthesis.  Different prostaglandin subtypes also result from COX-2 actions on 
arachidonic acid, therefore it would be more accurate to determine MSC signal 
through the release of prostaglandins. 
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Fig.  4.7 PGE2 produced by MSC is required for suppression of fibroblast 
proliferation.  1 x 105 fibroblasts were seeded in a 24 well plate and allowed to form 
a confluent monolayer.  The cells were scratched and fresh medium was added.  FGF 
(10ng/ml) was added as a positive control.  MSC CM from cells previously treated in 
the presence or absence of NS398 or DMSO control were concentrated.  The resulting 
protein was then added to designated wells.  [3H]-Thymidine was added to each well 
and incubated for 3 days.  Cultures were harvested, washed, lysed and [3H]-Thymidine 
incorporation was quantified and results were expressed in counts per minute (CPM).  
Data representative of two experiments. 
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4.7  Investigations of role of HGF in MSC induced epithelial proliferation 
 As previously discussed, HGF is an important paracrine factor involved in the 
proliferation and migration of epithelial and endothelial cells.  Given the positive 
influence of MSC CM on lung epithelial cell proliferation, MSC were examined for 
production of HGF.  Supernatant from MSC was tested by ELISA for the presence of 
HGF, the cells were also stimulated with TNFα, a pro-inflammatory cytokine up-
regulated in fibrosis.  MSC were shown to constitutively produce HGF, but once 
stimulated with TNFα, HGF levels significantly increased (Fig.  4.8). 
 In order to examine a role for HGF in MSC induction of lung epithelial cell 
proliferation, a neutralising antibody for the HGF receptor was added to the culture 
system.  LA4 cells were plated and scratched in the presence or absence of MSC CM, 
HGF receptor neutralising antibody or the isotype control added at varying 
concentrations to the MSC CM wells.  The wells receiving the isotype control had an 
increased rate of closure compared to the other treatment wells.  The scratch assay is 
concluded once the first group reaches 100% closure, as a consequence of this  rapid 
response from the isotype control wells, the MSC alone group showed no difference 
to the media alone group.  This approach could not therefore be used to definitively 
make any claim on the role of HGF in this system.  However, the groups that received 
the HGF receptor inhibitor did not close the wound area as quickly as the MSC CM 
or medium alone groups.  Though not significant this trend indicated that a potential 
role for HGF should be investigated by other approaches (Fig.  4.9). 
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Fig.  4.8 Stimulation of MSC by inflammatory cytokines results in increased 
expression of HGF.  MSC CM media was tested for levels of HGF by ELISA.  MSC 
were cultured in a 6 well plate at 2x106 cells/well.  50ng/ml of TNFα was added to 
each designated well and cultured for 24 hours.  Medium alone was also examined to 
test for potential HGF in the serum. The supernatant was tested as described in section 
2.21, and the concentration read off a standard curve in pg/ml (p***<0.001).  Statistics 
measured using ANOVA, n=3. 
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Fig.  4.9 HGF neutralising antibody titration in LA4 scratch assay.  LA4 cells 
(1x105) were cultured in a 6 well plate and allowed to form a confluent monolayer.  
MSC CM was concentrated, and the resulting protein was added to designated wells.  
HGF receptor antagonist or isotype control was added to designated wells at increasing 
concentrations from 1µg/ml to 10µg/ml.  The wells were cultured until the first group 
reached 100% closure.  All wells were fixed and stained and the width of each scratch 
was measured and graphed as a percentage of closure as described in section 2.19. 
n=2.   
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4.8 HGF Knockdown MSC retain their stem cell characteristics 
Given that the HGFR neutralising antibody failed to successfully facilitate the 
investigation of a role for HGF in MSC promotion of epithelial repair, alternative 
means to block HGF signalling in MSC were explored.  Following the success of 
shRNA knockdown in previous experiments, constructs targeting murine HGF were 
designed.  After much optimisation, MSC stably knocked down for HGF were 
generated.   
Transducing the MSC with lentivirus did not alter the basic MSC 
characteristics.  Figure 4.10 shows that HGF knocked down (KD) MSC still expressed 
all the required cell surface markers, similar to the profile seen in non-transduced cells.  
MSC demonstrated adherence to plastic and were capable of differentiating in bone, 
fat and cartilage (Fig.  4.11). 
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Fig.  4.10 Surface marker expression on HGF knocked down MSC.  BALB/c 
knocked down MSC were characterised by looking at the expression levels of a variety 
of cell surface markers (Red Line) against their corresponding isotypes (Black Line).  
10,000 events were recorded for each marker.  These results are representative of at 
least three experiments. 
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Fig.  4.11 Trilineage differentiation of HGF knock down MSC.  HGF knock down 
MSC (5x104) were cultured for 21 days in control medium, osteogenic medium (A), 
or adipogenic medium (B).  Cultures were stained with Alazarin Red for bone and Oil 
Red O for fat.  2x105 MSC were centrifuged at 200xG for 8 min to form a cell pellet, 
control medium or chondrocyte medium was added to the tube and the cells were 
cultured for 21 as a 3D cell mass.  After 21 days trizol was added to the cell pellet, 
following RNA extraction and cDNA synthesis, the mRNA was tested for the 
chondrocyte markers aggrecan and collagen IIa (C).  The results are representative of 
two experiments.  
A. 
B. 
C. 
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4.9  Conditioned medium from HGF knocked down MSC no longer supports 
the proliferation of lung epithelial cells. 
The GFP positive MSC that were puromycin resistant were collected and 
tested for HGF expression.  Non-transduced MSC, HGF knock down MSC and non-
silencing control MSC were plated into 6 well plates and cultured for 24 hours, 
supernatants were collected and examined for HGF by ELISA.  (Fig.  4.12).  The cells 
were tested at multiple passages, showing significant reduction in HGF production.   
The HGF knockdown MSC CM was used in culture with LA4 cells to 
determine the importance of HGF in MSC induced proliferation of epithelial cells.  
LA4 cells were plated as a monolayer in 6 well plates, scratched and cultured with 
tritiated thymidine.  Non-transduced MSC CM, HGF knockdown MSC CM or non-
silencing control MSC CM was added to designated wells and cultured for 72h.  The 
baseline proliferation of the LA4 cells was determined in the well containing just 
medium.  Cultures with HGF knocked down MSC CM had significantly lower levels 
of proliferation compared to those containing non transduced MSC CM.  Non-
silencing control MSC CM resulted in higher levels of proliferation but not statistically 
elevated compared to the non-transduced MSC (Fig.  4.13).   
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Fig.  4.12 Expression of HGF in HGF knocked down MSC    HGF knock down 
MSC CM, non-transduced MSC CM, and non-silencing control MSC CM was tested 
for levels of HGF by ELISA.  MSC were cultured in a 6 well plate at 2x106 cells/well 
for 24 hours.  The supernatant was tested as described in section 2.21, and the 
concentration read off a standard curve in pg/ml (p**<0.001).  Data representative of 
three experiments. 
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Fig.  4.13 HGF is responsible for MSC induced LA4 proliferation.  1 x 105 
epithelial cells were plated in a 24 well plate and allowed to form a confluent 
monolayer.  The cells were scratched and fresh medium was added.  MSC, HGF KD 
MSC and non-silencing control MSC CM was concentrated and the resulting 
supernatent was then added to designated wells.  [3H]-Thymidine was added to each 
well and incubated for 3 days.  Cultures were harvested, washed, lysed and combined 
with 2 ml of β-scintillation fluid.  [3H]-Thymidine incorporation was quantified by a 
β-scintillation counter and results were expressed in counts per minute (CPM).  Data 
representative of two experiments. 
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4.10 HGF does not rescue epithelial cells from TNFα induced apoptosis. 
 In addition to the role of HGF in proliferation of epithelial cells, the growth 
factor has also been associated with a protective role against cell apoptosis.  Previous 
studies have demonstrated HGF has the capacity to protect cardiac myocytes from 
oxidative stress induced apoptosis (Kitta et al., 2001) and kidney epithelial cells from 
cyclosporine A induced apoptosis (Fornoni et al., 2001).  In order to determine 
whether HGF was influencing apoptosis in this model, epithelial cells were subjected 
to TNFα induced apoptosis, mimicking the effects of TNFα in the disease state.  
Increasing levels of HGF were then added to culture, beginning at levels 
physiologically produced by MSC.  Figure 4.14 shows that even at higher levels of 
20ng/ml, HGF had no effect on either early (lower right quadrant) or late apoptosis 
(upper right quadrant).  This result indicates that the influence of MSC derived HGF 
in this model is unlikely to be via prevention of the apoptosis of lung epithelial cells. 
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Fig.  4.14 TNFα induced apoptosis is not alleviated by HGF at concentrations 
produced by MSC.  1x105 LA4 cells were seeded into a 24 well plate and allowed to 
form a confluent monolayer.  50ng/ml of TNFα was added to induce apoptosis in the 
cells.  HGF was added to the culture medium in increments from 1ng/ml to 20ng/ml.  
Apoptosis was measured using annexin V and propidium iodide staining followed by 
flow cytometry analysis. N=3. 
  
LA4 LA4+TNF 
LA4+TNF+HGF 1ng/ml LA4+TNF+HGF 5ng/ml 
LA4+TNF+HGF 10ng/ml LA4+TNF+HGF 20ng/ml 
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4.9  Summary 
 In this chapter primary lung fibroblasts and lung alveolar epithelial cells were 
treated with conditioned media form treated and untreated MSC.  These data 
established a potential role for MSC in the proliferation of epithelial cells and 
inhibiting the activation and proliferation of fibroblasts. 
 The alternative effects of MSC on different lung cells was established using a 
scratch assay of wound closure.  MSC CM promoted the migration of both epithelial 
cells and fibroblasts into the site of damage.  However, MSC CM maintained control 
over fibroblast homeostasis, inhibiting their activation and proliferation.  In the 
context of wound healing and fibrosis, the opposing interplay between MSC, epithelial 
cells and fibroblasts could be exploited for its therapeutic potential.  Fibroblasts are 
vital in wound healing and promoting their migration into the site of injury may aid 
wound closure but the un-checked proliferation and activation of fibroblasts leads to 
disease progression, both of these latter traits are inhibited by MSC.  The second 
crucial process in healing is remodelling, where fibrotic tissue is replaced with 
functional lung epithelial tissue.  MSC promotion of epithelial cell proliferation could 
support the re-epithelialisation of tissue damaged by fibrosis in the lung. 
 Previous work showed the importance of MSC signalling through contact 
dependent methods, here MSC paracrine effects were investigated.  Experiments 
blocking PGE2 production by MSC reversed MSC inhibition of fibroblast 
proliferation.  Interestingly, expression of the lipid mediator by MSC is also increased 
in an inflammatory environment associated with early fibrosis.  The same is true of 
the growth factor HGF, a known mitogen for epithelial cells.  Using shRNA 
technology to knock down HGF expression in MSC, HGF was shown to be 
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responsible for MSC driven epithelial proliferation.  These data provide a strong basis 
for MSC therapy in pulmonary fibrosis on two fronts.  Firstly, MSC can suppress the 
excessive proliferation and activation of fibroblasts by PGE2, and secondly, through 
HGF by encouraging the growth and replenishment of functional alveolar epithelial 
cells.   
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Chapter 5 
The effects of MSC treatment upon bleomycin induced lung 
fibrosis. 
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5.1 Introduction 
 The clinical management of lung fibrosis currently focuses on treating the 
symptoms but not the underlying cause, which in many cases remains unknown.  As 
discussed in the introduction, initial treatment includes corticosteroids and 
immunosuppressive drugs, while cytotoxic drugs are used to improve lung function.  
Ultimately, lung transplantation remains the end result for many patients who don’t 
respond to treatment.  Trials to find novel targets are ongoing with pre-clinical 
experimental data assisting the search for potential drug candidates.  In the previous 
chapter, the effect of murine MSC on pulmonary cells was examined with regard to 
potential benefits for treatment of fibrosis.  In order to examine the effect of murine 
MSC therapy in vivo, the bleomycin mouse model of pulmonary fibrosis was used.   
Bleomycin is a chemotherapeutic drug used to treat a variety of tumours, 
however in approximately 5% of cases it adversely induces pulmonary toxicity and 
fibrosis (Walters and Kleeberger, 2008).  This side effect has been utilised in animals 
to create a model of pulmonary fibrosis.  As discussed in the introduction, the model 
is used mostly in C57BL/6 mice as BALB/c mice were poor responders (Schrier et al., 
1983).  The model consists of a single intra-tracheal instillation that results in 
inflammation and increased production of collagen.  Physiological changes are 
observed over 3-4 weeks (Izbicki et al., 2002), thereafter the model begins to resolve, 
and in as few as 5 weeks there is little to no evidence of fibrotic lesions.  The resolution 
of fibrosis in the mouse model is inconsistent with the human disease.  In the absence 
of a chronic stimulus often associated with human fibrosis, murine lungs regenerate 
and remove the collagen deposits.  Despite the limitations of the model, bleomycin 
induced fibrosis still provides the best reproducible animal model of pulmonary 
fibrosis.  Many of the drugs currently being tested in clinical trials were initially tested 
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in bleomycin mouse models, be they for preventative or therapeutic use (Moeller et 
al., 2008).   
This study sought to examine the hypothesis that MSC could improve pathology in 
bleomycin induced fibrosis.  With an aim to refine the bleomycin murine model of 
fibrosis resulting in a more accurate representation of therapeutic intervention, 
consequently using this model to determine MSC efficacy as a cellular therapy in 
fibrosis.  This chapter also examined the importance of MSC derived HGF with 
regards to any positive outcome in treatment.   
 
5.2 MSC reduce pathology in a bleomycin induced murine model of fibrosis 
 The standard model of bleomycin induced fibrosis involves intra-tracheal 
instillation (IT) of bleomycin at a concentration of 4U/kg.  In this model bleomycin 
was administered by intranasal inhalation (IN) under anaesthetic.  Previous work 
performed in the laboratory using crystal violet stain, demonstrated that IN 
administration of liquid leads to comprehensive permeation throughout the lung.  An 
initial study aimed to ensure the model worked under these modified conditions and 
that the administration of allogeneic murine MSC to a control mouse had no adverse 
effects.  The PBS treated lungs showed little sign of fibrotic damage, with no major 
changes to the lung architecture, and only small collagen deposits around bronchioles.  
These observations were consistent at day 7 (Fig.  5.1 A&B), day 14 (Fig.  5.  C&D), 
and day 28 (Fig.  5.1 E&F).  Delivery of allogeneic MSC intravenously to mice that 
received PBS IN resulted in a similar pathology to PBS control groups, with no 
statistical difference in their pathological score (Fig 5.1 G).  Bleomycin treated groups 
displayed deposition of collagen in alveolar spaces and around bronchioles by day 7, 
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there was thickening of alveolar septae but the lung structure was largely preserved 
(Fig 5.1 A&B).  At day 14 the alveolar septae had clearly thickened with larger 
collagen deposits radiating from the bronchioles (Fig 5.1 C&D).  At day 28, fibrotic 
masses could be observed in over 20% of the microscopic field, and the alveolar spaces 
are enlarged with contiguous fibrotic thickening (Fig 5.1 E&F).   
 Administration of allogeneic MSC to bleomycin treated mice resulted in an 
improvement in pathology on day 7 and 14, there was still thickening of the alveolar 
septa but less collagen deposition around the bronchioles (Fig 5.1 A&B, C&D).  At 
day 28, there was a statistically significant improvement in pathological scoring (Fig 
5.1 G), with reduced fibrotic deposition in alveolar spaces and rarefied fibrotic masses.  
Alveolar septae displayed only localised thickening and lung structure was maintained 
(Fig 5.1 E&F). 
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Figure 5.1 Allogeneic Murine MSC administration reduces lung pathology in a 
bleomycin model.  Representative images of transverse lung histological sections at 
day 7 (A&B), day 14 (C&D), and day 28 (E&F).  Airway fibrosis was detected by 
trichrome staining for collagen deposition as described in section 2.26. Fibrotic masses 
are indicated by the green arrows, thickening septae are indicated by red arrows. 
Histological scoring was performed by at least 2 researchers (G), n=5. 
 
 
G. 
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5.3 Syngeneic and allogeneic murine MSC reduce bleomycin pathology. 
 The bleomycin model, as mentioned above, is performed in C57BL/6 mice.  In 
order to establish whether reduction in pathology is affected by treatment with 
allogeneic or syngeneic MSC, a small pilot study was performed.  C57BL/6 mice were 
treated with bleomycin IN and injected IV with BALB/c MSC or C57BL/6 MSC 6 
hours later.  Lungs were collected on day 28 and examined for collagen deposition by 
trichrome staining.  The cytokine and growth factor profile of the lungs was also 
examined by RT-PCR.   
As with the initial pilot, the PBS control group maintained a normal lung 
architecture with minimal collagen deposition around the bronchioles (Fig 5.2 A&B).  
The bleomycin treated group had enlarged alveolar septa and heavy collagen 
deposition around bronchioles (Fig 5.2 A&B).  Systemic administration of either 
C57BL/6 MSC or BALB/c MSC resulted in an improvement in pathology compared 
to the bleomycin treated mice.  MSC treated lungs showed signs of some architectural 
damage but only isolated fibrotic masses, both allogeneic and syngeneic MSC 
treatments resulted in reduced fibrotic thickening around the bronchioles compared to 
bleomycin treated lungs (Fig 5.2 A&B).   
Lung mRNA was tested by real time PCR for a panel of cytokines and growth 
factors relating to inflammation and fibrosis.  At day 28 the expression of both 
inflammatory (Fig 5.2 C) and fibrotic (Fig 5.2 D) genes were up regulated following 
exposure to bleomycin when compared to the PBS control mRNA.  Treatment with 
either BALB/c or C57BL/6 MSC reduced expression levels of the inflammatory 
cytokines TNFα, and IL-1β, as well as the fibrotic markers TGFβ and fibronectin in 
comparison to the bleomycin treated group.  However, the data did not reach statistical 
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significance, the resolving nature of the model more than likely accounting for this.  
At day 28 the lungs are already beginning to recover from the single dose of 
bleomycin.  Sampling lungs at an earlier time point was therefore tested as a means to 
improve the statistical relevance of MSC effect on gene expression. 
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Figure 5.2 Histology and PCR results from allogeneic and syngeneic murine MSC 
treatment of bleomycin induced lung fibrosis.  C57BL/6 mice were treated with a 
single IN dose of bleomycin (4U/kg).  BALB/c or C57BL/6 MSC were administered 
6h later by tail vein injection.  Lungs were harvested at day 28.  Representative images 
of transverse lung sections at 28 days (A&B).  Airway fibrosis was detected by 
trichrome staining for collagen deposition.  Fibrotic masses are indicated by the green 
arrows, thickening septae are indicated by red arrows.  Real time PCR expression of 
inflammatory and fibrotic genes (C) from whole lung mRNA.  Histology and real time 
data is representative of at least 2 replicates.   
C. 
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5.4 Time course of fibrotic development 
 The bleomycin model is characterised by an initial inflammatory response 
followed by fibrosis.  The time point at which a therapy is given can determine whether 
or not the treatment can be considered an anti-inflammatory therapy, designed to limit 
the disease by combatting the side effects or whether it can be considered a treatment 
against established fibrosis.  In order to determine the time course of the bleomycin 
model a pilot study was conducted, collecting samples every 3 days for 28 days.  The 
lungs from these mice were analysed by PCR for a panel of inflammatory and fibrotic 
genes.  By establishing the time at which fibrosis occurs, the accurate time to give 
MSC as a treatment can be determined, the results can also establish the optimum time 
point to collect samples in order to observe any potential improvement following MSC 
treatment.   
 When compared to basal levels at day 0, TNFα expression significantly 
increased by day 9 and peaked at day 15, after which there was a gradual decrease for 
the next 16 days (Fig 5.3 A).  IL-1β expression was also significantly increased by day 
15, however given the values either side of day 15 this may be an outlier in data 
collation (Fig.  5.3 B).  These results indicate the inflammatory response associated 
with bleomycin treatment begins at approximately day 9 peaking at day 15 and 
reducing thereafter.  The fibrosis associated growth factor TGFβ increased gradually 
from day 3, reaching a significant high at day 15 compared to levels observed at day 
0 (Fig 5.3 C).  HGF levels were examined, appearing to gradually increase over the 
course of the study but never reaching statistical significance (Fig 5.3 D).  As 
demonstrated in chapter 4, HGF is a growth factor associated with epithelial growth 
and wound repair.  A potential correlation between the positive effects of MSC on 
pathology and expression of HGF following MSC administration required further 
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examination.  The above results showed the onset of fibrosis occurs at day 15, with 
inflammation beginning 6 days earlier allowing future studies using MSC to 
discriminate between anti-inflammatory responses and anti-fibrotic ones.   
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Fig 5.3 Real Time PCR on Lung samples of Bleomycin time course.  C57BL/6 
mice were treated with bleomycin by IN.  Four mice were sacrificed every 3 days for 
28 days and the lungs were processed for RNA isolation.  Following cDNA synthesis, 
real time PCR was run for selected inflammatory (A&B) or fibrotic (C&D) markers.  
The results were graphed and analysed for statistical relevance (* represents p< 0.05) 
A B 
C D 
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5.5 Allogeneic murine MSC protection from bleomycin induced fibrosis is 
dependent on the time of administration. 
 In order to differentiate between MSC as an anti-inflammatory treatment and 
an anti-fibrotic therapeutic, the administration of MSC was delayed until the onset of 
fibrosis.  Based on the results from the previous section MSC were given at day 0 and 
day 9.  HGF KD MSC and non-silencing control MSC, characterised in chapter 4, 
were also administered at day 9.  This time point was chosen in the effort to determine 
a role for MSC released HGF as a therapeutic target in repair of bleomycin induced 
fibrotic damage.  Lungs were collected on day 15 and day 21, as expression levels of 
fibrotic genes appear to diminish after this point. 
 As with previous studies, PBS control mice maintained a normal lung 
architecture and low levels of inflammatory cytokines (Fig 5.4 & Fig 5.5).  Bleomycin 
treated mice displayed extensive collagenous masses and enlarged alveolar spaces, as 
well as alveolar septum thickening at both day 15 and day 21 (Fig.  5.4 A, B&C).  
There was also an increase in TNFα and IL-1β levels at day 15.  TNFα levels were 
generally reduced at day 21, however IL-1β expression was still up-regulated in the 
bleomycin group compared to PBS lungs (Fig.  5.5 A&B).  At day 15 there was little 
difference in lung pathology of mice that received allogeneic MSC at day 0 compared 
to day 9, however, by day 21 lungs from mice treated with MSC on day 0 show a 
reduced pathological score, significantly reduced IL-1β levels and a significant 
increase in HGF expression compared to groups where MSC were given on day 9 (Fig 
5.4 A&B);(Fig.  5.5).  3T3 fibroblast cells were administered at the same time points 
as MSC as a control, The cells, particularly those administered at day 9 increased 
TNFα and TGFβ levels at day 15 but this did not translate into increased pathological 
scoring (Fig 5.4);(Fig.  5.5).  While greater statistical relevance was established when 
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studying gene expression at day 21, the histological scores from MSC treatment failed 
to reach statistical relevance suggesting extra time in needed for the physiological 
effects of increased fibrotic gene expression to take effect.  The above results 
demonstrate the timing of not only therapeutic administration but also data collection 
is critical in bleomycin studies. 
 Unsurprisingly, there was no difference between untreated MSC and HGF KD 
MSC administered at day 9.  Delayed administration of MSC appears to impair their 
protective effect when compared to bleomycin treated mice, therefore any detrimental 
effect to blocking HGF production by MSC could not be established (Fig.  5.4 C&F).  
These results suggest MSC may not be an ideal candidate for anti-fibrotic therapy as 
administration of MSC during the onset of fibrosis failed to reduce of reverse the 
course of the disease.   
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Figure 5.4 MSC administration improves lung pathology.  Representative images 
of transverse lung pathology (magnification x100) from bleomycin treated mice at day 
15 (A) and day 21 (B&C).  MSC or control 3T3 cells were administered by IV either 
on day 0 or day 9 (A&B).  HGF KD MSC and non-silencing control MSC were 
administered by IV on day 9 (C).  Airway fibrosis was detected by trichrome staining 
for collagen deposition.  Fibrotic masses are indicated by the green arrows, thickening 
septae are indicated by red arrows.  Histological scoring was performed by at least 2 
researchers and scores are an average of sections from 5 animals (D, E, F).   
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Fig 5.5 Real Time PCR on Lung samples of Bleomycin treated mice at day 15 and 
day 21.  C57BL/6 mice were treated with bleomycin by IN.  5 mice were sacrificed 
on day15 and day 21 and the lungs were processed for RNA isolation.  Following 
cDNA synthesis, real time PCR was run for selected inflammatory (A&B) or fibrotic 
(C&D) markers.   
C. 
D. 
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5.6 Summary 
In this chapter allogeneic MSC were systemically administered to bleomycin 
treated mice on day 0 resulting in improved pathology.  This was most evident in a 
reduction of collagenous plaque deposition, reduction in the thickness of alveolar 
septum and preservation of lung architecture.  These observations were evident 
following administration of either allogeneic or syngeneic MSC.  Treatment of mice 
with allogeneic MSC had adverse effects on healthy mice.   
A time course study delineating the onset of inflammation and that of fibrosis 
following administration of bleomycin allowed for more accurate conclusions to be 
drawn about the role of MSC as a prophylactic or a therapeutic treatment.  Previous 
work from chapter 3 showed the importance of MSC in maintaining a regulatory 
phenotype resulting in a reduction in inflammation.  MSC were also shown to inhibit 
the proliferation and activation of fibroblasts while promoting re-epithelialisation.  
When the potential of these phenomena were examined in vivo, MSC administered at 
day 9, the onset of a fibrotic milieu, were shown to not be as effective as MSC 
administered at day 0.  This interesting data provided a strong basis for MSC in 
treatment of early onset inflammation, however elucidation of benefits in delayed 
treatment will require further study. 
Taken together these results achieved the aims set forth at the beginning of the 
study.  Analysis of the bleomycin model determined the optimum time points for 
administration of therapeutics with a view to treatment of inflammation or fibrosis.  
MSC were shown to effectively reduce pathology, reduce inflammatory cytokines and 
increase levels of HGF but not when administration is delayed.  For this reason the 
potential benefits of HGF produced by MSC could not be determined in knockdown 
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studies, as HGF KD MSC were delivered at day 9.  A correlation could be made 
between the benefits seen with early MSC treatment and the subsequent increase in 
HGF levels.  Despite this, and considering human patients will have pre-existing 
fibrosis, MSC are not likely to be a suitable candidate in anti-fibrotic therapies where 
fibrosis is established. 
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Chapter 6 
Discussion 
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The present study sought to understand exactly how MSC mediate their positive 
effects in disease systems.  The specific aims were to discover the contact dependent 
signal through which MSC modulate the responses of immune cells, namely T cells 
and DC.  Various technologies and approaches such as neutralising antibodies, siRNA, 
and shRNA knockdown were employed to investigate potential key mechanisms of 
action in MSC.  These techniques were also used to determine the effects of MSC 
paracrine signalling on pulmonary cells, with an aim to examine MSC mechanisms of 
action in vivo.  The bleomycin model of fibrosis was investigated and refined to more 
accurately represent therapeutic intervention.  Knowledge gained about MSC 
modulation of immunity and influence over pulmonary cells in vitro was employed to 
establish the efficacy of MSC as a cellular therapy in fibrosis. 
 A range of studies have identified the soluble factors involved in MSC 
suppression of immune cell functions.  TGFβ and PGE2 play a role in the regulation 
of T cell proliferation, development and the expansion of a Treg population (English 
et al., 2007, English et al., 2009, Ge et al., 2010, Nemeth et al., 2010).  PGE2 is also 
involved in MSC regulation of mast cell migration and NK cell proliferation (Brown 
et al., 2011, Spaggiari et al., 2006, Su et al., 2011), while IL-6 plays an important role 
in suppression of DC maturation (Djouad et al., 2007).  Despite the obvious 
importance of soluble factors, some of these publications describe a role for contact 
signalling, with transwell and conditioned media (CM) experiments failing to 
reproduce the results observed in co-culture systems (English et al., 2009, Spaggiari 
et al., 2006).  These seemingly conflicting findings suggest either a sequential or 
synergistic role for contact and soluble factors in MSC immunomodulation.  However, 
large gaps remain in our knowledge of the contact dependent mechanisms involved in 
MSC signalling.   
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Notch signalling is involved in many cell fate decisions (Furukawa et al., 2000, 
Hoyne et al., 2000, Hellstrom et al., 2007), displaying wide expression across 
numerous immune cells including MSC.  What made Notch signalling an interesting 
candidate in MSC immunomodulation was its involvement in T cell regulation (Yvon 
et al., 2003, Samon et al., 2008) and DC maturation (Cheng et al., 2003, Bugeon et 
al., 2008).  Global inhibition of Notch signalling in vitro by GSI resulted in a reduction 
of TGFβ induced FoxP3 expression in T cells and reduced their ability to supress 
allogeneic proliferation (Samon et al., 2008).  In vivo, GSI delivery resulted in 
autoimmune hepatitis like symptoms associated with dysfunctional TGFβ signalling 
(Samon et al., 2008).  Over expression of Jagged 1 in EBV-lymphoblastoid B cells 
(LCLs) led to reduced production of IFNγ, IL-2 and IL-5 by T cells with increased 
expression of TGFβ, indicating a regulatory phenotype (Yvon et al., 2003).  These 
results suggested that MSC signalling through Notch ligands and receptors could have 
regulatory effects on T cells, with a strong indication of an important role for Jagged 
1.  Interestingly a similar story was observed in DC, when isolated from Notch 1 
deficient mice they displayed a reduced maturation profile, indicating a role for Notch 
signalling in DC maturation (Cheng et al., 2003).  A specific role was also 
demonstrated through over expression studies, resulting in accumulation in immature 
DC precursors (Cheng et al., 2003).   
The data presented in chapter 3 demonstrated that allogeneic murine bone 
marrow derived MSC suppress both T cells and DC through the Notch signalling 
pathway, specifically the Notch ligand Jagged 1.  Global inhibition of Notch signalling 
using GSI and targeted inhibition of Jagged 1 signalling resulted in abrogation of MSC 
mediated suppression of DC maturation, antigen presentation and regulatory T cell 
expansion.  While disruption of Jagged 1 signalling was sufficient to impede MSC 
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expansion of Treg cells, soluble factors partially compensated for the absence of a cell 
contact signal on DC.  In addition to a successful Notch signal, MSC inhibition of DC 
maturation and antigen presentation required a soluble factor, IL-6, as shown using a 
neutralisation approach.  Thus far, studies into MSC inhibition of DC function have 
focused on either contact signalling or soluble factors, stating a requirement for cell-
cell contact but not identifying the ligand involved.  The data herein is the first to 
identify and demonstrate the requirement of both cell contact signalling, in the form 
of Jagged 1 and the soluble factor IL-6.  DC that encountered MSC displayed a “semi-
mature” phenotype capable of inhibiting antigen specific T cell proliferation.  These 
DC were also capable of Treg cell induction.  Though the up-regulation of a Treg 
population is a known consequence of tolerogenic DC and T cell co-culture, this is the 
first time tDC have been shown to induce Treg cells from a null population.   
As discussed in Chapter 3, several studies have provided evidence of MSC 
promoting the up-regulation of the Treg associated transcription factor FoxP3, the 
resulting accumulation of Treg  cells  were shown to be functional both in vitro 
(English et al., 2009) and in vivo (Ge et al., 2010, Kavanagh and Mahon, 2011).  The 
present study, while also demonstrating the up regulation of FoxP3 expressing cells, 
addressed the as yet unresolved issue of MSC expansion over MSC induction of a 
Treg population.  Cell sorting techniques allowed the removal of all 
CD25+FoxP3eGFP+ cells from a naïve CD4+ population.  Subsequent co-culture with 
MSC proved MSC are incapable of inducing Treg cells from a null population in this 
system, rather they support the expansion of a pre-existing population.  This novel 
result has important implications for MSC use in cell therapy.  The efficacy of MSC 
in diseases associated with depleted levels of Treg such as autoimmune hepatitis may 
be reduced (Vierling, 2011).  A recent study by Kavanagh et al. elegantly 
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demonstrated the significance of MSC expansion of Treg in an in vivo model of 
allergic airway inflammation.  MSC were shown to reduce lung pathology and cell 
infiltration through expansion of Treg, an effect that was abrogated when Treg 
populations were depleted (Kavanagh and Mahon, 2011). 
MSC interactions with DC are now widely understood to produce a 
“tolerogenic” DC (tDC); (Beyth et al., 2005, Bugeon et al., 2008, Morelli and 
Thomson, 2007, Nauta et al., 2006).  This phenomenon was also investigated in 
Chapter 3 by examining OVA driven proliferation of DO11.10 CD4+ T cells.  DC that 
had encountered MSC (MSC educated DC) demonstrated lower expression of MHC 
Class II and CD86 on the cell surface and had a tolerogenic phenotype, consistent with 
a tDC population defined by Morelli et al.  (Morelli and Thomson, 2007).  OVA 
stimulated tDC co-cultured with OVA primed DO11.10 CD4+ T cells, suppressed the 
antigen driven proliferation of T cells when compared to mature OVA presenting DC.  
Furthermore the cells were shown to directly induce Treg cells from a null population.  
It is therefore reasonable to assume that tDC inhibition of T cell proliferation is as a 
result of Treg induction.  This hypothesis is supported by several studies where tDC 
were shown to up-regulate Treg cells (Ge et al., 2010, Li et al., 2008, Zhang et al., 
2009).  Though Li et al. demonstrated tDC induction of alloantigen specific Treg cells 
(Li et al., 2008), the finding herein is the first instance of Treg induction by MSC 
educated DC from a null population.  Zhang et al.  demonstrated similar tDC mediated 
T cell suppression, however the model used here expanded on this study by 
demonstrating tDC suppression of antigen specific T cells (Zhang et al., 2009).  The 
practical use of tDC has been demonstrated in an in vivo model of kidney 
transplantation, whereby the infusion of tDC improved graft tolerance, decreased 
donor T cell proliferation and increased the levels of CD25+FoxP3+ cells in the donor 
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spleen (Ge et al., 2009).  Taken together these observations suggest a complementary 
approach to MSC immunomodulation.  MSC induce a regulatory tDC population, 
capable of suppressing T cell proliferation and inducing Treg cells in vitro.  
Additionally, MSC in turn promote the expansion of Treg cells maintaining an 
immunosuppressive environment.   
The precise mechanisms underlying MSC modulation of T cells and DC were 
investigated in this study, initially employing global suppression of Notch signalling, 
before determining the exact ligand utilised by MSC.  An essential role for cell contact 
in murine MSC signalling to T cells was established initially by Krampera et al. 
(Krampera et al., 2003).  This view was expanded by Selmani et al. and English et al., 
whereby a requirement for cell contact between MSC and T cells was confirmed, while 
observing a non-redundant role for soluble factors.  (Selmani et al., 2008, English et 
al., 2009).  Selective inhibition of TGFβ and PGE2 demonstrated their role in MSC 
expansion of Treg cells.  Transwell experiments had determined a role for cell-cell 
contact in this system (English et al., 2009).  As mentioned previously, the Notch 
family of receptors and ligands presented interesting candidates in MSC cell-cell 
signalling.  They were shown here to be widely expressed by both MSC and T cells, 
while previous work by the Mahon lab showed they were also expressed by DC (L.  
Tobin, PhD Thesis NUI Maynooth).  Liotta et al., found that the ability of MSC to 
inhibit T cell proliferation was significantly reversed when Notch signalling was 
interrupted through the addition of a Notch signalling inhibitor (DAPT) or a Jagged-1 
neutralisation antibody.  In support of these findings, this study found suppression of 
Notch signalling by GSI resulted in a reduction of MSC driven expansion of Treg 
cells.  More recently a study by Del Papa et al. identified Notch 1 on CD4+ cells as the 
principle receptor involved in MSC recruitment of inducible Treg (iTreg).  Based on 
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these findings, Del Papa et al. make a number of incorrect assumptions foremost 
among these were: the iTreg used there were isolated by CD25 enrichment, whereas 
CD25 is more commonly associated with natural Treg.  Del Papa also assumed 
blockade of Notch signalling by GSI on the T cell resulted in iTreg recruitment.  
However, MSC also express Notch receptors and therefore cannot be eliminated from 
influencing the outcome.  Although it is conceivable that MSC signal through the 
Notch 1 receptor, a definitive conclusion cannot be drawn from that report (Del Papa 
et al., 2013). 
Jagged 1 was chosen as the principle ligand for investigation, as previously 
published data using soluble Jagged 1 suggested a strong role in Treg expansion (Yvon 
et al., 2003) and induction of tolerogenic DC (Bugeon et al., 2008).  Yvon et al.  
demonstrated that antigen presenting B cells overexpressing Jagged-1 were capable of 
reducing IFNγ, IL-5 and IL-2 secretion from naïve T cells, while up regulating the 
production of TGF-β, a soluble factor associated with a regulatory T cell phenotype 
(Yvon et al., 2003).  Whereas DC maturation with soluble Jagged 1 resulted in 
increased expression of IL-10 and IL-2, and DC promoted the proliferation of 
CD4+CD25+ T cells (Bugeon et al., 2008).  A number of approaches were tested to 
inhibit MSC signalling through Jagged 1.  Initial failure with neutralising antibodies 
and the limited duration of siRNA silencing led to adoption of a lentiviral shRNA 
knockdown strategy.  This sophisticated approach allowed for the production of 
lentiviral particles containing shRNA constructs against Jagged 1.  Once infected with 
the virus, the cell’s own transcription machinery would produce Jagged 1 shRNA to 
maintain continuous knockdown of the ligand.  MSC infected with the lentivurus were 
examined for mRNA and protein expression of Jagged 1.  They were also 
characterised to ensure they maintained their unique cell surface expression profile 
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and trilineage differentiation potential.  Co-culture experiments using Jagged 1 
knocked down MSC and CD4+ T cells resulted in abrogation of Treg expansion by 
MSC.  The considerable decrease in CD25+FoxP3eGFP+ strongly suggested that MSC 
promotion of Treg expansion occurs through Jagged 1 signalling.  A caveat to 
interpreting these results lies in the non-silencing control which showed knockdown 
of Jagged 1 both at an mRNA, and a protein level.  Based on these finding the 
remaining Notch ligands were examined for reduced expression.  Jagged 2 is not 
expressed by MSC but Delta like ligand 1 expression remained unaffected by either 
Jagged 1 shRNA or non-silencing control lentiviral transduction.  This aberrant 
reduction in Jagged 1 could be attributed to plasmid DNA contained in the lentiviral 
units stimulating the TLR3 receptor expressed by MSC.  TLR3 signalling on MSC 
results in down regulation of Jagged 1 (Liotta et al., 2008).  Given that TLR3 
stimulation did not affect the expression of other Notch ligands on MSC, these results 
still strongly suggest Jagged 1 is the contact signal between MSC and T cells in Treg 
expansion.  Further evidence to support a role for Jagged 1 in MSC signalling was 
demonstrated using the Notch inhibitor DAPT and a Jagged 1 neutralising antibody, 
where inhibition of signalling resulted in abrogation of MSC suppression of T cell 
proliferation.  Novel results described herein suggest neutralisation of Jagged 1 
signalling in the previously mentioned study impeded MSC expansion of Treg leading 
to unsuppressed proliferation of T cells.  Taken together these results indicate a 
definitive role for Jagged 1 in MSC expansion of Treg cells. 
 The relevance of Notch signalling in MSC expansion of Treg cells and the 
expression of Notch receptors and ligands on DC (L.  Tobin, PhD thesis) suggested a 
further role for the pathway in MSC modulation of DC.  Several studies have identified 
a role for Notch signalling in DC maturation (Cheng et al., 2007, Cheng et al., 2003, 
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Weijzen et al., 2002).  Previous work by the Mahon group used GSI to demonstrate a 
role for Notch in MSC inhibition of DC maturation.  This study furthered this work 
by proving GSI mediated inhibition of Notch signalling also resulted in suppression 
of MSC induction of tolerogenic DC.  OVA stimulated DC cultured in the presence of 
MSC and GSI, no longer possessed the ability to promote T cell proliferation in an 
antigen driven model of proliferation.  This suggested that the Notch signalling 
pathway was involved in MSC induction of a tolerogenic DC population.  These 
findings are consistent with a study by Li et al., where DC matured in the presence of 
MSC and the Notch inhibitor DAPT resulted in increased T cell proliferation and IFNγ 
production (Li et al., 2008).  However, the results described here are more relevant, 
given the inhibition of antigen specific T cell proliferation.   
Co-culture of DC with Jagged 1 knocked down MSC only partially reversed 
MSC induced inhibition of maturation, suggesting Jagged-1 is involved in MSC 
signalling to DC, but there are other contributors to this effect, such as soluble factors.  
In support of this hypothesis, MSC derived IL-6 was shown to play a crucial role in 
the inhibition of DC differentiation (Djouad et al., 2007, English et al., 2008).  The 
addition of an IL-6 neutralising antibody in conjunction with Jagged-1 knock down 
MSC to DC co-culture experiments resulted in restoration of the maturation markers, 
MHC Class II and CD86 to levels equivalent to those seen in the mature DC.  From 
these results it is reasonable to conclude for the first time that direct cell contact 
through Notch/Jagged-1 and the release of IL-6 were required for MSC to achieve the 
full modulatory effect on DC maturation.  A recent study by Zhang and colleagues, 
further supports the importance of the Notch signalling pathway in immune regulation.  
Using siRNA techniques, tDC regulation of lymphocyte proliferation was 
demonstrated to be dependent on Jagged 2 signalling (Zhang et al., 2009).  Taken 
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together these results complete the story of Notch signalling in MSC modulation of T 
cells and DC.  Jagged 1 expression, as well as IL-6 production by MSC induces a 
regulatory tDC.  These cells in turn reduce lymphocyte proliferation in a Jagged 2 
dependent manner, while also inducing a Treg population.  MSC signalling, again 
through Jagged 1, promotes the expansion of said Treg cells.  These observations have 
important ramifications for the Notch signalling family as potential therapeutic targets 
in MSC immunomodulation.  Figure 6.1 illustrates the interplay between MSC, DC 
and T cells, it also depicts the role of contact and soluble factors in this system. 
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Fig.  6.1 The role of Notch signalling in MSC immunomodulation.  Jagged 1 
stimulation of the Notch receptor on T cells and DC by MSC leads to expansion of 
Treg cells, as well as inhibition of DC maturation and DC presentation of antigen.  
Soluble factors are involved in both processes.  TGFβ and PGE2 play an important 
role in MSC expansion of Treg, while IL-6 release from MSC works in conjunction 
with Jagged 1 to achieve MSC modulation of DC.  tDC suppression of lymphocyte 
proliferation occurs in a Jagged 2 dependent manner (Zhang et al., 2009). 
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 The immunological influence of MSC does not lie solely in immune cell 
suppression.  In chapter 4, MSC manipulation of pulmonary cells was examined in 
vitro to explore potential benefits that might be exploited in an in vivo model of 
pulmonary fibrosis.  The lung is one of the first sites MSC can be detected after IV 
administration in mice (Gao et al., 2001).  Some studies in pulmonary disease models 
suggest that MSC mediate their effects through engraftment in the lung and 
differentiation to alveolar cells, resulting in repair of damaged tissue (Ortiz et al., 
2003, Rojas et al., 2005).  Conversely, it has been proposed that MSC mediate repair 
through cell education and trophic manipulation of the micro-environment (Kotton et 
al., 2005, Phinney and Prockop, 2007, Duffield and Bonventre, 2005, Caplan and 
Dennis, 2006).  Given the heterogeneity of in vitro cultured MSC, the concepts of 
regeneration and trophic repair may not be mutually exclusive, (Phinney and Prockop, 
2007, English et al., 2013).  Following the data generated in Chapter 3, Chapter 4 
examined MSC in the context of paracrine signalling and cell manipulation.  MSC 
conditioned medium (CM) was shown to have dynamic effects pertaining to fibrotic 
therapy, encouraging the migration and proliferation of alveolar epithelial cells while 
suppressing the activation and proliferation of pulmonary fibroblasts.   
 Initial data from Chapter 4 served to address scepticism with regards to 
distinguishing MSC from generic fibroblasts (Haniffa et al., 2009).  Characterisation 
was performed on primary lung isolated fibroblasts.  While cell surface expression 
was the same as MSC, pulmonary fibroblasts did not differentiate into bone, fat or 
cartilage.  In contrast, results from Haniffa et al., demonstrated the trilineage 
differentiation potential of dermal fibroblasts.  However, this may be a result of 
pulmonary versus dermal origin or contamination of such cultures with dermal MSC 
(Haniffa et al., 2007).  Finally, MSC and fibroblasts were examined for expression of 
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αSMA and vementin, both are cytoskeletal components and are expressed by MSC, 
however, up-regulation of αSMA is associated with the activated form of fibroblasts, 
myofibroblasts.  The population of fibroblasts isolated in this study were not 
stimulated and did not express αSMA.  Taken together these results distinguish MSC 
from pulmonary fibroblasts in this system. 
 Several studies have provided evidence to suggest the growth factor HGF and 
the arachidonic acid metabolite PGE2 play significant roles in maintaining the course 
of normal wound healing.  Reduction in PGE2 levels in fibrotic human lung is 
associated with increased alveolar epithelial cell apoptosis and reduced sensitivity of 
fibroblasts to Fas ligand mediated apoptosis (Maher et al., 2010).  COX2 deficient 
mice also demonstrate an increased susceptibility to pulmonary fibrogenesis as a result 
of diminished PGE2 levels (Bonner et al., 2002, Hodges et al., 2004).  HGF is a 
homeostatic mediator known to exert protective effects on epithelial cells (Matsumoto 
and Nakamura, 1993).  Bleomycin induced lung injury in mice has been linked to an 
imbalance in the levels of pro-HGF and HGF (Phin et al., 2010).  Administration of 
the growth factor in vivo is also associated with attenuation of collagen deposition in 
bleomycin treated C57/BL6 mice (Dohi et al., 2000).  MSC have previously been 
shown to constitutively produce PGE2 both in human (English et al., 2009, Ryan et 
al., 2007) and in murine MSC (L.  Tobin, unpublished data).  TNFα stimulation of 
MSC increased release of HGF, a cytokine highly expressed in pulmonary fibrosis 
(Ortiz et al., 1998).  These observations suggested a pivotal role for HGF and PGE2 
in MSC treatment of pulmonary fibrosis.   
Replicating pulmonary fibrosis for in vitro study presents a difficult challenge 
for researchers.  A variety of studies have examined various roles for MSC in 
pulmonary fibrosis in vivo.  However, there is a void in our understanding of the basic 
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effects of MSC on individual cell types in this system.  In order to establish a role for 
MSC in vivo, pulmonary cells were examined for beneficial effects following MSC 
treatment in functional in vitro assays  Several studies have previously examined 
fibroblast migration using a scratch model of wound healing (Walter et al., 2010, 
Smith et al., 2010, Fronza et al., 2009).  Walter et al. used an immortalised cell line 
of dermal fibroblasts to demonstrate accelerated migration in response to MSC CM 
(Walter et al., 2010).  Following on from this work, data from chapter 4 demonstrated 
MSC CM significantly encouraged the migration of primary pulmonary fibroblasts.  
Alveolar epithelial cells were also assessed, with MSC CM promoting their migration 
into the site of damage in the in vitro scratch model of wound healing.  In order to 
confirm reconstitution of the wound area was a result of migration as opposed to 
proliferation, both cell types were examined for tritiated thymidine uptake.  While 
MSC CM promoted the proliferation of alveolar epithelial cells, fibroblasts 
proliferation was significantly inhibited.  These results demonstrate MSC favour the 
migration and proliferation of epithelial cells and while MSC encourage the migration 
of fibroblast they also inhibit fibroblast proliferation.  Closer examination of this 
system also revealed MSC CM reduced TGFβ induced activation of fibroblasts to 
myofibroblasts, determined by αSMA expression.  Contrary to these findings, a study 
by Smith et al. showed paracrine signalling by MSC increased the migration and 
proliferation of dermal fibroblasts (Smith et al., 2010).  However, Smith and 
colleagues used dermal fibroblast in their study which may react differently to MSC 
CM, the data herein however, was obtained using primary lung fibroblasts an approach 
more relevant to pulmonary fibrosis studies.   
Taken together these results support a role for MSC in pulmonary repair and 
treatment of fibrosis.  Fibroblasts play a vital role in wound healing, migrating to the 
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site of damage where they are involved in wound contraction and closure.  Here MSC 
were shown to actively promote fibroblast migration while also controlling the level 
of proliferation and activation.  Pathogenesis is associated with the disproportionate 
activation of fibroblasts leading to excessive collagen deposition.  Here MSC are 
shown for the first time to regulate all three major aspects of fibroblast homeostasis 
allowing for normal wound repair.  Additionally MSC promoted both the migration 
and proliferation of alveolar epithelial cells, thus consolidating their potential role in 
tissue repair by encouraging re-epithelialisation.   
Data from a number of studies into fibroblast proliferation suggested a role for 
PGE2 (Boyle et al., 1999, Moore et al., 2003, Pan et al., 2001).  In vitro studies of 
alveolar epithelial cells demonstrated that inhibition of fibroblast proliferation was 
mediated through PGE2 signalling (Moore et al., 2003).  Here, MSC production of 
PGE2 was blocked using a COX2 inhibitor (NS398), CM from NS398 treated MSC 
was no longer capable of inhibiting fibroblast proliferation, with proliferation 
reverting to basal levels observed with conventional medium.  This novel data 
establishes MSC production of PGE2 as a potential therapeutic candidate in treatment 
of early fibrosis.  In an effort to explore MSC potential in repair of established fibrosis, 
the soluble factor responsible for MSC induced epithelial expansion was determined.  
As previously discussed, HGF presented a likely candidate for MSC modulation of 
epithelial cells.  Using the shRNA technologies described in Chapter 3, HGF 
expression was knocked down in MSC.  As before, lentiviral transduction of MSC did 
not influence their defining characteristics, but significantly lowered secretion of 
HGF.  CM collected from HGF knockdown MSC was cultured with epithelial cells, 
the results of which demonstrated an essential role for HGF in MSC induced 
proliferation.  Similar results were observed in fetal intestinal epithelial cells where 
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HGF secreted by MSC, enhanced their viability and proliferation (Weil et al., 2009).  
The aim of Chapter 4 was to identify potential therapeutic roles for MSC in vitro for 
further examination in vivo.  This goal was achieved with the novel finding that MSC 
regulate the homeostasis of fibroblasts, reducing proliferation in a PGE2 dependent 
manner.  They also promoted the migration and proliferation of epithelial cells through 
secretion of HGF, suggesting a role in both prevention and repair of pulmonary 
fibrosis.  Figure 6.2 illustrates the effects of MSC CM on epithelial cells and fibroblast 
in the setting of pulmonary fibrosis. 
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Fig.  6.2 The effect of MSC CM on pulmonary cells.  MSC CM encourage the 
migration of alveolar epithelial cells and fibroblasts to the site of damage, but inhibit 
fibroblast proliferation in a PGE2 dependent manner.  MSC CM also inhibit TGFβ 
driven activation of fibroblast to myofibroblasts.  MSC CM encourages the 
proliferation of alveolar epithelial cells in a HGF dependent manner. 
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The capacity of MSC to therapeutically manipulate the immune system and 
pulmonary cells in order to prevent or repair fibrotic damage to the lung was examined 
in Chapter 5.  The bleomycin model of pulmonary fibrosis is a well-established murine 
model of fibrotic disease, several studies involving MSC treatment have already been 
documented (Moodley et al., 2003, Ortiz et al., 2007, Ortiz et al., 2003, Rojas et al., 
2005).  Early studies looked at MSC with a view to encourage reconstitution of the 
lung through engraftment (Ortiz et al., 2003, Rojas et al., 2005), later MSC were 
studied for their immunomodulatory properties.  Ortiz et al. demonstrated in vitro that 
MSC CM could inhibit the proliferation of an IL-1α dependent T cell line through 
production of an IL-1 receptor antagonist.  MSC CM was also shown to inhibit 
macrophage production of TNFα through the same mechanism.  Following this, MSC 
administration to bleomycin treated mice was shown to be more effective at reducing 
IL-1 and TNFα in lung mRNA and BAL fluid, than recombinant IL-1 receptor 
antagonist.  These results suggest MSC immunomodulatory properties, demonstrated 
in Chapter 3, could play a beneficial role in MSC treatment of fibrosis.  In vitro studies 
in Chapter 4 established a definitive role for MSC in modulation of pulmonary cells, 
however targeting inflammation associated with fibrosis offers a further target for 
MSC therapy. 
A pilot study was used to confirm bleomycin induced damage and the benefits 
of MSC treatment, as the model was previously untested in the Mahon lab.  There is 
variability in the route of administration in literature pertaining to bleomycin, be it 
intravenous (IV);(Lawson et al., 2005), intratracheal (IT)(Chaudhary et al., 2006, Iyer 
et al., 1999), or   subcutaneous (SC) (Ortiz et al., 1998, Yaekashiwa et al., 1997).  IV 
administration is believed to more accurately mimic chemotherapeutic administration 
with slower onset of fibrosis, typically 6-8 weeks.  Direct administration into the lung 
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results in faster onset and is more efficient for studying mechanisms of pathogenesis, 
but can result in variable distribution of fibrotic lesions (Lawson et al., 2005).  
Unpublished work by the Mahon lab, used crystal violet to demonstrate IN inhalation 
results in extensive distribution of a liquid inoculum.  For the purposes of this study, 
IN administration was selected for delivery of bleomycin, followed by IV 
administration of MSC.  This pilot study demonstrated systemic delivery of MSC can 
significantly improve airway pathology from bleomycin induced damage and collagen 
deposition.  The effect was only significant after day 28 (Fig 5.1), an unsurprising 
result given the predicted peak of fibrotic pathology occurs from day 21 to day 28.  
Importantly, allogeneic MSC administration to PBS treated mice had no adverse effect 
on the architecture of the lung, with histological scoring similar to that of mice given 
IV PBS (Fig.  5.1).  This results bears particular significance to the field of cellular 
therapy where adverse side effects to allogeneic MSC administration would severely 
diminish the attractiveness of MSC as a potential therapeutic.   
A small study examining the efficacy of allogeneic and syngeneic MSC was 
examined at day 28 for improvement in pathology.  Previous in vivo studies indicated 
both allogeneic and syngeneic MSC offer effective treatment in a multitude of disease 
model systems (Kavanagh and Mahon, 2011, Choi et al., 2013).  No difference was 
detected between C57BL/6 MSC and BALB/c MSC, in all instances they reduced 
inflammatory cytokines to levels comparable with PBS treatment.  The same was true 
of the fibrotic markers TGFβ and fibronectin.  The failure to reach significance in this 
system was accounted for by the collection of lungs at day 28.  Bleomycin is a 
resolving model of pathogenesis (Moore and Hogaboam, 2008), therefore is it 
conceivable that inflammatory and fibrotic mRNA levels would not be as high at day 
28 compared to an earlier time point.  These observations could prove limiting for the 
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success of further experiments.  Therefore, a time course study was used to determine 
the onset of fibrosis and thus the optimum time for recovery of lungs.  This study also 
offered the opportunity to establish a time frame of maximal inflammatory signalling, 
and onset of fibrosis.  The bleomycin model of fibrosis is now known to divide into 
two distinct phases.  An initial inflammatory phase brought about by immune cell 
infiltration to the site of damage, followed by a fibrotic phase resulting from fibroblast 
recruitment and proliferation (Moeller et al., 2008).  The timing of administration of 
potential therapeutics is essential for distinguishing between preventative anti-
inflammatory therapy and anti-fibrotic therapy.  Particular attention was given to 
TNFα, IL-1β, and TGFβ as these markers play well defined roles in fibrosis (Moodley 
et al., 2003, Ortiz et al., 2007, Ortiz et al., 1998, Chaudhary et al., 2006).  HGF levels 
were also determined for the purposes of distinguishing the growth factor as a potential 
target in MSC therapy.  Real time analysis showed a significant increase in the two 
principle cytokines, TNFα and IL-1β starting at day 9 and 15 respectively.  TGFβ 
expression significantly increased by day 15, with HGF showing no significant 
increase or decrease during the study.  These results show inflammation beginning 
marginally before fibrosis, as such day 9 was chosen as an appropriate time point for 
administration of MSC, as inflammation has been established and the effects of MSC 
would more accurately reflect treatment of fibrosis.   
Data herein demonstrated that delayed delivery of MSC failed to protect the 
lung architecture from bleomycin induced damage.  In comparison to MSC 
administered on day 0, delayed dosing resulted in significantly lower levels of HGF 
mRNA in lung tissue collected on day 21.  The beneficial effects of HGF outlined in 
Chapter 4 suggest early administration could result in increased repair and faster 
migration to the site of damage.  A critical observation here was that MSC 
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administered at day 0 would benefit from earlier stimulation by TNFα, with levels 
increasing by day 3.  As discussed earlier, TNFα stimulation of MSC increases 
production of HGF and PGE2.  Increased PGE2 could reduce the activation and 
proliferation of fibroblasts alleviating excessive collagen deposition.  This theory is 
supported by reduced levels of IL-1β at day 21 in mice given MSC at day 0 compared 
to bleomycin treated mice, a result not achieved by MSC administered at day 9.  A 
study by Ortiz et al.  into the engraftment of MSC in bleomycin induced injury, 
showed similar results.  MSC were administered at day 0 and day 7, but protective 
effects were only observed from MSC administered directly after bleomycin 
challenge.  A possible explanation given for reduced engraftment was the release of 
cytokines and mitogens from inflammatory cells, affecting homing of MSC, which 
could conceivably be reduced by day 7.  This hypothesis is not incompatible with the 
findings here.   
One of the aims of Chapter 5 was to refine the bleomycin murine model of 
fibrosis to more accurately represent therapeutic intervention.  This goal was achieved 
through studying the time course of the model with relation to onset of inflammation 
and fibrosis.  Administration of therapeutics at day 0 is common practice in bleomycin 
animal models and reports have claimed beneficial results from MSC under these 
conditions (Moodley et al., 2009, Ortiz et al., 2007, Rojas et al., 2005).  However, this 
study elegantly demonstrates the importance of timing with regards to how MSC are 
exerting a positive effect.  Early administration of MSC improved pathology but not 
by ameliorating direct fibrosis.  Delayed administration had no effect on reducing 
established fibrosis and was not as effective at reducing inflammation.  These results 
have important implications on future therapeutic candidate studies, with the success 
of potential anti-fibrotic therapies being determined by their efficacy following 
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delayed administration in the bleomycin model.  The limitations of the bleomycin 
model were further highlighted in an interesting study by Chaudhary et al.  The 
importance of timing in administration of therapeutics was supported using an anti-
inflammatory drug and an anti-fibrotic drug.  Both drugs showed a reduction in TGFβ 
and pro-collagen 1 expression following administration at day 0.  However, 
administration at day 10, rescinded the beneficial effects observed with use of the anti-
inflammatory drug.  This study by Chaudhary and colleagues into pharmacological 
intervention and the data here using cell therapy changes our understanding of the 
bleomycin model, demonstrating how the accuracy of in vivo testing can be skewed 
by inappropriate use of an animal model (Chaudhary et al., 2006).  A further important 
observation form this study was the failure to derive meaningful results from HGF KD 
MSC given at day 9.  Evidence from Chapter 4 suggested HGF plays an important role 
in MSC induced tissue repair.  However, the ineffectual nature of delayed dosing in 
MSC administration meant no meaningful conclusion could be discerned from this 
aspect of the study.  These results reinforce the importance of diligence in animal 
testing, demonstrating how encouraging results observed in vitro do not always 
translate into beneficial outcomes in vivo. 
The immunological properties of MSC appear to target inflammation 
associated with the initial phase of fibrotic disease.  A role for MSC has been 
established in promoting a regulatory environment, encouraging the induction and 
expansion of anti-inflammatory immune cell phenotypes.  Trophic interactions with 
pulmonary cells also promote the migration and proliferation of epithelial cells, while 
regulating fibroblast growth and development.  In vivo, the protective effect of MSC 
may have far-reaching clinical applications but will depend on the accuracy of timing 
in administration.  This work shows that while MSC exhibit great potential in 
207 
 
treatment of inflammatory based diseases, they failed to achieve the level of repair 
required to improve the pathology of established fibrosis.  This work should influence 
future animal studies into anti-fibrotic candidates improving the potential for 
translation in human therapeutics.   
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